
<html lang="en"     class="pb-page"  data-request-id="3f31fbb0-5fd4-4be9-af26-e2800de7889a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2013.56.issue-23;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm401365h;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Enhanced Tumor Retention of a Radiohalogen Label for Site-Specific Modification of Antibodies" /></meta><meta name="dc.Creator" content="C. Andrew  Boswell" /></meta><meta name="dc.Creator" content="Jan  Marik" /></meta><meta name="dc.Creator" content="Michael J.  Elowson" /></meta><meta name="dc.Creator" content="Noe A.  Reyes" /></meta><meta name="dc.Creator" content="Sheila  Ulufatu" /></meta><meta name="dc.Creator" content="Daniela  Bumbaca" /></meta><meta name="dc.Creator" content="Victor  Yip" /></meta><meta name="dc.Creator" content="Eduardo E.  Mundo" /></meta><meta name="dc.Creator" content="Nicholas  Majidy" /></meta><meta name="dc.Creator" content="Marjie  Van Hoy" /></meta><meta name="dc.Creator" content="Saritha N.  Goriparthi" /></meta><meta name="dc.Creator" content="Anthony  Trias" /></meta><meta name="dc.Creator" content="Herman S.  Gill" /></meta><meta name="dc.Creator" content="Simon P.  Williams" /></meta><meta name="dc.Creator" content="Jagath R.  Junutula" /></meta><meta name="dc.Creator" content="Paul J.  Fielder" /></meta><meta name="dc.Creator" content="Leslie A.  Khawli" /></meta><meta name="dc.Description" content="A known limitation of iodine radionuclides for labeling and biological tracking of receptor targeted proteins is the tendency of iodotyrosine to rapidly diffuse from cells following endocytosis and..." /></meta><meta name="Description" content="A known limitation of iodine radionuclides for labeling and biological tracking of receptor targeted proteins is the tendency of iodotyrosine to rapidly diffuse from cells following endocytosis and..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 5, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401365h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401365h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401365h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401365h" /></link>
        
    
    

<title>Enhanced Tumor Retention of a Radiohalogen Label for Site-Specific Modification of Antibodies | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401365h" /></meta><meta property="og:title" content="Enhanced Tumor Retention of a Radiohalogen Label for Site-Specific Modification of Antibodies" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0008.jpeg" /></meta><meta property="og:description" content="A known limitation of iodine radionuclides for labeling and biological tracking of receptor targeted proteins is the tendency of iodotyrosine to rapidly diffuse from cells following endocytosis and lysosomal degradation. In contrast, radiometal–chelate complexes such as indium-111–1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (In-111-DOTA) accumulate within target cells due to the residualizing properties of the polar, charged metal-chelate-amino acid adduct. Iodine radionuclides boast a diversity of nuclear properties and chemical means for incorporation, prompting efforts to covalently link radioiodine with residualizing molecules. Herein, we describe the Ugi-assisted synthesis of [I-125]HIP-DOTA, a 4-hydroxy-3-iodophenyl (HIP) derivative of DOTA, and demonstration of its residualizing properties in a murine xenograft model. Overall, this study displays the power of multicomponent synthesis to yield a versatile radioactive probe for antibodies across multiple therapeutic areas with potential applications in both preclinical biodistribution studies and clinical radioimmunotherapies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401365h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401365h">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401365h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401365h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401365h&amp;href=/doi/10.1021/jm401365h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9418-9426</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401794v" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/jm4010434" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Enhanced Tumor Retention of a Radiohalogen Label for Site-Specific Modification of Antibodies</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=C.+Andrew++Boswell">C. Andrew Boswell</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jan++Marik">Jan Marik</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Elowson">Michael J. Elowson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Noe+A.++Reyes">Noe A. Reyes</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheila++Ulufatu">Sheila Ulufatu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniela++Bumbaca">Daniela Bumbaca</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Victor++Yip">Victor Yip</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eduardo+E.++Mundo">Eduardo E. Mundo</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas++Majidy">Nicholas Majidy</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marjie++Van+Hoy">Marjie Van Hoy</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Saritha+N.++Goriparthi">Saritha N. Goriparthi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony++Trias">Anthony Trias</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Herman+S.++Gill">Herman S. Gill</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon+P.++Williams">Simon P. Williams</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jagath+R.++Junutula">Jagath R. Junutula</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+J.++Fielder">Paul J. Fielder</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leslie+A.++Khawli">Leslie A. Khawli</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-467-4603. E-mail: <a href="/cdn-cgi/l/email-protection#0664697571636a6a286768627f46616368632865696b"><span class="__cf_email__" data-cfemail="81e3eef2f6e4ededafe0efe5f8c1e6e4efe4afe2eeec">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401365h&amp;href=/doi/10.1021%2Fjm401365h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9418–9426</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 16, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 September 2013</li><li><span class="item_label"><b>Published</b> online</span>5 November 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 December 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401365h" title="DOI URL">https://doi.org/10.1021/jm401365h</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9418%26pageCount%3D9%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DC.%2BAndrew%2BBoswell%252C%2BJan%2BMarik%252C%2BMichael%2BJ.%2BElowson%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D23%26contentID%3Djm401365h%26title%3DEnhanced%2BTumor%2BRetention%2Bof%2Ba%2BRadiohalogen%2BLabel%2Bfor%2BSite-Specific%2BModification%2Bof%2BAntibodies%26numPages%3D9%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9426%26publicationDate%3DDecember%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401365h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1026</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">28</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401365h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Enhanced Tumor Retention of a Radiohalogen Label for Site-Specific Modification of Antibodies&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;C.&quot;,&quot;last_name&quot;:&quot;Andrew Boswell&quot;},{&quot;first_name&quot;:&quot;Jan&quot;,&quot;last_name&quot;:&quot;Marik&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Elowson&quot;},{&quot;first_name&quot;:&quot;Noe&quot;,&quot;last_name&quot;:&quot;A. Reyes&quot;},{&quot;first_name&quot;:&quot;Sheila&quot;,&quot;last_name&quot;:&quot;Ulufatu&quot;},{&quot;first_name&quot;:&quot;Daniela&quot;,&quot;last_name&quot;:&quot;Bumbaca&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;Yip&quot;},{&quot;first_name&quot;:&quot;Eduardo&quot;,&quot;last_name&quot;:&quot;E. Mundo&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;Majidy&quot;},{&quot;first_name&quot;:&quot;Marjie&quot;,&quot;last_name&quot;:&quot;Van Hoy&quot;},{&quot;first_name&quot;:&quot;Saritha&quot;,&quot;last_name&quot;:&quot;N. Goriparthi&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;Trias&quot;},{&quot;first_name&quot;:&quot;Herman&quot;,&quot;last_name&quot;:&quot;S. Gill&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;P. Williams&quot;},{&quot;first_name&quot;:&quot;Jagath&quot;,&quot;last_name&quot;:&quot;R. Junutula&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;J. Fielder&quot;},{&quot;first_name&quot;:&quot;Leslie&quot;,&quot;last_name&quot;:&quot;A. Khawli&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;9418-9426&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401365h&quot;},&quot;abstract&quot;:&quot;A known limitation of iodine radionuclides for labeling and biological tracking of receptor targeted proteins is the tendency of iodotyrosine to rapidly diffuse from cells following endocytosis and lysosomal degradation. In contrast, radiometal–chelate complexes such as indium-111–1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (In-111-DOTA) accumulate within target cells due to the residualizing properties of the polar, charged metal-chelate-amino acid adduct. Iodine radionuclides boast a diversity of nuclear properties and chemical means for incorporation, prompting efforts to covalently link radioiodine with residualizing molecules. Herein, we describe the Ugi-assisted synthesis of [I-125]HIP-DOTA, a 4-hydroxy-3-iodophenyl (HIP) derivative of DOTA, and demonstration of its residualizing properties in a murine xenograft model. Overall, this study displays the power of multicomponent synthesis to yield a versatile radioactive probe for antibodies across multiple therapeutic areas with potential appl&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401365h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401365h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401365h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401365h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401365h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401365h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401365h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401365h&amp;href=/doi/10.1021/jm401365h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401365h" /></input><a href="/doi/pdf/10.1021/jm401365h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401365h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401365h%26sid%3Dliteratum%253Aachs%26pmid%3D24131491%26genre%3Darticle%26aulast%3DBoswell%26date%3D2013%26atitle%3DEnhanced%2BTumor%2BRetention%2Bof%2Ba%2BRadiohalogen%2BLabel%2Bfor%2BSite-Specific%2BModification%2Bof%2BAntibodies%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D23%26spage%3D9418%26epage%3D9426%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jmcmar.2013.56.issue-23/production/jmcmar.2013.56.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A known limitation of iodine radionuclides for labeling and biological tracking of receptor targeted proteins is the tendency of iodotyrosine to rapidly diffuse from cells following endocytosis and lysosomal degradation. In contrast, radiometal–chelate complexes such as indium-111–1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (In-111-DOTA) accumulate within target cells due to the residualizing properties of the polar, charged metal-chelate-amino acid adduct. Iodine radionuclides boast a diversity of nuclear properties and chemical means for incorporation, prompting efforts to covalently link radioiodine with residualizing molecules. Herein, we describe the Ugi-assisted synthesis of [I-125]HIP-DOTA, a 4-hydroxy-3-iodophenyl (HIP) derivative of DOTA, and demonstration of its residualizing properties in a murine xenograft model. Overall, this study displays the power of multicomponent synthesis to yield a versatile radioactive probe for antibodies across multiple therapeutic areas with potential applications in both preclinical biodistribution studies and clinical radioimmunotherapies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The antigen specificity of monoclonal antibodies is a powerful attribute that allows the specific in vivo delivery of payloads, including chemotherapeutic drugs and radionuclides.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> To date, only two radioimmunotherapeutic agents have been approved for clinical use, and both feature murine monoclonal antibodies targeting the CD20 receptor for treatment of lymphoma.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Tositumomab is administered with the β-emitting iodine radionuclide, <sup>131</sup>I, attached via tyrosine residues as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A. Ibritumomab tiuxetan is administered with the β-emitting yttrium radionuclide, <sup>90</sup>Y, attached using tiuxetan, an isothiocyanate analogue of diethylenetriamine pentaacetic acid (DTPA), through lysine residues via thiourea bonds.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> This labeling strategy is somewhat analogous to the complexation of the indium radionuclide, <sup>111</sup>In, by 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), whose succinimidyl ester can form amide bonds via lysine as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected nonresidualizing (A) and residualizing (B–D) methods of radiolabeling antibodies including (A) oxidative tyrosine radioiodination, (B) lysine modification with radiometal chelate, (C) lysine modification with charged iodinated groups,<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> and (D) thiol modification with the novel compound <b>6</b>, designated [<sup>125</sup>I]HIP-DOTA, that can be attached to either the Fc region or the heavy (HC) or light (LC) chains of an antibody containing engineered cysteine residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Beyond their clinical utility, radioimmunoconjugates are also useful as tools in preclinical and translational research for studying conventional, nonradioactive antibody therapeutics.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Noninvasive small animal imaging modalities, whole-body autoradiography, and invasive biodistribution studies can assist drug development by providing valuable mechanistic information including confirmation of target localization, screening for off-target uptake, and assessing receptor occupancy. In addition to <sup>131</sup>I, <sup>125</sup>I is commonly used for such studies, with the latter having the advantages of a roughly 10-fold lower γ energy, the absence of a β particle emission, and a much longer decay half-life (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Table S1">Supporting Information, Table S1</a>).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Single photon emission computed tomography (SPECT) imaging may be performed with <sup>123</sup>I, <sup>131</sup>I, and <sup>125</sup>I, the latter being limited to preclinical small animal cameras. Positron emission tomography (PET) with <sup>124</sup>I is also feasible,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> although the highly energetic emissions limit the image quality.</div><div class="NLM_p">Labeling of antibodies with radiometals results in a different cellular retention of radioactivity relative to iodotyrosine-based labeling.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> For both labeling methods, antibodies undergo receptor-mediated endocytosis and lysosomal degradation. However, a third critical step, cellular efflux of the radiolabel with its covalently associated amino acid, does not readily occur for radiometal-labeled antibodies (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Unlike [<sup>125</sup>I]iodotyrosine, which diffuses out of the cell (intact or as free iodide) following proteolysis, <sup>111</sup>In-DOTA–lysine cannot easily cross the plasma membrane due to its charge and polarity.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Because of its tendency to become intracellularly trapped, <sup>111</sup>In-DOTA is referred to as a residualizing label.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic depicting the cellular fates of nonresidualizing and residualizing labels following antibody binding to an internalizing cell-surface antigen. Antibodies labeled by both methods undergo receptor-mediated endocytosis and lysosomal degradation. Diffusion of radioactivity out of the lysosome and/or cell occurs readily for iodotyrosine but is resisted for radiometal–chelate complexes and other residualizing labels.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Significant effort has been made to derive strategies for labeling antibodies with radioiodine such that residualization occurs in a similar manner as for radiometals. This reflects, in part, the wide availability of iodine radionuclides with diverse nuclear properties, in terms of both decay half-lives and emission energies (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Table S1">Supporting Information, Table S1</a>), and an abundant knowledge of halogen radiochemistry.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> For instance, the decay half-lives of <sup>111</sup>In and <sup>125</sup>I are 2.8 and 60 days, respectively, making the latter radionuclide far better suited for long-term preclinical studies. This is especially true for antibodies, whose pharmacokinetic half-lives are often on the order of 1–2 weeks. Another consideration is that the γ energy of <sup>125</sup>I is nearly 10-fold lower relative to <sup>111</sup>In, with lower energy emissions often associated with superior autoradiographic image quality and lower radiation exposure to workers. A residualizing iodine probe would combine the long decay half-life and low energy of <sup>125</sup>I with the superior tumor accretion of radiometals while providing a facile translational route to clinical imaging (via <sup>123</sup>I or <sup>124</sup>I) or radioimmunotherapy (via <sup>131</sup>I)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Table S1">Supporting Information, Table S1</a>).</div><div class="NLM_p">To date, strategies used to derive residualizing iodine probes include the use of (i) nonmetabolizable carbohydrates, (ii) nonmetabolizable peptide adducts, and/or (iii) highly charged moieties. The carbohydrate derivative dilactitol-<sup>125</sup>I-tyramine is a member of the first class of residualizing radioiodine probes.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, the use of carbohydrates poses a potential risk, as pendant sugar groups are important for binding of antibodies to Fc receptors and other critical functions.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Representing the second class is the residualizing peptide, IMP-R4 (MCC-Lys(MCC)-Lys(X)-<span class="smallcaps smallerCapital">d</span>-Tyr-<span class="smallcaps smallerCapital">d</span>-Lys(X)-OH, where MCC is 4-(<i>N</i>-maleimidomethyl)-cyclohexane-1-carbonyl and X is 1-((4-thiocarbonylamino)benzyl)-DTPA).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This approach relies on a synthetic peptide that is conjugated with the chelate DTPA, whose charge imparts residualizing properties.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Selected examples of the third class are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>C, many of which require the use of organostannane intermediates in their syntheses.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> Overall, we sought to design a simple residualizing iodine probe that is accessible to laboratories with basic organic synthesis capabilities while avoiding the use of bulky peptides, carbohydrates, organostannanes, and lengthy synthetic routes.</div><div class="NLM_p last">Herein, we report the Ugi multicomponent synthesis,<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> radiolabeling, and biological evaluation of a residualizing radiohalogen probe, [<sup>125</sup>I]HIP-DOTA, (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>D). The probe was site-specifically conjugated to an engineered THIOMAB<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (i.e., a full-length antibody having engineered cysteine residues) and demonstrated to exhibit superior tumor uptake relative to a conventional tyrosine radioiodinated control antibody. This novel method for introducing radioiodine labels into antibodies is a useful preclinical tool for studying the biodistribution, metabolism, and excretion of antibody therapeutics. Furthermore, antibodies labeled with residualizing radionuclides offer unique advantages as both diagnostic and radioimmunotherapeutic agents because they may provide a more sustained retention of radioactivity inside tumor cells.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Assuming that efficacy is related to tumor radiation exposure, the use of residualizing radioimmunotherapeutic agents may encourage high target radiation exposure and favorable clinical responses.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82083" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82083" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In choosing a synthetic strategy, we considered that our molecule should consist of three critical functional components: an iodotyrosine-like moiety, an activated group for antibody conjugation, and a residualizing anchor. The success of residualizing peptides, which contain iodotyrosine, suggested that a hydroxyphenyl residue is a sufficient scaffold on which to introduce radioiodine.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This avoided the necessity of tin precursors, which are necessary to produce the <i>N</i>-succinimidyl <i>m</i>-iodobenzoate derivatives whose corresponding antibody conjugates are depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>C. The choice of the macrocyclic polyaminopolycarboxylic acid DOTA was based on both its known ability to residualize<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and on its commercial availability with a wide array of functional groups.</div><div class="NLM_p">We sought a chemical reaction with the ability to rapidly combine multiple chemical components in high yields and with ample flexibility in reactant structure. These requirements led us to the Ugi multicomponent reaction involving a ketone or aldehyde, an amine, an isocyanide, and a carboxylic acid to form a bisamide.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> Indeed, there is one previous report of the Ugi reaction applied to synthesis of ditopic chelating agents.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">We used formaldehyde, a primary amine-functionalized DOTA derivative (compound <b>1</b>), 4-hydroxyphenylacetic acid, and ethyl isocyanoacetate as our four commercially available Ugi components (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The ethyl ester <b>2</b> was converted to the acid <b>3</b> by saponification using lithium hydroxide. All attempts to synthesize the succinimidyl ester of this acid, our original desired molecule, were unsuccessful, with the formation of dimers (phenolic esters) evident by mass spectrometry. This problem was averted by changing from a lysine- to a cysteine-based conjugation strategy, taking advantage of recent developments in antibody engineering to introduce site-specific cysteines.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Our previous work demonstrated that the maleimide functionality is compatible with the oxidative conditions of radioiodination.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> This guided our synthetic route to introduce a maleimide group by coupling the acid to <i>N</i>-(2-aminoethyl)maleimide using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), yielding the shelf compound <b>4</b> in only three steps (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) as compared to the six-step synthesis of the protected tin precursor of SIB-DOTA (SIB = <i>N</i>-succinimidyl-3-iodobenzoate).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Compounds <b>2</b>, <b>3</b>, and <b>4</b> eluted on a RP-HPLC gradient at 14.8, 13.8, and 13.7 min, respectively (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S1">Supporting Information, Figure S1</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Synthetic route to the shelf compound, maleimide <b>4</b>, and its radiolabeling and antibody conjugation to LC-V205C thio-trastuzumab.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our radiochemical strategy initially involved use of the mild oxidant, <i>N</i>-chlorosuccinimide, to achieve iodination in chloroform on the hydroxyphenyl group. However, we subsequently discovered that maleimide <b>4</b> is sufficiently water-soluble to allow a more efficient labeling in aqueous 0.1% acetic acid in a test tube that is precoated with the water insoluble oxidizing agent, 1,3,4,6-tetrachloro-3α,6α-diphenylglucoluril (i.e., “Iodogen”) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The intermediate [<sup>125</sup>I]<b>5</b> had a retention time of 15.5 min on reversed-phase HPLC (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S2">Supporting Information, Figure S2</a>) and could be detected in terms of both [<sup>127</sup>I] and [<sup>125</sup>I] by mass spectrometry (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S3–S4">Supporting Information, Figure S3–S4</a>). Compound <b>5</b> could be purified from free iodide and oxidant using reverse-phase solid-phase extraction cartridges, but this step was not necessary for the Iodogen method. Acid deprotection yielded the triacid [<sup>125</sup>I]<b>6</b>, with completeness of reaction monitored by reverse-phase radio-HPLC (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S5">Supporting Information, Figure S5</a>). This 4-hydroxy-3-iodophenyl derivative of DOTA, compound [<sup>125</sup>I]<b>6</b>, was designated [<sup>125</sup>I]HIP-DOTA. After exhaustive removal of acid by repeated addition and evaporation of toluene, the thiol-containing antibody could be introduced for thiol-maleimide coupling. Any remaining free thiols were reacted with iodoacetic acid to avoid dimerization or formation of adducts with thiol-containing endogenous proteins. All radioimmunoconjugates were analyzed for purity by size-exclusion HPLC and compared to the profile of unlabeled trastuzumab (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S6–S7">Supporting Information, Figure S6–S7</a>).</div><div class="NLM_p">The site-specificity of our labeling strategy was confirmed by SDS-PAGE analysis including both protein staining and phosphorimaging (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Digestion with the endoprotease Lys-C was able to distinguish radiolabeled Fc from Fab. Similarly, reduction by dithiothreitol was able to resolve radiolabeled light chain (LC) from radiolabeled HC/Fc regions.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SDS-PAGE analysis by protein staining (top) and phosphorimaging (bottom) of trastuzumab labeled site specifically with [<sup>125</sup>I]<b>6</b> through its heavy chain (HC-A114C), light chain (LC-V205C), and Fc (Fc-S396C) region. Digestion of antibodies with the endoprotease, Lys-C, results in cleavage between the Fab and Fc regions. In contrast, dithiothreitol (DTT) reduction separates the heavy (still attached to Fc) and light chains. Differential exposure of radioactivity in selected bands is evident despite equal loading of proteins, demonstrating the site-specificity of labeling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of our previous experience with THIOMAB technology, we anticipated differences in stability between the heavy chain (HC-A114C), light chain (LC-V205C), and crystallizable fragment (Fc-S396C) radioimmunoconjugate variants (Kabat numbering is used).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> This hypothesis was confirmed using an in vitro plasma stability assay in which each of the [<sup>125</sup>I]<b>6</b>-labeled trastuzumab derivatives was incubated in mouse plasma at 37 °C. Consistent with the previously reported stabilities of antibody–drug conjugates,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> the rank order of plasma stability for our site-specific conjugates was LC > HC > Fc (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S8–S10">Supporting Information, Figure S8–S10</a>). These site specific differences in stability likely result from the local electrostatic environment (i.e., charged residues) causing variations in the rate of succinimide ring hydrolysis, which prevents further maleimide exchange with reactive thiols and enhances stability.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The loss of the main (intact) peak at 18 min was accompanied by the appearance of two new peaks. An earlier peak at 16.5 min was attributed to protein aggregation and/or dimerization, while a later peak at 19 min was consistent with the retention time of albumin, an abundant plasma protein that is known to possess a reactive thiol.</div><div class="NLM_p">To evaluate the ability of compound <b>6</b>, HIP-DOTA, to residualize, a biodistribution study was performed in the previously validated KPL-4 xenograft mouse model<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> of human epidermal growth factor receptor 2 (HER2)-expressing breast cancer as previously reported.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The radioimmunoconjugates [<sup>125</sup>I]<b>6</b>-[HC]–, [<sup>125</sup>I]<b>6</b>-[LC]–, and [<sup>125</sup>I]<b>6</b>-[Fc]–trastuzumab were directly compared with tyrosine-labeled <sup>125</sup>I-trastuzumab prepared by the Chizzonite (i.e., indirect Iodogen) method. Trastuzumab labeled with <sup>111</sup>In-DOTA, a known residualizing probe, was coadministered with each radioiodinated antibody to serve as an internal control. Simultaneous measurement of both <sup>125</sup>I and <sup>111</sup>In in a single sample is feasible due to the distinct γ energies of these two radionuclides.</div><div class="NLM_p">The plasma clearance profiles for all three radioimmunoconjugates were overlapping (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A), indicating that the tumor uptakes of radioactivity for <sup>111</sup>In-DOTA-, [<sup>125</sup>I]<b>6</b>-, and <sup>125</sup>I-labeled trastuzumab were not influenced by systemic exposure and that modification of the antibody with [<sup>125</sup>I]<b>6</b> did not deleteriously affect its pharmacokinetics. The lack of difference among [<sup>125</sup>I]<b>6</b>–trastuzumab variants, despite differences in plasma stability, reflects the inability of the radiometric pharmacokinetic assay to distinguish between intact antibody and [<sup>125</sup>I]<b>6</b>–albumin, a likely product of maleimide exchange with reactive thiols.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma pharmacokinetics (A) and biodistribution at 3 days (B) of trastuzumab radiolabeled by various methods in KPL-4 xenograft-bearing mice. Trastuzumab was labeled with <sup>125</sup>I by traditional tyrosine modification (black), by site-specific (HC-A114C/LC-V205C/Fc-S396C) modification with [<sup>125</sup>I]<b>6</b> (blue, green, and red, respectively), or by lysine modification with <sup>111</sup>In-DOTA (gray). Uptake is expressed as percentage of injected dose per g of tissue (%ID/g).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At 3 days, tumor uptake for each of the three [<sup>125</sup>I]<b>6</b>–trastuzumab variants was more than triple that of <sup>125</sup>I–trastuzumab with values of 24.6 ± 4.2 (HC-A114C), 27.7 ± 1.4 (LC-V205C), 21.2 ± 1.8 (Fc-S396C), and 6.1 ± 0.3 (tyrosine-modified) percentage of injected dose per gram (%ID/g), respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). By comparison, 3-day tumor uptake of <sup>111</sup>In-DOTA–trastuzumab was even higher at 48.7 ± 3.8%ID/g. These data suggest that [<sup>125</sup>I]<b>6</b>-associated catabolites are residualized to a greater extent than [<sup>125</sup>I]iodotyrosine. Apart from tumor, the radioactivity levels in tissues obtained by trastuzumab labeled by the five different methods were largely similar. A higher renal uptake of radioactivity was observed for [<sup>125</sup>I]<b>6</b>–trastuzumab, particularly the Fc variant, relative to <sup>125</sup>I–trastuzumab. Renal levels of radioactivity following injection of <sup>125</sup>I-, <sup>125</sup>I-<b>6</b>- (HC), <sup>125</sup>I-<b>6</b>- (LC), <sup>125</sup>I-<b>6</b>- (Fc), and <sup>111</sup>In-DOTA-labeled trastuzumab were roughly 3, 10, 8, 20 and 6%ID/g, respectively. In addition, both splenic and hepatic uptake of <sup>111</sup>In were higher than for any of the [<sup>125</sup>I]-labeled molecules.</div><div class="NLM_p">At 1 week, the trends in tumor and tissue uptake were somewhat similar to those observed in the 3-day data, although the residualization of <sup>111</sup>In-DOTA appears to be more sustained than [<sup>125</sup>I]<b>6</b> (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S11">Supporting Information, Figure S11</a>). Mean tumor uptakes were 6.9 ± 3.7 (HC-A114C), 8.2 ± 3.8 (LC-V205C), 5.9 ± 0.7 (Fc-S396C), 1.7 ± 0.3 (tyrosine-modified), and 21.2 ± 5.6(<sup>111</sup>In-DOTA)%ID/g, respectively. The levels of <sup>111</sup>In uptake in %ID/g for liver (7.2) and spleen (13) were considerably higher than that for any of the <sup>125</sup>I-labeled analogues.</div><div class="NLM_p">Noninvasive single photon emission computed tomography (SPECT) imaging was performed in live, anesthetized KPL-4 tumor-bearing mice in order to complement the biodistribution study arm (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, upper). X-ray computed tomography (CT) was performed prior to SPECT without movement or bed adjustment to allow anatomical coregistration of radioactivity with tissue structures. Seventy-two hour SPECT-CT images of mice receiving a single intravenous injection of radiolabeled trastuzumab qualitatively revealed tumor-to-blood ratios in the following rank order: <sup>111</sup>In-DOTA > <sup>125</sup>I-<b>6</b> (LC-V205C) > <sup>125</sup>I-<b>6</b> (HC-A114C) > <sup>125</sup>I-<b>6</b> (Fc-S396C) > <sup>125</sup>I (tyrosine-modified). The better agreement between <sup>111</sup>In-DOTA and [<sup>125</sup>I]<b>6</b> by SPECT-CT in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, relative to Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, may be explained by higher receptor occupancy and/or altered internalization rates due to the higher doses of radiolabeled antibody necessary for image acquisition.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. SPECT-CT imaging (upper) at 24 and 72 h and whole-body autoradiographic imaging (lower) at 72 h indicate relative degrees of tracer residualization in KPL-4 xenograft-bearing mice following intravenous administration of trastuzumab radiolabeled by five different methods. In the three-dimensional volume renderings from a coronal perspective (upper), the skeletal images are derived from the X-ray (anatomical) CT data while the relative levels of radioactivity from the SPECT data are indicated in a false-color scale. Tumor-to-blood (T:B) ratios of radioactive uptake are shown. Post-mortem cryosection images from a sagittal perspective (lower) were acquired from the same mice as in the upper panel. False-colored phosphorimages (left) and digital photographs (right) are shown for each mouse in the tumoral plane. Tissues are labeled as tumor (T), liver (L), and kidney (K).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Whole-body localization of radioactivity in KPL-4 tumor-bearing mice was determined by autoradiography (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, lower). Digital photographs of the sagittal cryosections allow anatomical coregistration. The same rank order of relative tumor uptake (upper panel) was qualitatively observed: <sup>111</sup>In-DOTA > [<sup>125</sup>]I<b>6</b> (LC-V205C) > [<sup>125</sup>]I<b>6</b> (HC-A114C) > [<sup>125</sup>]I<b>6</b> (Fc-S396C) > <sup>125</sup>I (tyrosine-modified). Elevated renal uptake, especially for the Fc variant of <sup>125</sup>I-<b>6</b>–trastuzumab, was evident by both SPECT and autoradiography and recapitulated the data obtained by organ harvest in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>. In the midline plane (lower panel), a strikingly high uptake of radioactivity in the thyroid gland was the dominant feature in the <sup>125</sup>I–trastuzumab (tyrosine-modified) autoradiograph (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S12">Supporting Information, Figure S12</a>) despite the NaI blocking doses administered at both 24 and 1 h prior to dosing. The absence of this feature in the SPECT images could be explained by image artifacts near the top/bottom of the images or by the thyroid lying outside of the reconstructed field-of-view, which is smaller for SPECT than for CT on our system. In contrast, mostly blood pool uptake was visible in the midline plane for the other four variants (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S12">Supporting Information, Figure S12</a>). The image quality and resolution for <sup>111</sup>In-DOTA was noticeably inferior to the <sup>125</sup>I-labeled variants, as evident from the degree of pixelation and bleed-over (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). This observation may be attributed to the roughly 10-fold γ energy of <sup>111</sup>In relative to <sup>125</sup>I.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42144" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42144" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The HC-A114C, LC-V205C, and Fc-S396C variants of [<sup>125</sup>I]<b>6</b>–trastuzumab yielded more than triple the tumor radioactivity relative to traditional tyrosine radioiodination at 3 days postinjection but still fell short (roughly 50%) of <sup>111</sup>In-DOTA (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). The presence of the metal in the latter may be the reason for this discrepancy; however, previous studies showed that the presence of In<sup>3+</sup> did not affect the level of residualization in antibodies labeled with DTPA-appended radioiodinated peptides.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Furthermore, as others have noted,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> chelates have an ability to scavenge iron or other adventitious metals in tissue culture media or in vivo. Importantly, DOTA forms complexes with transition metals, alkaline earth metals (e.g., calcium), and several lanthanides.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The stabilities (log <i>K</i><sub>d</sub>, defined as dissociation constant) for the transition metal complexes of DOTA range from 24 to 29 for Fe(III) to 19–21 for Zn(II), with a less stable value of 16 for the Ca(II) complex.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The promiscuous complexation chemistry of DOTA makes it possible that a range of metal ions could be bound in the chelator cavity within a biological matrix, but iron is of particular relevance because of its presence in circulating plasma proteins such as transferrin.</div><div class="NLM_p">Alternatively, the level of tumor residualization of [<sup>125</sup>I]<b>6</b>-associated catabolites may be inferior to that of <sup>111</sup>In-DOTA–lysine, potentially placing HIP-DOTA at a disadvantage with respect to radiometal-based labels. However, size exclusion radiochromatographic analysis of kidney homogenates from a follow-up study in nontumor-bearing mice revealed higher levels of nonintact, low molecular weight radiocatabolites for [<sup>125</sup>I]<b>6</b>-[HC]–trastuzumab relative to <sup>125</sup>I-trastuzumab (65 and 5% of renal radioactivity, respectively) (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S13">Supporting Information, Figure S13</a>). Importantly, these data demonstrate that renal accumulation of [<sup>125</sup>I]<b>6</b>-associated radioactivity occurs independently of tumor uptake and are further supported by in vitro evidence of partial deconjugation in plasma (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S8–S10">Supporting Information, Figure S8–S10</a>). Another possibility is that dehalogenation, cleavage of the halogen–carbon bond, is affecting the probe’s tumor retention (see below).</div><div class="NLM_p">Enzymatic dehalogenation also contributes to the underlying discrepancy in tumor uptake between targeted molecules labeled with radiohalogens and radiometals. Although mostly concentrated in the thyroid, dehalogenases are also present elsewhere including the liver and kidneys.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> The use of organostannane precursors to derive charged metaiodobenzoate derivatives as residualizing iodine probes (see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>C) is intended to avert this problem by eliminating the presence of a phenol group, thus escaping specific molecular recognition by these enzymes.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> Indeed, similar strategies have yielded nonresidualizing iodine probes that are more resistant to dehalogenation.<a onclick="showRef(event, 'ref25 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref25 ref32 ref33">(25, 32, 33)</a> However, both the present and previous work<a onclick="showRef(event, 'ref17 ref34'); return false;" href="javascript:void(0);" class="ref ref17 ref34">(17, 34)</a> demonstrate that even 2-iodophenol derivatives may be successfully incorporated into residualizing probes. Consequently, the efflux of iodotyrosine and/or its catabolites following lysosomal proteolysis may be a more vexing problem than enzymatic dehalogenation. However, it is important to note that dehalogenases are specific for mono- or diiodinated <span class="smallcaps smallerCapital">l</span>-tyrosine, therefore the <span class="smallcaps smallerCapital">d</span>-tyrosine-containing IMP-R4 and the Ugi-derived [<sup>125</sup>I]<b>6</b> might not even be recognized by these enzymes.</div><div class="NLM_p">Higher renal uptake of the HC-A114C, LC-V205C, and Fc-S396C analogues of [<sup>125</sup>I]<b>6</b> thio-trastuzumab, relative to <sup>125</sup>I-trastuzumab, was expected based on our previous experience with residualizing labels.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In particular, the Fc variant demonstrated high renal and lower tumor uptakes (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B), consistent with its poor plasma stability (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S10">Supporting Information, Figure S10</a>). Administration of a basic amino acid such as lysine is a potential future strategy to lower the renal uptake associated with [<sup>125</sup>I]<b>6</b>, as it has been previously demonstrated to reduce renal tubular reabsorption of radiometal-labeled antibody fragments by neutralization of negative charges within the luminal tubular cell surface.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Despite the differences in both in vitro plasma stability (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S8–S10">Supporting Information, Figure S8–S10</a>) and in vivo radioactivity levels in tumor and kidneys (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B), no differences in plasma pharmacokinetics were observed among the three analogues of [<sup>125</sup>I]<b>6</b>–trastuzumab (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). Since albumin is the most abundant free thiol-containing plasma protein, maleimide exchange from trastuzumab to albumin is a likely scenario that is further supported by the appearance of radiolabeled albumin in the in vitro plasma stability study (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S10">Supporting Information, Figure S10</a>). The similar clearances of the HC, LC, and Fc analogues may reflect the fact that both immunoglobulins and albumin are protected from lysosomal degradation by the recycling receptor, the neonatal Fc receptor (FcRn), thereby promoting long serum half-lives in both cases.</div><div class="NLM_p">Although the present study utilized a THIOMAB version of trastuzumab with engineered cysteines,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> the maleimide derivative [<sup>125</sup>I]<b>6</b> has the potential to be conjugated to any thio-containing protein. Although THIOMAB labeling confers advantages such as excellent batch-to-batch reproducibility, it does require the production, time, and expense of locating an appropriate site to introduce the unpaired cysteine into an antibody. For those who prefer to work with conventional antibodies, established methods allow conjugation to hinge-region thiols made available through mild reduction. Alternatively, thiols may be introduced to any antibody through the ε-amino groups of lysine residues by use of a heterobifunctional linker.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Although the current approach offers several advantages over traditional radioiodination, further refinements could offer significant improvements. For instance, a future generation derivative of <b>6</b> allowing direct conjugation to lysines could additionally circumvent the problematic stability of thioether bonds which are highly dependent on the local electrostatic environment. This could improve label stability in vivo by eliminating losses to reverse Michael reactions and reducing overall renal uptake.</div><div class="NLM_p">The ability to conjugate a residualizing probe to thiols may be useful as a quantitative means to estimate cumulative drug delivery of antibody–drug conjugates in which chemotherapeutic drugs are conjugated using similar chemical methodologies.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In addition, a residualizing halogen probe could benefit the development of radioimmunotherapeutic agents labeled with the β-emitter, <sup>131</sup>I (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Table S1">Supporting Information, Table S1</a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Moreover, aside from its residualizing properties, the presence of DOTA in [<sup>125</sup>I]<b>6</b> lends the possibility of incorporating a metal to yield a multimodal probe. The DOTA chelate forms very kinetically stable complexes with larger +3 metal cations including the γ emitter <sup>111</sup>In, the low energy β/negatron (β<sup>–</sup>) emitter lutetium-177 (<sup>177</sup>Lu), the high energy β-emitter yttrium-90 (<sup>90</sup>Y), the positron (β<sup>+</sup>) emitter yttrium-86 (<sup>86</sup>Y),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and nonradioactive gadolinium (<sup>nat</sup>Gd) as a magnetic resonance spectroscopy contrast agent.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p last">We have developed a facile, tin-free, three-step synthetic route to a residualizing probe amenable to oxidative radioiodination and antibody labeling. In particular, the multicomponent Ugi reaction proved to be an efficient means for covalently linking our three desired components: a charged residualizing anchor, a phenol for iodine incorporation, and an activated linker for antibody conjugation. When conjugated to trastuzumab, a marketed anti-HER2 antibody, this novel probe demonstrated a 3–4-fold increase, relative to traditional tyrosine radioiodination, in tumor uptake at 3 days postinjection. Overall, our synthetic route to [<sup>125</sup>I]<b>6</b>, a novel residualizing radioiodine probe, is potentially useful for targeted radioimmunotherapy of cancer and may also benefit preclinical and translational research efforts for antibodies across multiple therapeutic areas.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13008" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13008" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> General Synthetic Methods</h3><div class="NLM_p">Unless otherwise noted, all reactions were run under an argon atmosphere in oven-dried glassware. Reactions were stirred using Teflon-coated magnetic stirrer bars. Reactions were monitored using thin layer silica gel chromatography (TLC) using 0.25 mm silica gel 60F plates with fluorescent indicator from EMD Chemicals. Plates were visualized under UV light. Products were purified via preparative reverse phase chromatography with UV detection at 254 nm using a gradient of 5–50% water/ACN (0.1% formic acid) at 70 mL/min in 10 min; the column was a Phenomenex Gemini-NX 10 μ C18 110 Å, 100 mm × 30.00 mm.</div><div class="NLM_p">Acetonitrile (CH<sub>3</sub>CN) and trifluoroacetic acid (TFA) were purchased from EMD Chemicals. Acetic acid (CH<sub>3</sub>COOH), ethyl isocyanoacetate, deuterated chloroform (CDCl<sub>3</sub>), and <i>N</i>-chlorosuccinimide (NCS) were purchased from Alpha Aesar. Chloroform (CHCl<sub>3</sub>) was purchased from Mallinckrodt. Methanol (MeOH) was purchased from J. T. Baker. 4-Hydroxyphenylacetic acid was purchased from Sigma-Aldrich. Lithium hydroxide monohydrate (LiOH·H<sub>2</sub>O) was purchased from Acros. Paraformaldehyde was purchased from TCI America. 2-Maleimidoethylamine hydrochloride was purchased from Oakwood Products. 2-Aminoethyl-monoamide-DOTA-tris(<i>t</i>-butyl ester) hydrobromide was purchased from Macrocyclics, Inc.</div><div class="NLM_p last">NMR spectra were acquired on either a Bruker 300 UltraShield (<sup>1</sup>H at 300 MHz, <sup>13</sup>C at 75 MHz) or a Bruker Avance II 400 (<sup>1</sup>H at 400 MHz, <sup>13</sup>C at 100 MHz) magnetic resonance spectrometer. <sup>1</sup>H chemical shifts are reported relative to the residual solvent peak (chloroform = 7.26 ppm) as follows: chemical shift (δ), (multiplicity, integration). <sup>13</sup>C chemical shifts are reported relative to the residual deuterated solvent <sup>13</sup>C signals (CDCl<sub>3</sub> = 77.16 ppm). High resolution LC-MS was performed using an Agilent 1200 series LC with PLRP-S, 1000 Å, column (50 mm × 2.1 mm, Varian Inc.) coupled to an Agilent 6220 Accurate-Mass TOF LC/MS mass spectrometer.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Chromatography</h3><div class="NLM_p">Reversed-phase radiochromatography was performed using an Agilent 1200 HPLC system coupled with a γ-RAM model 4 radioactive detector (LabLogic, formerly IN/US) running Laura version 4 software. A flow rate of 1 mL/min and a 30 min gradient of 5% A, 95% B to 95% A, 5% B were utilized where A = 0.1% trifluoroacetic acid (aq) and B = acetonitrile.</div><div class="NLM_p last">Size-exclusion radiochromatography was performed using an Agilent 1100 HPLC system coupled with a Raytest Gabi Star radioactive flow monitor running ChemStation software. The colum was a BioSep SEC S-3000, 300 mm × 7.8 mm, 5 μm (Phenomenex). The mobile phase was PBS, and the flow rate was 0.5 mL/min for 32 min (isocratic). The ChemStation analogue to digital converter was set to 25000 units/mV, peak width 2 s, slit 4 nM (Agilent Technologies). Radioactivity was detected with a raytest Gabi Star radiodetector in line with a standard Agilent 1100 HPLC module system. The data were collected using ChemStation for LC 3D Systems (revision B.01.03[204]).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Chemistry</h3><div class="NLM_p">Purities of nonradioactive compounds were assessed by UV monitoring during analytical RP-HPLC and found to be 100, 96.3, and 93.1% for <b>2</b>, <b>3</b>, and <b>4</b>, respectively (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, Figure S1">Supporting Information, Figure S1</a>).</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> Tri-<i>tert</i>-butyl-2,2′,2″-(10-(6-(2-(4-hydroxy-phenyl)acetyl)-2,8,11-trioxo-12-oxa-3,6,9-triaza-tetradecyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (<b>2</b>)</h4><div class="NLM_p last">To a 50 mL round-bottom flask were added the following: tri-<i>tert</i>-butyl-2,2′,2″-(10-(2-((2-aminoethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (0.5025 g, 0.724 mmol), paraformaldehyde (0.022 g, 0.724 mmol, 1 equiv), 4-hydroxyphenylacetic acid (0.110 g, 0.724 mmol, 1 equiv), and ethyl isocyanoacetate (0.081 g, 0.724 mmol, 1 equiv). The mixture was refluxed in 10 mL of MeOH under argon at 70 °C for 5 h. After solvent removal in vacuo, purification was achieved by preparative reverse-phase HPLC (gradient from 100% water containing 0.1% formic acid to 50% water with 0.1% formic acid/50% CH<sub>3</sub>CN). Lyophilization yielded a fluffy white hygroscopic solid; 58.3%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.87 (m, 1H), 8.48 (m, 1H), 7.03 (m, 2H), 6.81 (m, 2H), 6.34 (br s, 1H), 4.20–2.80 (m, 36H), 1.45 (s, 27H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 173.66, 173.23, 170.18, 169.99, 169.77, 169.65, 167.67, 156.60, 156.40, 130.36, 130.04, 125.58, 116.03, 115.81, 82.11, 82.02, 81.98, 81.93, 61.34, 61.24, 56.61, 55.81, 55.48, 52.81, 52.54, 52.06, 50.79, 50.58, 49.99, 49.74, 49.25, 48.77, 47.08, 41.43, 39.59, 37.97, 28.13, 14.16. HRMS (<i>m</i>/<i>z</i>): [M]<sup>+</sup> for C<sub>44</sub>H<sub>73</sub>N<sub>7</sub>O<sub>12</sub> 892.5395, found 892.5368.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> 2-(2-(2-(4-Hydroxyphenyl)-<i>N</i>-(2-(2-(4,7,10-tris(2-(<i>tert</i>-butoxy)-2-oxoethyl)-1,4,7,10-tetra-azacyclododecan-1-yl)acetamido)ethyl)acetamido) acetamido)acetic Acid (<b>3</b>)</h4><div class="NLM_p last">To a 50 mL round-bottom flask loaded with <b>2</b> (0.260 g, 0.291 mmol) was added LiOH·H<sub>2</sub>O (0.018 g, 0.437 mmol, 1.5 equiv), 6 mL of EtOH, and 2 mL of H<sub>2</sub>O. The reaction was stirred at room temperature for 12 h. After solvent removal in vacuo, purification was achieved by preparative reverse-phase HPLC (gradient from 100% 0.1% formic acid in water to 50% 0.1% formic acid in water/50% CH<sub>3</sub>CN). Lyophilization yielded a fluffy white hygroscopic solid; 65.5%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.34 (m, 1H), 8.57 (s, 1H), 7.02 (m, 2H), 6.86 (m, 2H), 5.82 (br s, 1H), 4.10–2.80 (m, 34H), 1.43 (s, 27H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 174.37, 173.76, 173.47, 170.14, 169.72, 169.24, 166.96, 156.90, 156.73, 130.30, 129.92, 124.58, 116.17, 115.92, 81.91, 81.86, 81.73, 56.55, 55.74, 52.98, 52.61, 52.25, 51.88, 51.84, 50.55, 49.16, 49.06, 47.69, 43.65, 43.63, 43.21, 39.51, 38.29, 37.84, 28.15. HRMS (<i>m</i>/<i>z</i>): [M]<sup>+</sup> for C<sub>42</sub>H<sub>69</sub>N<sub>7</sub>O<sub>12</sub> 864.5082, found 864.5082.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Tri-<i>tert</i>-butyl-2,2′,2″-(10-(14-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)-6-(2-(4-hydroxyphenyl)-acetyl)-2,8,11-trioxo-3,6,9,12-tetraazatetradecyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (<b>4</b>)</h4><div class="NLM_p last">To a 50 mL round-bottom flask loaded with <b>3</b> (0.113 g, 0.131 mmol) were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.038 g, 0.198 mmol, 1.5 equiv) and 2-maleimidoethylamine·HCl (0.035 g, 0.198 mmol, 1.5 equiv). The mixture was dissolved in 10 mL of CH<sub>3</sub>CN and stirred for 12 h at room temperature. After solvent removal in vacuo, purification was achieved by preparative reverse-phase HPLC (gradient from 100% 0.1% formic acid in water to 50% 0.1% formic acid in water/50% CH<sub>3</sub>CN). Lyophilization yielded a fluffy white hygroscopic solid; 41.4%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.02 (m, 1H), 8.07 (m, 1H), 7.01 (m, 2H), 6.79 (m, 2H), 6.65 (s, 1H), 4.23–2.80 (m, 34H), 1.45 (s, 27H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 173.67, 173.43, 171.04, 170.33, 170.26, 170.08, 169.94, 169.86, 168.64, 156.55, 156.47, 134.16, 130.33, 130.06, 125.57, 125.09, 115.95, 115.84, 81.93, 81.87, 81.81, 81.70, 56.63, 56.08, 55.90, 53.12, 52.01, 50.95, 49.79, 49.41, 49.39, 47.22, 43.44, 43.07, 39.58, 39.15, 38.25, 38.10, 37.74, 37.34, 28.17. HRMS (<i>m</i>/<i>z</i>): [M]<sup>+</sup> for C<sub>48</sub>H<sub>75</sub>N<sub>9</sub>O<sub>13</sub> 986.5562, found 986.5579. Purity was determined to be 93.1% by RP-HPLC.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Radiochemistry</h3><div class="NLM_p">A 5 μL aliquot of a 1 mg/mL solution of <b>4</b> in chloroform was evaporated to dryness by N<sub>2</sub> blowdown. The residue was dissolved in 100 μL of 0.1% CH<sub>3</sub>COOH (aq) followed by the addition of 3 μL (1 mCi) of Na<sup>125</sup>I in 0.1 N NaOH (aq) (Perkin-Elmer). The mixture was briefly vortexed and transferred to a glass test tube (Pierce) that is precoated with 1,3,4,6-tetrachloro-3α,6α-diphenylglucoluril (i.e., Iodogen). The radioiodination reaction was allowed to proceed without heating for 5 min with gentle intermittent shaking every 30 s on an Eppendorf thermomixer. The solution was transferred to a 5 mL glass vial and characterized by reversed-phase HPLC without purification. After solvent (i.e., water) removal by rotary evaporation, a 0.5 mL quantity of 95% trifluoroacetic acid/5% water was added followed by magnetic stirring for 2 h. Complete removal of acid by rotary evaporation was facilitated by successive additions of toluene in 250 μL aliquots followed by an overnight vacuum. To the residue, still in a 5 mL glass vial, was added 50 μL of phosphate-buffered saline, pH 7.4 (PBS). After a brief vortex, a pH strip was used to ensure that the pH was in the range of 6.5–7.5. This aqueous solution was quickly transferred to a freshly thawed 500 μg aliquot of deblocked ThioMab (thio-trastuzumab–HC-A114C (9.7 mg/mL), thio-trastuzumab–LC-V205C (15.1 mg/mL), or thio-trastuzumab–Fc-S396C (5 mg/mL) (Kabat numbering); Genentech, Inc.), followed by an additional 150 μL of PBS. These ThioMabs were engineered such that site-specific amino acid residues were mutated to cysteine.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> If necessary, the final pH was carefully adjusted to 7.5 by addition of 50 mM borate buffer pH 8.5 in 10 μL increments. The reaction mixture was constantly mixed at 350 rpm for 1 h, followed by addition of a 2-fold molar excess of iodoacetic acid to quench, for an additional 10 min, any remaining free thiols. The amount of radioactivity in these reactions ranged from 500 to 527 μCi, with the remainder of the initial 1 mCi presumably lost by sticking to vials and/or volatility during vacuum. The desired radioimmunoconjugates were purified using PBS-equilibrated NAP5 desalting columns (GE Healthcare) and analyzed by size exclusion chromatography. Final product activities were 255, 298, and 224 μCi for the HC-A114C, LC-V205C, and Fc-S396C variants, respectively. These corresponded to conjugation yields of 62, 55, and 50%.</div><div class="NLM_p last">Trastuzumab was radiolabeled by traditional means, through its tyrosine residues, with <sup>125</sup>I by a modified indirect Chizzonite method as previously described (840 μCi, 88% radiochemical yield).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Trastuzumab was conjugated to DOTA and radiolabeled with <sup>111</sup>In as previously described (1.19 mCi, 71% radiochemical yield).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> SDS-PAGE</h3><div class="NLM_p last">Samples of [<sup>125</sup>I]<b>6</b>-labeled thio-trastuzumab (LC-V205C, HC-A114C, and Fc-S396C) in phosphate buffered saline were analyzed by sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE). For the endoproteinase lys-C digestion, 2.5 μg of each antibody (5 × 10<sup>6</sup> cpm) was combined with 1 μL of reconstituted (0.5 mg/mL) lys-C (lysyl endopeptidase, Wako, cat. 129-02541) and incubated at pH 8 for 1 h at 37 °C. Following the incubation, the antibodies were combined with NuPAGE 4× LDS sample buffer (pH 8.4) (cat. NP0007) and water. For the dithiothreitol (DTT) reductions, 2.5 μg of each antibody was combined directly with sample buffer, DTT, and water. Antibodies from both preparations were incubated at 70 °C for 10 min, then applied to a NuPAGE 4–12% Bis-Tris gel (cat. NP0321BOX) with NuPAGE 1× MOPS SDS running buffer (cat. NP0001). The gel was stained with Coomassie Blue R250 dye. All NuPAGE reagents were obtained from Invitrogen, Corp. The gel was exposed for 5 min at room temperature to phosphor-imaging plates (YBIP 2025MS; Fuji Film Medical Systems, Inc.) and scanned using a Fuji Film BAS-5000 scanner (Fuji Film Medical Systems, Inc.) to obtain digital images of the radioactivity in the gel.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In Vitro Plasma Stability</h3><div class="NLM_p last">The LC-V205C, HC-A114C, and Fc-S396C (Kabat numbering) versions of [<sup>125</sup>I]<b>6</b>–trastuzumab were added to CD-1 mouse plasma (Bioreclamation, LLC) at 2 × 10<sup>7</sup> counts per min (cpm)/mL. The mixture was incubated at 37 °C with gentle rotation for 0, 6, 24, and 96 h. The samples were transferred to dry ice and stored at −70 °C until analysis by size-exclusion HPLC.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Biodistribution and Pharmacokinetics</h3><div class="NLM_p last">All animal studies were conducted in accordance with the guidelines of the American Association for Accreditation of Laboratory Animal Care and the Genentech Institutional Animal Care and Use Committee. The HER2-expressing (3+) human breast cancer cell line KPL-4, obtained in 2006 from Dr. J. Kurebayashi,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> was used in most studies. The cells were cultured in RPMI 1640 media plus 1% <span class="smallcaps smallerCapital">l</span>-glutamine with 10% FBS. The KPL-4 cell line was authenticated by short tandem repeat profiling (AMEL, X; CSF1PO, 11,13; D13S317, 12; D16S539, 12; D5S818, 11,13; D7S820, 9,10; TH01, 9; TPOX, 8; vWA, 14,19) and by single-nucleotide polymorphism genotyping. Both methods indicate that KPL-4 cells are unique when compared with a database of more than 1000 human cancer cell lines. C.B-17 Icr SCID (severe combined immunodeficient; Inbred) female mice (Charles River Laboratories), weighing between 20 and 25 g were inoculated in the right mammary fat pad with approximately 3 million KPL-4 cells in a 50:50 suspension of Hanks’ Buffered Salt Solution (Invitrogen) and Matrigel (BD Biosciences) in at most 0.2 mL/mouse. When mean tumor volume reached at least 250 mm<sup>3</sup>, mice received a single bolus intravenous injection via the tail vein containing <sup>111</sup>In-trastuzumab (5 μCi) together with either <sup>125</sup>I-trastuzumab (5 μCi) or <sup>125</sup>I-<b>6</b>-trastuzumab (5 μCi). The total protein doses associated with these radiolabeled trastuzumab tracers were 0.4 mg/kg for [<sup>125</sup>I]<b>6</b> (HC-A114C), 0.5 mg/kg for [<sup>125</sup>I]<b>6</b> (LC-V205C), 0.3 mg/kg for [<sup>125</sup>I]<b>6</b> (Fc-S396C), and 0.2 mg/kg for <sup>125</sup>I (tyrosine-labeled). To minimize thyroid sequestration of <sup>125</sup>I, 100 μL of 30 mg/mL of sodium iodide was intraperitoneally administered 1 and 24 h before dosing. Blood samples were collected at 5 min, 2 h, 1, 3, and 7 days postinjection via retroorbital bleed, with terminal tissue harvests performed at 3 and 7 days postinjection. Terminally collected samples included liver, spleen, kidneys, lungs, intestine (ileum), muscle (gastrocnemius), blood, and tumor. Tissues were counted for radioactivity using a 2480 Wizard<sup>2</sup> automatic gamma counter (Perkin-Elmer). Counts per minute values were used to calculate the percent of injected dose per gram of tissue (%ID/g) as previously described.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> SPECT-CT Imaging</h3><div class="NLM_p last">In vivo distribution was obtained by single photon emission computed tomography/X-ray computed tomography (SPECT-CT) using modification of previously reported methods.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Radiolabeling procedures were identical as for the biodistribution study. Doses of radiolabeled trastuzumab were 202 μCi for [<sup>125</sup>I]<b>6</b> (HC-A114C), 156 μCi for [<sup>125</sup>I]<b>6</b> (LC-V205C), 164 μCi for [<sup>125</sup>I]<b>6</b> (Fc-S396C), 414 μCi for <sup>125</sup>I (tyrosine-labeled), and 514 μCi for <sup>111</sup>In-DOTA. These doses were calculated such that each mouse would receive a protein dose of 10 mg/kg without adjustment in specific activity. Immediately after CT acquisition, SPECT images were acquired in a window centered at 35.5 keV for <sup>125</sup>I or on two 20% windows centered at the 173- and 247-keV photopeaks of <sup>111</sup>In using a high-resolution 5-pinhole collimator and a 5.5 cm radius of rotation. Mice were subsequently euthanized under sedation and tissues collected for whole-body autoradiography. SPECT quantitation was accomplished using Amira software (TGS).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Whole-Body Autoradiography</h3><div class="NLM_p last">KPL-4 tumor-bearing mice were assessed by quantitative whole-body autoradiography. The mice from the SPECT-CT imaging study were sacrificed after the final noninvasive imaging scan at three days postinjection. Animals were processed for whole-body cryosectioning, exposed, and imaged as described previously.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17"><a href="/doi/suppl/10.1021/jm401365h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">NMR spectra, chromatographic data, mass spectra, plasma stability profiles, renal metabolite analysis, and additional biodistribution and whole-body autoradiography data. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401365h/suppl_file/jm401365h_si_001.pdf">jm401365h_si_001.pdf (1.0 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm401365h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">C. Andrew Boswell</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c3a1acb0b4a6afafeda2ada7ba83a4a6ada6eda0acae"><span class="__cf_email__" data-cfemail="52303d2125373e3e7c333c362b1235373c377c313d3f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jan Marik</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Elowson</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noe A. Reyes</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheila Ulufatu</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniela Bumbaca</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor Yip</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eduardo E. Mundo</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas Majidy</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marjie Van Hoy</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Saritha N. Goriparthi</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony Trias</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Herman S. Gill</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon P. Williams</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jagath R. Junutula</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul J. Fielder</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leslie A. Khawli</span> - <span class="hlFld-Affiliation affiliation">Genentech Research and Early Development, 1 DNA Way MS 463A, South San Francisco 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors have held financial interest as employees of Genentech, a member of the Roche Group. Herceptin (trastuzumab) is marketed in the U.S. by Genentech and internationally by Roche.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1501e1540-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Helga Raab, Rachana Ohri, Emily Chan, Gillian Smelick, Joe Ware, Rami Hannoush, Michelle Schweiger, Jose Imperio, Kirsten Messick, Nicole Valle, Cynthia Young, Nina Ljumanovic, Bernadette Johnstone, and Shannon Stainton.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i19" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i19"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i20" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i20"> Abbreviations Used</h2><tr><td class="NLM_term">CD20</td><td class="NLM_def"><p class="first last">cluster of differentiation 20</p></td></tr><tr><td class="NLM_term">DOTA</td><td class="NLM_def"><p class="first last">1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid</p></td></tr><tr><td class="NLM_term">DTPA</td><td class="NLM_def"><p class="first last">diethylenetriaminepentaacetic acid</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">Fc</td><td class="NLM_def"><p class="first last">fragment crystallizable</p></td></tr><tr><td class="NLM_term">HC</td><td class="NLM_def"><p class="first last">heavy chain</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HIP</td><td class="NLM_def"><p class="first last">4-hydroxy-3-iodophenyl</p></td></tr><tr><td class="NLM_term">%ID/g</td><td class="NLM_def"><p class="first last">percentage of injected dose per g</p></td></tr><tr><td class="NLM_term">keV</td><td class="NLM_def"><p class="first last">kiloelectron volt</p></td></tr><tr><td class="NLM_term">LC</td><td class="NLM_def"><p class="first last">light chain</p></td></tr><tr><td class="NLM_term">MCC</td><td class="NLM_def"><p class="first last"><i>N</i>-maleimidomethyl)-cyclohexane-1-carbonyl</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immunodeficient</p></td></tr><tr><td class="NLM_term">SGMIB</td><td class="NLM_def"><p class="first last"><i>N</i>-succinimidyl 4-guanidinomethyl-3-iodobenzoate</p></td></tr><tr><td class="NLM_term">SIB</td><td class="NLM_def"><p class="first last"><i>N</i>-succinimidyl-3-iodobenzoate</p></td></tr><tr><td class="NLM_term">SIPMB</td><td class="NLM_def"><p class="first last"><i>N</i>-succinimidyl-3-[<sup>131</sup>I]iodo-4-phosphonomethylbenzoate</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06330" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06330" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Wu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0lgt67A1Krx6lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNature%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1137%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Davies, A. J.</span><span> </span><span class="NLM_article-title">Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3614</span><span class="NLM_x">–</span> <span class="NLM_lpage">3628</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3614-3628&author=A.+J.+Davies&title=Radioimmunotherapy+for+B-cell+lymphoma%3A+Y-90+ibritumomab+tiuxetan+and+I-131+tositumomab"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DA.%2BJ.%26atitle%3DRadioimmunotherapy%2520for%2520B-cell%2520lymphoma%253A%2520Y-90%2520ibritumomab%2520tiuxetan%2520and%2520I-131%2520tositumomab%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3614%26epage%3D3628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brechbiel, M. W.</span><span> </span><span class="NLM_article-title">Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view</span> <span class="citation_source-journal">Nucl. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">757</span><span class="NLM_x">–</span> <span class="NLM_lpage">778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1016%2Fj.nucmedbio.2007.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=17921028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFeiu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2007&pages=757-778&author=C.+A.+Boswellauthor=M.+W.+Brechbiel&title=Development+of+radioimmunotherapeutic+and+diagnostic+antibodies%3A+an+inside-out+view"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view</span></div><div class="casAuthors">Boswell, C. Andrew; Brechbiel, Martin W.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">757-778</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Only a handful of radiolabeled antibodies (Abs) have gained US Food and Drug Administration (FDA) approval for use in clin. oncol., including four immunodiagnostic agents and two targeted radioimmunotherapeutic agents.  Despite the advent of nonimmunogenic Abs and the availability of a diverse library of radionuclides, progress beyond early Phase II radioimmunotherapy (RIT) studies in solid tumors has been marginal.  Furthermore, [18F]fluorodeoxyglucose continues to dominate the mol. imaging domain, underscored by a decade-long absence of any newly approved Ab-based imaging agent (none since 1996).  Why has the development of clin. successful Abs for RIT been limited to lymphoma What obstacles must be overcome to allow the FDA approval of immuno-positron emission tomog. (immuno-PET) imaging agents How can we address the unique challenges that have thus far prevented the introduction of Ab-based imaging agents and therapeutics for solid tumors Many poor decisions have been made regarding radiolabeled Abs, but useful insight can be gained from these mistakes.  The following review addresses the phys., chem., biol., clin., regulatory and financial limitations that impede the progress of this increasingly important class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWac-JAg4C47Vg90H21EOLACvtfcHk0lgt67A1Krx6lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFeiu77K&md5=8351453e5e8524c7146da9cc71641c71</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2007.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2007.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26aulast%3DBrechbiel%26aufirst%3DM.%2BW.%26atitle%3DDevelopment%2520of%2520radioimmunotherapeutic%2520and%2520diagnostic%2520antibodies%253A%2520an%2520inside-out%2520view%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2007%26volume%3D34%26spage%3D757%26epage%3D778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Vaidyanathan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalutsky, M. R.</span><span> </span><span class="NLM_article-title">A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: <i>N</i>-succinimidyl 4-guanidinomethyl-3-[<sup>131</sup>I]iodobenzoate ([<sup>131</sup>I]SGMIB)</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">438</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc0001490" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD3MXislKiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=428-438&author=G.+Vaidyanathanauthor=D.+J.+Affleckauthor=J.+Liauthor=P.+Welshauthor=M.+R.+Zalutsky&title=A+polar+substituent-containing+acylation+agent+for+the+radioiodination+of+internalizing+monoclonal+antibodies%3A+N-succinimidyl+4-guanidinomethyl-3-%5B131I%5Diodobenzoate+%28%5B131I%5DSGMIB%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Polar Substituent-Containing Acylation Agent for the Radioiodination of Internalizing Monoclonal Antibodies: N-Succinimidyl 4-Guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB)</span></div><div class="casAuthors">Vaidyanathan, Ganesan; Affleck, Donna J.; Li, Jean; Welsh, Phil; Zalutsky, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">428-438</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The objective of this study was to develop an acylation agent for the radioiodination of monoclonal antibodies that would maximize retention of the label in tumor cells following receptor- or antigen-mediated internalization.  The strategy taken was to add a polar substituent to the labeled arom. ring to impede transport of labeled catabolites across lysosomal and cell membranes after antibody degrdn.  Prepn. of unlabeled N-succinimidyl 4-guanidinomethyl-3-iodobenzoate (SGMIB) was achieved in six steps from 3-iodo-4-methylbenzoic acid.  Prepn. of 4-guanidinomethyl-3-[131I]iodobenzoic acid from the silicon precursor, 4-(N1,N2-bis-tert-butyloxycarbonyl)guanidinomethyl-3-trimethylsilylbenzoic acid proceeded in less than 5% radiochem. yield.  A more successful approach was to prep. [131I]SGMIB directly from the tin precursor, N-succinimidyl 4-(N1,N2-bis-tert-butyloxycarbonyl)guanidinomethyl-3-trimethylstannylbenzoate, which was achieved in 60-65% radiochem. yield.  A rapidly internalizing anti-epidermal growth factor receptor variant III antibody L8A4 was labeled using [131I]SGMIB in 65% conjugation efficiency and with preservation of immunoreactivity. Paired-label in vitro internalization assays demonstrated that the amt. of radioactivity retained in cells after internalization for L8A4 labeled with [131I]SGMIB was 3-4-fold higher than that for L8A4 labeled with 125I using either Iodogen or [125I]SIPC.  Catabolite assays documented that the increased retention of radioiodine in tumor cells for antibody labeled using [131I]SGMIB was due to pos. charged, low mol. wt. species.  These results suggest that [131I]SGMIB warrants further evaluation as a reagent for labeling internalizing antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTgKj6Gpbii7Vg90H21EOLACvtfcHk0lguOLXy-bgV2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXislKiu7g%253D&md5=65bb874502a26b04b761bbeca56416e3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fbc0001490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0001490%26sid%3Dliteratum%253Aachs%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DAffleck%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWelsh%26aufirst%3DP.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26atitle%3DA%2520polar%2520substituent-containing%2520acylation%2520agent%2520for%2520the%2520radioiodination%2520of%2520internalizing%2520monoclonal%2520antibodies%253A%2520N-succinimidyl%25204-guanidinomethyl-3-%255B131I%255Diodobenzoate%2520%2528%255B131I%255DSGMIB%2529%26jtitle%3DBioconjugate%2520Chem.%26date%3D2001%26volume%3D12%26spage%3D428%26epage%3D438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Shankar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidyanathan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalutsky, M. R.</span><span> </span><span class="NLM_article-title"><i>N</i>-Succinimidyl 3-[<sup>131</sup>I]iodo-4-phosphonomethylbenzoate ([<sup>131</sup>I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc025636p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlequw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=331-341&author=S.+Shankarauthor=G.+Vaidyanathanauthor=D.+Affleckauthor=P.+C.+Welshauthor=M.+R.+Zalutsky&title=N-Succinimidyl+3-%5B131I%5Diodo-4-phosphonomethylbenzoate+%28%5B131I%5DSIPMB%29%2C+a+negatively+charged+substituent-bearing+acylation+agent+for+the+radioiodination+of+peptides+and+mAbs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">N-Succinimidyl 3-[131I]Iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a Negatively Charged Substituent-Bearing Acylation Agent for the Radioiodination of Peptides and mAbs</span></div><div class="casAuthors">Shankar, Sriram; Vaidyanathan, Ganesan; Affleck, Donna; Welsh, Phillip C.; Zalutsky, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-341</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An important criterion in design of acylation agents for the radioiodination of internalizing monoclonal antibodies (mAbs) is to maximize the retention of radioiodine in the tumor following mAb intracellular processing.  We have previously shown that labeling methods that generate pos. charged catabolites have enhanced tumor retention.  Herein we have extended this strategy to investigate the potential utility of labeling internalizing mAbs with an acylation agent that yielded labeled catabolites that would be neg. charged at lysosomal pH.  The neg. charged acylation agent, N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), was prepd. from its tin precursor, N-succinimidyl 4-di-tert-butylphosphonomethyl-3-trimethylstannylbenzoate (tBu-SPMTB), in 40% radiochem. yield.  The free acid, 3-[131I]iodo-4-phosphonomethylbenzoic acid ([131I]IPMBA), was also prepd. from the corresponding precursor, 4-di-tert-butylphosphonomethyl-3-trimethylstannylbenzoic acid (tBu-PMTBA), in 80% radiochem. yield.  The rapidly internalizing mAb L8A4 was conjugated to [131I]SIPMB in 25-40% yield with preservation of its immunoreactivity.  Internalization and processing in the U87ΔEGFR glioma cell line was studied in a paired label format with L8A4 labeled with 125I using the Iodogen method.  Retention of initially bound radioactivity in these cells at 24 h from [131I]SIPMB-labeled mAb was approx. 6-fold higher than that for directly labeled mAb.  Catabolite anal. demonstrated that this difference reflected an order of magnitude higher retention of low mol. wt. species in these cells.  The [131I]SIPMB-L8A4 conjugate was intact over the first 2 h; thereafter, lysine-[131I]SIPMB was the predominant catabolite.  In contrast, L8A4 labeled using Iodogen rapidly gave rise to mono-[125I]iodotyrosine within 2 h, which then cleared rapidly from the cells.  These results suggest that SIPMB could be a potent candidate for labeling internalizing mAbs and warrant further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRVCKOZlLgRLVg90H21EOLACvtfcHk0lguOLXy-bgV2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlequw%253D%253D&md5=0b1303531683396585a47d8a5f969089</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fbc025636p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc025636p%26sid%3Dliteratum%253Aachs%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DAffleck%26aufirst%3DD.%26aulast%3DWelsh%26aufirst%3DP.%2BC.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26atitle%3DN-Succinimidyl%25203-%255B131I%255Diodo-4-phosphonomethylbenzoate%2520%2528%255B131I%255DSIPMB%2529%252C%2520a%2520negatively%2520charged%2520substituent-bearing%2520acylation%2520agent%2520for%2520the%2520radioiodination%2520of%2520peptides%2520and%2520mAbs%26jtitle%3DBioconjugate%2520Chem.%26date%3D2003%26volume%3D14%26spage%3D331%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Vaidyanathan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalutsky, M. R.</span><span> </span><span class="NLM_article-title">SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6929</span><span class="NLM_x">–</span> <span class="NLM_lpage">6939</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=6929-6939&author=G.+Vaidyanathanauthor=B.+J.+Whiteauthor=D.+J.+Affleckauthor=X.+G.+Zhaoauthor=P.+C.+Welshauthor=D.+McDougaldauthor=J.+Choiauthor=M.+R.+Zalutsky&title=SIB-DOTA%3A+a+trifunctional+prosthetic+group+potentially+amenable+for+multi-modal+labeling+that+enhances+tumor+uptake+of+internalizing+monoclonal+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DWhite%26aufirst%3DB.%2BJ.%26aulast%3DAffleck%26aufirst%3DD.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%2BG.%26aulast%3DWelsh%26aufirst%3DP.%2BC.%26aulast%3DMcDougald%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26atitle%3DSIB-DOTA%253A%2520a%2520trifunctional%2520prosthetic%2520group%2520potentially%2520amenable%2520for%2520multi-modal%2520labeling%2520that%2520enhances%2520tumor%2520uptake%2520of%2520internalizing%2520monoclonal%2520antibodies%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D6929%26epage%3D6939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumbaca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielder, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawli, L. A.</span><span> </span><span class="NLM_article-title">Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations</span> <span class="citation_source-journal">AAAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1208%2Fs12248-012-9374-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=22648903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFWit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=612-618&author=C.+A.+Boswellauthor=D.+Bumbacaauthor=P.+J.+Fielderauthor=L.+A.+Khawli&title=Compartmental+tissue+distribution+of+antibody+therapeutics%3A+experimental+approaches+and+interpretations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations</span></div><div class="casAuthors">Boswell, C. Andrew; Bumbaca, Daniela; Fielder, Paul J.; Khawli, Leslie A.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">612-618</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Monoclonal antibodies have provided many validated and potential new therapeutic candidates for various diseases encompassing the realms of neurol., ophthalmol., immunol., and esp. oncol.  The mechanism of action for these biol. mols. typically involves specific binding to a sol. ligand or cell surface protein in order to block or alter a mol. pathway, induce a desired cellular response, or deplete a target cell.  Many antigens reside within the interstitial space, the fluid-filled compartment that lies between the outer endothelial vessel wall and the plasma membranes of cells.  This mini-review examines the concepts relevant to the kinetics and behavior of antibodies within the interstitium with a special emphasis on radiometric measurement of quant. pharmacol.  Mol. probes are discussed to outline chem. techniques, selection criteria, data interpretation, and relevance to the study of antibody pharmacokinetics.  The importance of studying the tissue uptake of antibodies at a compartmental level is highlighted, including a brief overview of receptor occupancy and its interpretation in radiotracer studies.  Exptl. methods for measuring the spatial compn. of tissues are examd. in terms of relative vascular, interstitial, and cellular vols. using solid tumors as a representative example.  Exptl. methods and physiol. based pharmacokinetic modeling are introduced as distinct approaches to distinguish between free and bound fractions of interstitial antibody.  Overall, the review outlines the available methods for pharmacokinetic measurements of antibodies and physiol. measurements of the compartments that they occupy, while emphasizing that such approaches may not fully capture the complexities of dynamic, heterogeneous tumors and other tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8CMde9lWmd7Vg90H21EOLACvtfcHk0lgBApHitGYGqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFWit7c%253D&md5=aba3c854ae7af154dff08f3c0365671c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1208%2Fs12248-012-9374-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-012-9374-1%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26aulast%3DBumbaca%26aufirst%3DD.%26aulast%3DFielder%26aufirst%3DP.%2BJ.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26atitle%3DCompartmental%2520tissue%2520distribution%2520of%2520antibody%2520therapeutics%253A%2520experimental%2520approaches%2520and%2520interpretations%26jtitle%3DAAAPS%2520J.%26date%3D2012%26volume%3D14%26spage%3D612%26epage%3D618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wilbur, D. S.</span><span> </span><span class="NLM_article-title">Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling</span> <span class="citation_source-journal">Bioconjugate Chem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc00018a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A280%3ADyaK3s%252FpvFWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1992&pages=433-470&author=D.+S.+Wilbur&title=Radiohalogenation+of+proteins%3A+an+overview+of+radionuclides%2C+labeling+methods%2C+and+reagents+for+conjugate+labeling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling</span></div><div class="casAuthors">Wilbur D S</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">433-70</span>
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    </div><div class="casAbstract">Direct labeling of proteins with radionuclides of iodine will continue to be the method of choice to answer questions addressed in many future studies.  However, it seems likely that a increasing number of applications of radiohalogenated proteins will require, or benefit from, conjugate labeling.  While many radiohalogen conjugates have been studied, a large proportion of them have only undergone preliminary studies to date, leaving a question of their overall utility.  Phenolic conjugates give good radioiodination labeling yields, but mixtures of radiohalogenated products and problems with in vivo stability can be expected.  This fact, along with the fact that phenolic compounds do not have a general application to radiohalogens, makes them less attractive than other alternatives.  Radiohalogen labeling through the use of organometallic intermediates has proven to be facile, resulting in high yields of high specific activity labeled small-molecule conjugates.  Although the choice of which organometallic intermediate to use may depend somewhat on the radionuclide employed, arylstannanes appear to have the most general applicability.  Fluorine-18 labeling of small-molecule conjugates has been best accomplished by ipso aromatic nucleophilic substitution (exchange) reactions.  Radiohalogenated small molecules have been prepared which can be conjugated with specific functional groups (e.g. amines, sulfhydryl groups, and carbohydrates) or conjugated nonspecifically with groups in the proximity of the conjugate when it is photolyzed.  On the basis of previous studies, good conjugation yields (i.e. 60-90%) can be expected for reactions with specific groups, whereas low yields (i.e. 1-5%) can be expected for conjugations with reactive nitrenes and carbenes.  However, recent developments in the chemistry of conjugates that produce nitrenes and carbenes will likely improve the radiolabeling yields.  There have been too few comparative studies to readily assess which is the best approach to take when beginning a study involving radiohalogenation of a protein or peptide.  However, it is clear that radiohalogenated conjugates of proteins can offer an advantage over direct labeling in that conjugates may be designed which provide some control over in vivo stability and secondary distribution of metabolites.  Conjugates can be prepared which are designed to utilize in vivo biochemical processes to release a radiohalogenated small molecule from a tissue (i.e. kidney or liver) or retain the radioactivity at the target tissue (e.g. tumor).  Aside from the designing of conjugates with linking molecules for desired biological effects, the ultimate future goal for the radiolabeling chemical should be to prepare protein conjugates which can be radiohalogenated in a single one-step procedure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUoGk4A6rPKcAKB7Fa-xrUfW6udTcc2eanFWwF0uo59bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FpvFWktA%253D%253D&md5=a54a3d73963329ff4c62d93b41b4f032</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fbc00018a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc00018a001%26sid%3Dliteratum%253Aachs%26aulast%3DWilbur%26aufirst%3DD.%2BS.%26atitle%3DRadiohalogenation%2520of%2520proteins%253A%2520an%2520overview%2520of%2520radionuclides%252C%2520labeling%2520methods%252C%2520and%2520reagents%2520for%2520conjugate%2520labeling%26jtitle%3DBioconjugate%2520Chem%26date%3D1992%26volume%3D3%26spage%3D433%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Nayak, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brechbiel, M. W.</span><span> </span><span class="NLM_article-title">Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc800299f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=825-841&author=T.+K.+Nayakauthor=M.+W.+Brechbiel&title=Radioimmunoimaging+with+longer-lived+positron-emitting+radionuclides%3A+potentials+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges</span></div><div class="casAuthors">Nayak, Tapan K.; Brechbiel, Martin W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">825-841</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Radioimmunoimaging and therapy has been an area of interest for several decades.  Steady progress has been made toward clin. translation of radiolabeled monoclonal antibodies for diagnosis and treatment of diseases.  Tremendous advances have been made in imaging technologies such as positron emission tomog. (PET).  However, these advances have so far eluded routine translation into clin. radioimmunoimaging applications due to the mismatch between the short half-lives of routinely used positron-emitting radionuclides such as 18F vs. the pharmacokinetics of most intact monoclonal antibodies of interest.  The lack of suitable positron-emitting radionuclides that match the pharmacokinetics of intact antibodies has generated interest in exploring the use of longer-lived positron emitters that are more suitable for radioimmunoimaging and dosimetry applications with intact monoclonal antibodies.  In this review, we examine the opportunities and challenges of radioimmunoimaging with select longer-lived positron-emitting radionuclides such as 124I, 89Zr, and 86Y with respect to radionuclide prodn., ease of radiolabeling intact antibodies, imaging characteristics, radiation dosimetry, and clin. translation potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHIpatPkW8rLVg90H21EOLACvtfcHk0lgBApHitGYGqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVWktA%253D%253D&md5=643de8bbc974fd0c1de9dd7360257a09</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fbc800299f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800299f%26sid%3Dliteratum%253Aachs%26aulast%3DNayak%26aufirst%3DT.%2BK.%26aulast%3DBrechbiel%26aufirst%3DM.%2BW.%26atitle%3DRadioimmunoimaging%2520with%2520longer-lived%2520positron-emitting%2520radionuclides%253A%2520potentials%2520and%2520challenges%26jtitle%3DBioconjugate%2520Chem.%26date%3D2009%26volume%3D20%26spage%3D825%26epage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Shih, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diril, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattes, M. J.</span><span> </span><span class="NLM_article-title">The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">899</span><span class="NLM_x">–</span> <span class="NLM_lpage">908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=8176479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK2cXlt1yqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1994&pages=899-908&author=L.+B.+Shihauthor=S.+R.+Thorpeauthor=G.+L.+Griffithsauthor=H.+Dirilauthor=G.+L.+Ongauthor=H.+J.+Hansenauthor=D.+M.+Goldenbergauthor=M.+J.+Mattes&title=The+processing+and+fate+of+antibodies+and+their+radiolabels+bound+to+the+surface+of+tumor+cells+in+vitro%3A+a+comparison+of+nine+radiolabels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels</span></div><div class="casAuthors">Shih, Lisa B.; Thorpe, Suzanne R.; Griffiths, Gary L.; Diril, Habibe; Ong, Gaik Lin; Hansen, Hans J.; Goldenberg, David M.; Mattes, M. Jules</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">899-908</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    </div><div class="casAbstract">Processing radiolabeled degrdn. products is the key factor affecting retention of antibodies within the cell.  In this study, the authors have analyzed the processing of antibodies labeled in nine different ways.  Antibodies were labeled with three different radioisotopes and seven different forms of 125I.  Eight of the radiolabels (except 188Re) were conjugated to the same antibody, MA103, and tested on the renal carcinoma cell line SK-RC-18 and/or the ovarian carcinoma cell line SK-OV-6.  Rhenium conjugation utilized the antibody RS7, the target cell line ME180 and three of the other radiolabels were also tested with this antibody-target cell combination for comparison.  Iodine conjugated to antibodies by conventional methods was rapidly released from the cell after antibody catabolism.  In contrast, iodinated moieties, such as dilactitol-tyramine and inulintyramine were retained within cells four to five times longer.  The use of radiolabels that are trapped within cells after antibody catabolism can potentially increase the dose of radiation delivered to the tumor, from the same amt. of radioactivity deposited by a factor of four or five.  The prolonged retention of 111In relative to 125I is not due to deiodination of iodine conjugates, but rather to intracellular retention of catabolic products contg. 111In, perhaps within lysosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0_XPmaUYEBrVg90H21EOLACvtfcHk0lh-kFHzvix0Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlt1yqs78%253D&md5=f401ef5ffc86967a29cb58d3a3d6c377</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DL.%2BB.%26aulast%3DThorpe%26aufirst%3DS.%2BR.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DDiril%26aufirst%3DH.%26aulast%3DOng%26aufirst%3DG.%2BL.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DMattes%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520processing%2520and%2520fate%2520of%2520antibodies%2520and%2520their%2520radiolabels%2520bound%2520to%2520the%2520surface%2520of%2520tumor%2520cells%2520in%2520vitro%253A%2520a%2520comparison%2520of%2520nine%2520radiolabels%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1994%26volume%3D35%26spage%3D899%26epage%3D908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Perera, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoncu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johns, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pypaert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Old, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toomre, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A. M.</span><span> </span><span class="NLM_article-title">Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1099</span><span class="NLM_x">–</span> <span class="NLM_lpage">1110</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=1099-1110&author=R.+M.+Pereraauthor=R.+Zoncuauthor=T.+G.+Johnsauthor=M.+Pypaertauthor=F.+T.+Leeauthor=I.+Mellmanauthor=L.+J.+Oldauthor=D.+K.+Toomreauthor=A.+M.+Scott&title=Internalization%2C+intracellular+trafficking%2C+and+biodistribution+of+monoclonal+antibody+806%3A+a+novel+anti-epidermal+growth+factor+receptor+antibody"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DR.%2BM.%26aulast%3DZoncu%26aufirst%3DR.%26aulast%3DJohns%26aufirst%3DT.%2BG.%26aulast%3DPypaert%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%2BT.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26aulast%3DToomre%26aufirst%3DD.%2BK.%26aulast%3DScott%26aufirst%3DA.%2BM.%26atitle%3DInternalization%252C%2520intracellular%2520trafficking%252C%2520and%2520biodistribution%2520of%2520monoclonal%2520antibody%2520806%253A%2520a%2520novel%2520anti-epidermal%2520growth%2520factor%2520receptor%2520antibody%26jtitle%3DNeoplasia%26date%3D2007%26volume%3D9%26spage%3D1099%26epage%3D1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Rogers, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franano, F. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connett, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M. J.</span><span> </span><span class="NLM_article-title">Identification of metabolites of <sup>111</sup>In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5714s</span><span class="NLM_x">–</span> <span class="NLM_lpage">5720s</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=5714s-5720s&author=B.+E.+Rogersauthor=F.+N.+Frananoauthor=J.+R.+Duncanauthor=W.+B.+Edwardsauthor=C.+J.+Andersonauthor=J.+M.+Connettauthor=M.+J.+Welch&title=Identification+of+metabolites+of+111In-diethylenetriaminepentaacetic+acid-monoclonal+antibodies+and+antibody+fragments+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DB.%2BE.%26aulast%3DFranano%26aufirst%3DF.%2BN.%26aulast%3DDuncan%26aufirst%3DJ.%2BR.%26aulast%3DEdwards%26aufirst%3DW.%2BB.%26aulast%3DAnderson%26aufirst%3DC.%2BJ.%26aulast%3DConnett%26aufirst%3DJ.%2BM.%26aulast%3DWelch%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520metabolites%2520of%2520111In-diethylenetriaminepentaacetic%2520acid-monoclonal%2520antibodies%2520and%2520antibody%2520fragments%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D5714s%26epage%3D5720s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Milenic, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brechbiel, M. W.</span><span> </span><span class="NLM_article-title">Antibody-targeted radiation cancer therapy</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=488-499&author=D.+E.+Milenicauthor=E.+D.+Bradyauthor=M.+W.+Brechbiel&title=Antibody-targeted+radiation+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilenic%26aufirst%3DD.%2BE.%26aulast%3DBrady%26aufirst%3DE.%2BD.%26aulast%3DBrechbiel%26aufirst%3DM.%2BW.%26atitle%3DAntibody-targeted%2520radiation%2520cancer%2520therapy%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D488%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Thorpe, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baynes, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chroneos, Z. C.</span><span> </span><span class="NLM_article-title">The design and application of residualizing labels for studies of protein catabolism</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1993&pages=399-405&author=S.+R.+Thorpeauthor=J.+W.+Baynesauthor=Z.+C.+Chroneos&title=The+design+and+application+of+residualizing+labels+for+studies+of+protein+catabolism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DS.%2BR.%26aulast%3DBaynes%26aufirst%3DJ.%2BW.%26aulast%3DChroneos%26aufirst%3DZ.%2BC.%26atitle%3DThe%2520design%2520and%2520application%2520of%2520residualizing%2520labels%2520for%2520studies%2520of%2520protein%2520catabolism%26jtitle%3DFASEB%2520J.%26date%3D1993%26volume%3D7%26spage%3D399%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Jefferis, R.</span><span> </span><span class="NLM_article-title">Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=356-362&author=R.+Jefferis&title=Recombinant+antibody+therapeutics%3A+the+impact+of+glycosylation+on+mechanisms+of+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJefferis%26aufirst%3DR.%26atitle%3DRecombinant%2520antibody%2520therapeutics%253A%2520the%2520impact%2520of%2520glycosylation%2520on%2520mechanisms%2520of%2520action%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D356%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattes, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newsome, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Improved iodine radiolabels for monoclonal antibody therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=12517786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvFKhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=111-118&author=R.+Steinauthor=S.+V.+Govindanauthor=M.+J.+Mattesauthor=S.+Chenauthor=L.+Reedauthor=G.+Newsomeauthor=B.+J.+McBrideauthor=G.+L.+Griffithsauthor=H.+J.+Hansenauthor=D.+M.+Goldenberg&title=Improved+iodine+radiolabels+for+monoclonal+antibody+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Improved Iodine Radiolabels for Monoclonal Antibody Therapy</span></div><div class="casAuthors">Stein, Rhona; Govindan, Serengulam V.; Mattes, M. Jules; Chen, Susan; Reed, Linda; Newsome, Guy; McBride, Bill J.; Griffiths, Gary L.; Hansen, Hans J.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A major disadvantage of 131iodine (I)-labeled monoclonal antibodies (MAbs) for radioimmunotherapy has been the rapid diffusion of iodotyrosine from target cells after internalization and catabolism of the radioiodinated MAbs.  We recently reported that a radioiodinated, diethylenetriaminepentaacetic acid-appended peptide, designated immunomedics' residualizing peptide 1 (IMP-R1), was a residualizing iodine label that overcame many of the limitations that had impeded the development of residualizing iodine for clin. use.  To det. the factors governing the therapeutic index of the labeled MAb, as well as the factors required for prodn. of radioiodinated MAb in high yield and with high specific activity, variations in the peptide structure of IMP-R1 were evaluated.  A series of radioiodinated, diethylenetriaminepentaacetic acid-appended peptide moieties (IMP-R1 through IMP-R8) that differed in overall hydrophilicity and charge were compared.  Radioiodinations of the peptides followed by conjugations to disulfide-reduced RS7 (an anti-epithelial glycoprotein-1 MAb) furnished radioimmunoconjugates in good overall incorporations, with immunoreactivities comparable to that of directly radioiodinated RS7.  Specific activities of up to 8 mCi/mg and yields > 80% have been achieved.  In vitro processing expts. showed marked increases in radioiodine retention with all of the adducts; radioiodine retention at 45 h was up to 86% greater in cells than with directly iodinated RS7.  Each of the 125I-peptide-RS7 conjugates was compared with 131I-RS7 (labeled by the chloramine-T method) in paired-label biodistribution studies in nude mice bearing human lung tumor xenografts.  All of the residualizing substrates exhibited significantly enhanced retention in tumor in comparison to directly radioiodinated RS7, but the nontarget uptakes differed significantly among the residualizing labels.  The best labels were IMP-R4 and IMP-R8, showing superior tumor-to-non-tumor ratios by virtue of high tumor uptake and retention and low normal organ uptake, as well as superior radiochem. properties.  The therapeutic efficacy of 131I-IMP-R4-RS7 was compared with that of conventionally 131I-labeled RS7 and 90yttrium-RS7 in the nude mice lung cancer model.  The therapeutic efficacy of 131I-IMP-R4-RS7 and 90yttrium-RS7 were equiv., and both agents yielded significantly improved control of tumor growth compared with conventional 131I-labeled RS7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0ALo7p9Ech7Vg90H21EOLACvtfcHk0ljmceu1B5AMLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvFKhtg%253D%253D&md5=45c0808b7d874b461ad5c20c828aec18</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DR.%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DMattes%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DReed%26aufirst%3DL.%26aulast%3DNewsome%26aufirst%3DG.%26aulast%3DMcBride%26aufirst%3DB.%2BJ.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DImproved%2520iodine%2520radiolabels%2520for%2520monoclonal%2520antibody%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D111%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Govindan, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattes, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karacay, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span> </span><span class="NLM_article-title">Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing <span class="smallcaps smallerCapital">d</span>-amino acids</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc980075g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK1MXptVSisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=231-240&author=S.+V.+Govindanauthor=M.+J.+Mattesauthor=R.+Steinauthor=B.+J.+McBrideauthor=H.+Karacayauthor=D.+M.+Goldenbergauthor=H.+J.+Hansenauthor=G.+L.+Griffiths&title=Labeling+of+monoclonal+antibodies+with+diethylenetriaminepentaacetic+acid-appended+radioiodinated+peptides+containing+d-amino+acids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid-Appended Radioiodinated Peptides Containing D-Amino Acids</span></div><div class="casAuthors">Govindan, Serengulam V.; Mattes, M. Jules; Stein, Rhona; McBride, Bill J.; Karacay, Habibe; Goldenberg, David M.; Hansen, Hans J.; Griffiths, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-240</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimal use of radioiodinated internalizing monoclonal antibodies (mAbs) for radio-immunotherapy necessitates the development of practical methods for increasing the level of retention of 131I in the tumor.  Lysosomally trapped ("residualizing") iodine radiolabels that have been previously designed are based mostly on carbohydrate-tyramine adducts, but these methods have drawbacks of low overall yields and/or high levels of mAb aggregation.  We have developed a method using thiol-reactive diethylenetriaminepentaacetic acid (DTPA)-peptide adducts wherein the peptides are assembled with one or more D-amino acids, including D-tyrosine.  Two such substrates, R-Gly-D-Tyr-D-Lys[1-(p-thiocarbonylaminobenzyl)DTPA], referred to as IMP-R1, and [R-D-Ala-D-Tyr-D-Tyr-D-Lys]2(CA-DTPA), referred to as IMP-R2, wherein R is 4-(N-maleimidomethyl)cyclohexane-1-carbonyl, were synthesized by prepg. functional group-protected peptides on a solid phase, selectively derivatizing the lysine side chain with 1-(p-isothiocyanatobenzyl)DTPA or DTPA dianhydride (CA-DTPA), deprotecting other functional groups, and finally derivatizing the peptide's N-terminus so it contained a maleimide group.  Radioiodinations of the peptides followed by conjugations to disulfide-reduced mAbs, carried out as a one-vial procedure, resulted in 32-89% overall yields, at specific activities of 1.8-11.1 mCi/mg, with less than 2% aggregation.  Two internalizing mAbs, LL2 (anti-CD 22 B-cell lymphoma mAb) and RS7 (an anti-adenocarcinoma mAb which targets EGP-1 antigen), labeled with this procedure exhibited a 2-3-fold better cellular retention in Ramos and Calu-3 tumor cell lines, in vitro, resp., compared to the same mAbs radioiodinated with the chloramine-T method.  The rationale for the new approach, syntheses, radiochem. and in vitro data are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7tvCUmZNebVg90H21EOLACvtfcHk0ljmceu1B5AMLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXptVSisg%253D%253D&md5=c4e4e629db5533b344268542e0c0ccd4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc980075g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc980075g%26sid%3Dliteratum%253Aachs%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DMattes%26aufirst%3DM.%2BJ.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DMcBride%26aufirst%3DB.%2BJ.%26aulast%3DKaracay%26aufirst%3DH.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26atitle%3DLabeling%2520of%2520monoclonal%2520antibodies%2520with%2520diethylenetriaminepentaacetic%2520acid-appended%2520radioiodinated%2520peptides%2520containing%2520d-amino%2520acids%26jtitle%3DBioconjugate%2520Chem.%26date%3D1999%26volume%3D10%26spage%3D231%26epage%3D240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ugi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fetzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbruckner, C.</span><span> </span><span class="NLM_article-title">Versuche mit Isonitrilen</span> <span class="citation_source-journal">Angew. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1959</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1959&pages=386&author=I.+Ugiauthor=R.+Meyrauthor=U.+Fetzerauthor=C.+Steinbruckner&title=Versuche+mit+Isonitrilen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUgi%26aufirst%3DI.%26aulast%3DMeyr%26aufirst%3DR.%26aulast%3DFetzer%26aufirst%3DU.%26aulast%3DSteinbruckner%26aufirst%3DC.%26atitle%3DVersuche%2520mit%2520Isonitrilen%26jtitle%3DAngew.%2520Chem.%26date%3D1959%26volume%3D71%26spage%3D386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Domling, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugi, I. I.</span><span> </span><span class="NLM_article-title">Multicomponent Reactions with Isocyanides</span> <span class="citation_source-journal">Angew. Chem., Int. Ed. Engl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3168</span><span class="NLM_x">–</span> <span class="NLM_lpage">3210</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=3168-3210&author=A.+Domlingauthor=I.+I.+Ugi&title=Multicomponent+Reactions+with+Isocyanides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DUgi%26aufirst%3DI.%2BI.%26atitle%3DMulticomponent%2520Reactions%2520with%2520Isocyanides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D2000%26volume%3D39%26spage%3D3168%26epage%3D3210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1038%2Fnbt.1480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=18641636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=925-932&author=J.+R.+Junutula&title=Site-specific+conjugation+of+a+cytotoxic+drug+to+an+antibody+improves+the+therapeutic+index"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span></div><div class="casAuthors">Junutula, Jagath R.; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D.; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S.; Lu, Yanmei; Meng, Y. Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C.; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin; Flagella, Kelly; Venook, Rayna; Ross, Sarajane; Spencer, Susan D.; Wong, Wai Lee; Lowman, Henry B.; Vandlen, Richard; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Mallet, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">925-932</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs.  However, conventional drug conjugation strategies yield heterogeneous conjugates with relatively narrow therapeutic index (max. tolerated dose/curative dose).  Using leads from the authors' previously described phage display-based method to predict suitable conjugation sites, the authors engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb Ig folding and assembly, or alter antigen binding.  When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models.  Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepd. by conventional approaches.  The favorable in vivo properties of the near-homogeneous compn. of this conjugate suggest that this strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4HIiPBABzRLVg90H21EOLACvtfcHk0ljmceu1B5AMLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D&md5=d55f59594fb6349d0337dfed2783e83c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1480%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DSite-specific%2520conjugation%2520of%2520a%2520cytotoxic%2520drug%2520to%2520an%2520antibody%2520improves%2520the%2520therapeutic%2520index%26jtitle%3DNature%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D925%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">DeNardo, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeNardo, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroger, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukis, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meares, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, S.</span><span> </span><span class="NLM_article-title">Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Clin. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.3816%2FCLM.2000.n.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A280%3ADC%252BD3MnlsVCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=118-126&author=G.+L.+DeNardoauthor=S.+J.+DeNardoauthor=R.+T.+O%E2%80%99Donnellauthor=L.+A.+Krogerauthor=D.+L.+Kukisauthor=C.+F.+Mearesauthor=D.+S.+Goldsteinauthor=S.+Shen&title=Are+radiometal-labeled+antibodies+better+than+iodine-131-labeled+antibodies%3A+comparative+pharmacokinetics+and+dosimetry+of+copper-67-%2C+iodine-131-%2C+and+yttrium-90-labeled+Lym-1+antibody+in+patients+with+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma</span></div><div class="casAuthors">DeNardo G L; DeNardo S J; O'Donnell R T; Kroger L A; Kukis D L; Meares C F; Goldstein D S; Shen S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-26</span>
        ISSN:<span class="NLM_cas:issn">1526-9655</span>.
    </div><div class="casAbstract">Radioimmunotherapy using radiolabeled monoclonal antibodies against tumor-associated antigens has been efficacious, particularly in the treatment of radiosensitive malignancies such as lymphoma.  Antilymphoma monoclonal antibody Lym-1, labeled with copper-67 ((67)Cu), iodine-131 ((131)I), or yttrium-90 ((90)Y), has been effective salvage therapy for patients with non-Hodgkin's lymphoma.  Although (131)I has had the dominant role in radioimmunotherapy thus far, several properties of radiometals are preferable.  A total of 70 patients with B-lymphocytic non-Hodgkin's lymphoma were studied using (67)Cu-2IT-BAT-Lym-1, (131)I-Lym-1, or (111)In-2IT-BAD-Lym-1.  Because (90)Y does not have good emissions for imaging, indium-111 ((111)In), its analogue, was used as a surrogate to estimate (90)Y-2IT-BAD-Lym-1 pharmacokinetics and radiation dosimetry.  Subsets of four patients in each group received (67)Cu- and (131)I-labeled Lym-1 or (111)In- and (131)I-labeled Lym-1, allowing direct comparisons of the radioimmunoconjugates.  Sequential blood samples and planar images were used to quantitate radioimmunoconjugate in tissues in order to determine pharmacokinetics and radiation dosimetry. (67)Cu-2IT-BAT-Lym-1 and (90)Y-2IT-BAD-Lym-1 exhibited higher cumulated activity concentrations and radiation absorbed doses per unit of administered radioactivity for tumors than did (131)I-Lym-1.  The mean tumor cumulated activity (area under the time-activity curve) concentrations per unit of administered radioactivity for (67)Cu-2IT-BAT-Lym-1, (131)I-Lym-1, and (90)Y-2IT-BAD-Lym-1 were 96.89, 33.96, and 43.42 GBq-s/GBq/g, respectively.  The mean tumor radiation doses from (67)Cu-2IT-BAT-Lym-1, (131)I-Lym-1, and (90)Y-2IT-BAD-Lym-1 were 2.5, 1.0, and 6.6 Gy/GBq, respectively, because (90)Y deposits more radiation per unit of administered radioactivity.  Per unit of administered radioactivity, radiation doses from (67)Cu-2IT-BAT-Lym-1 and (131)I-Lym-1 to normal tissues were similar except that the liver received a higher dose from (67)Cu-2IT-BAT-Lym-1 than from (131)I-Lym-1; radiation doses to normal tissues from (90)Y-2IT-BAD-Lym-1 were generally higher.  Consequently, the therapeutic indices (ratio of radiation doses to tumor and normal tissues) for (67)Cu-2IT-BAT-Lym-1, and less generally for (90)Y-2IT-BAD-Lym-1, were more favorable when compared to those for (131)I-Lym-1.  Data from the matched subsets of patients showed similar therapeutic indices to those for the groups of patients. (67)Cu-2IT-BAT-Lym-1 showed more potential than (131)I-Lym-1 or (90)Y-2IT-BAD-Lym-1 for non-Hodgkin's lymphoma radioimmunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQUuAA5tMMxoOWhZTslLrfffW6udTcc2eZOaKzr2ZBOpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnlsVCrug%253D%253D&md5=3ef62c67ce058435c12d377c68ae0b97</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3816%2FCLM.2000.n.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLM.2000.n.010%26sid%3Dliteratum%253Aachs%26aulast%3DDeNardo%26aufirst%3DG.%2BL.%26aulast%3DDeNardo%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DR.%2BT.%26aulast%3DKroger%26aufirst%3DL.%2BA.%26aulast%3DKukis%26aufirst%3DD.%2BL.%26aulast%3DMeares%26aufirst%3DC.%2BF.%26aulast%3DGoldstein%26aufirst%3DD.%2BS.%26aulast%3DShen%26aufirst%3DS.%26atitle%3DAre%2520radiometal-labeled%2520antibodies%2520better%2520than%2520iodine-131-labeled%2520antibodies%253A%2520comparative%2520pharmacokinetics%2520and%2520dosimetry%2520of%2520copper-67-%252C%2520iodine-131-%252C%2520and%2520yttrium-90-labeled%2520Lym-1%2520antibody%2520in%2520patients%2520with%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DClin.%2520Lymphoma%26date%3D2000%26volume%3D1%26spage%3D118%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Sharkey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattes, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juweid, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22</span> <span class="citation_source-journal">Cancer Immunol. Immunother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1007%2Fs002620050371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=9191878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK2sXktl2iurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1997&pages=179-188&author=R.+M.+Sharkeyauthor=T.+M.+Behrauthor=M.+J.+Mattesauthor=R.+Steinauthor=G.+L.+Griffithsauthor=L.+B.+Shihauthor=H.+J.+Hansenauthor=R.+D.+Blumenthalauthor=R.+M.+Dunnauthor=M.+E.+Juweidauthor=D.+M.+Goldenberg&title=Advantage+of+residualizing+radiolabels+for+an+internalizing+antibody+against+the+B-cell+lymphoma+antigen%2C+CD22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22</span></div><div class="casAuthors">Sharkey, Robert M.; Behr, Thomas M.; Mattes, M. Jules; Stein, Rhona; Griffiths, Gary L.; Shih, Lisa B.; Hansen, Hans J.; Blumenthal, Rosalyn D.; Dunn, Robert M.; Juweid, Malik E.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">LL2 is an anti-CD22 pan-B-cell monoclonal antibody which, when radiolabeled, has a high sensitivity for detecting B-cell, non-Hodgkin's lymphoma (NHL), as well as an antitumor efficacy in therapeutic applications.  The aim of this study was to det. whether intracellularly retained radiolabels have an advantage in the diagnosis and therapy of lymphoma with LL2.  In vitro studies showed that iodinated LL2 is intracellularly catabolized, with a rapid release of the radioiodine from the cell.  In contrast, residualizing radiolabels, such as radioactive metals, are retained intracellularly for substantially longer.  In vivo studies were performed using LL2-labeled with radioiodine by a non-residualizing (chloramine-T) or a residualizing method (dilactitol-tyramine, DLT), or with a radioactive metal (111In).  The biodistribution of a mixt. of 125I (non-residualizing chloramine-T compared to residualizing DLT), 111In-labeled LL2 murine IgG2a or its fragments [F(ab')2, Fab'], as well as its humanized, CDR-grafted form, was studied in nude mice bearing the RL human B-cell NHL cell line.  Radiation doses were calcd. from the biodistribution data according to the Medical International Radiation Dose scheme to assess the potential advantage for therapeutic applications.  At all assay times, tumor uptake was higher with the residualizing labels (i.e., 111In and DLT-125I) than with the non-residualizing iodine label.  For example, tumor/blood ratios of 111In-labeled IgG were 3.2-, 3.5- and 2.8-fold higher than for non-residualizing iodinated IgG on days 3, 7 and 14, resp.  Similar results were obtained for DLT-labeled IgG and fragments with residualized radiolabels.  Tumor/organ ratios also were higher with residualizing labels.  No significant differences in tumor, blood and organ uptake were obsd. between murine and humanized LL2.  The conventionally iodinated anti-CD20 antibody, 1F5, had tumor uptake values comparable to those of iodinated LL2, the uptake of both antibodies being strongly dependent on tumor size.  These data suggest that, with internalizing antibodies such as LL2, labeling with intracellularly retained isotopes has an advantage over released ones, which justifies further clin. trials with residualizing 111In-labeled LL2 for diagnosis, and residualizing 131I and 90Y labels for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUZUEOenuqNbVg90H21EOLACvtfcHk0lgYDhCletNbhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktl2iurY%253D&md5=72bc030830e660c544512669540ed4ad</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs002620050371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002620050371%26sid%3Dliteratum%253Aachs%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DBehr%26aufirst%3DT.%2BM.%26aulast%3DMattes%26aufirst%3DM.%2BJ.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DShih%26aufirst%3DL.%2BB.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DBlumenthal%26aufirst%3DR.%2BD.%26aulast%3DDunn%26aufirst%3DR.%2BM.%26aulast%3DJuweid%26aufirst%3DM.%2BE.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DAdvantage%2520of%2520residualizing%2520radiolabels%2520for%2520an%2520internalizing%2520antibody%2520against%2520the%2520B-cell%2520lymphoma%2520antigen%252C%2520CD22%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D1997%26volume%3D44%26spage%3D179%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Li, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bugaj, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erion, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. J.</span><span> </span><span class="NLM_article-title">DOTA-<span class="smallcaps smallerCapital">d</span>-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">728</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc015590k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFahurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=721-728&author=W.+P.+Liauthor=J.+S.+Lewisauthor=J.+Kimauthor=J.+E.+Bugajauthor=M.+A.+Johnsonauthor=J.+L.+Erionauthor=C.+J.+Anderson&title=DOTA-d-Tyr%281%29-octreotate%3A+a+somatostatin+analogue+for+labeling+with+metal+and+halogen+radionuclides+for+cancer+imaging+and+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">DOTA-D-Tyr1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy</span></div><div class="casAuthors">Li, Wen Ping; Lewis, Jason S.; Kim, Joonyoung; Bugaj, Joseph E.; Johnson, Michael A.; Erion, Jack L.; Anderson, Carolyn J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">721-728</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The goal of this study was to evaluate a somatostatin receptor ligand, DOTA-D-Tyr1-octreotate (DOTA-DY1-TATE), that has the chelator 1,4,7,10-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (DOTA) attached to the D-Tyr1 residue, allowing radiolabeling with both radiohalogens and radiometals.  A potential advantage of having a chelator attached to the Tyr1 residue is that halogen radiolabels may residualize or remain trapped in tumor cells rather than clear from the tumor.  DOTA-DY1-TATE was synthesized by solid-phase methods and radiolabeled with 61Cu, 64Cu, and 125I in high radiochem. purity and specific activity.  A competitive binding assay demonstrated that natCu-DOTA-DY1-TATE and DOTA-natI-DY1-TATE had comparable affinity to natIn-DTPA-OC in AR42J rat pancreatic tumor cells membranes.  61Cu-DOTA-DY1-TATE had a dissocn. const. (Kd) of 176.4 pM and a receptor concn. (Bmax) of 244.4 fmol/mg.  A tumor uptake of 1.515 %ID/g was detd. for 64Cu-DOTA-DY1-TATE and 0.814 %ID/g for DOTA-125I-DY1-TATE in AR42J tumor bearing Lewis rats at 1 h postinjection.  DOTA-125I-DY1-TATE remained in the tumor at a higher concn. out to 4 h postinjection, suggesting that the iodine may have residualized in the tumor cells.  MicroPET imaging of 64Cu-DOTA-DY1-TATE in AR42J tumor bearing rats and SCID mice at 2 h postinjection showed significant uptake and good contrast in the thigh tumors in the rat model and in the neck and thigh tumors of the mouse.  This study demonstrates that DOTA-DY1-TATE is a somatostatin analog that can be labeled with both metal and halogen radionuclides, and its 64Cu- and 125I-radiolabeled compds. showed somatostatin receptor-mediated uptake in normal and tumor tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonwvS8jTPGF7Vg90H21EOLACvtfcHk0lgYDhCletNbhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFahurk%253D&md5=30881b1597e077c40cfa8fb00ae78d38</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbc015590k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc015590k%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%2BP.%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DBugaj%26aufirst%3DJ.%2BE.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DErion%26aufirst%3DJ.%2BL.%26aulast%3DAnderson%26aufirst%3DC.%2BJ.%26atitle%3DDOTA-d-Tyr%25281%2529-octreotate%253A%2520a%2520somatostatin%2520analogue%2520for%2520labeling%2520with%2520metal%2520and%2520halogen%2520radionuclides%2520for%2520cancer%2520imaging%2520and%2520therapy%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26spage%3D721%26epage%3D728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Tei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gugliotta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avedano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovenzana, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Application of the Ugi four-component reaction to the synthesis of ditopic bifunctional chelating agents</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1039%2Fb907932g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=19830289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=4406-4414&author=L.+Teiauthor=G.+Gugliottaauthor=S.+Avedanoauthor=G.+B.+Giovenzanaauthor=M.+Botta&title=Application+of+the+Ugi+four-component+reaction+to+the+synthesis+of+ditopic+bifunctional+chelating+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Application of the Ugi four-component reaction to the synthesis of ditopic bifunctional chelating agents</span></div><div class="casAuthors">Tei, Lorenzo; Gugliotta, Giuseppe; Avedano, Stefano; Giovenzana, Giovanni B.; Botta, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4406-4414</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The Ugi four-component reaction (Ugi 4CR) of an amine, tri-tert-Bu 10-[H2N(CH2)nNHCOCH2]-1,4,7,10-tetraazadodecane-1,4,7-tricarboxylate [DOTAMA(OtBu)3CnNH2, 1, n = 2; 2, n = 6] with a carboxylic acid 10-[HO2C(CH2)5NHCOCH2]-1,4,7,10-tetraazadodecane-1,4,7-tricarboxylate [3, DOTAMA(OtBu)3C5CO2H], an aldehyde R1CHO and an isocyanide R2NC was exploited for the first time for prepn. of bifunctional ditopic chelators I [4-8, X = CO2tBu; M1, M2 = electron pair; R1 = H, C9H19, CbzNH(CH2)5; R2 = cyclohexyl, C18H37, CH2CO2Me; L1, L2, X = CO2H, R1 = H; R2 = cyclohexyl, C18H37, M = electron pair] and their gadolinium-yttrium complex [11, X = CO2-, M1 = Y, M2 = Gd; R1 = H, R2 = cyclohexyl] in a single synthetic step.  Variation of the components allows the insertion of another functional group into the α-acylaminoamide skeleton for further conjugation to biomols.  The optimal reaction conditions were found by using methanol as solvent and ultrasound irradn. at a power of 60 W (20 kHz) for 3 h.  The Gd(III) complexes of the dimeric ligands L1 and L2 were fully characterized in aq. media by relaxometric techniques with varying temp. and magnetic field strength.  The relaxivity of Gd2L1 and Gd2L2 (in the aggregated form), at 20 MHz and 310 K, are 5.6 and 20.0 mM-1 s-1, resp.  The enhanced value found for Gd2L2 indicates that this lipophilic complex forms micelles at concns. <0.1 mM.  Finally, the binding of Gd2L2 to human serum albumin (HSA) was investigated by proton relaxometry, and the affinity const. of the complex and the relaxivity of the macromol. adduct (rb1p = 38.1 mM-1 s-1; 20 MHz and 310 K) derived.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3QERuF4U7U7Vg90H21EOLACvtfcHk0lh_3UqWmJR78g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb7K&md5=09d6d929962527143300c0381d83d7f1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2Fb907932g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb907932g%26sid%3Dliteratum%253Aachs%26aulast%3DTei%26aufirst%3DL.%26aulast%3DGugliotta%26aufirst%3DG.%26aulast%3DAvedano%26aufirst%3DS.%26aulast%3DGiovenzana%26aufirst%3DG.%2BB.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DApplication%2520of%2520the%2520Ugi%2520four-component%2520reaction%2520to%2520the%2520synthesis%2520of%2520ditopic%2520bifunctional%2520chelating%2520agents%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26spage%3D4406%26epage%3D4414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Khawli, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, A. I.</span><span> </span><span class="NLM_article-title"><i>N</i>-(<i>m</i>-[<sup>125</sup>I]Iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies</span> <span class="citation_source-journal">Int. J. Radiat. Appl. Instrum. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1016%2F0883-2897%2892%2990113-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A280%3ADyaK38zjt1answ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1992&pages=289-295&author=L.+A.+Khawliauthor=A.+D.+van+den+Abbeeleauthor=A.+I.+Kassis&title=N-%28m-%5B125I%5DIodophenyl%29maleimide%3A+an+agent+for+high+yield+radiolabeling+of+antibodies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies</span></div><div class="casAuthors">Khawli L A; van den Abbeele A D; Kassis A I</div><div class="citationInfo"><span class="NLM_cas:title">International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-95</span>
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    </div><div class="casAbstract">In an effort to radiolabel antibodies, N-(m-[125I]iodophenyl)maleimide (m-[125I]IPM) was prepared by the demetallation of an N-[m-tri-(n-butyl)stannylphenyl]maleimide intermediate.  The unlabeled intermediate was synthesized in greater than or equal to 75% yield using a palladium catalyzed reaction of hexabutylditin with m-bromoaniline, followed by reaction with maleic anhydride and ring annulation.  All products were confirmed by NMR and elemental analysis.  Labeling with 125I was carried out in a biphasic mixture containing chloramine-T (radiochemical yield greater than or equal to 70%).  Rabbit IgG modified with the heterobifunctional crosslinking agent N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) and bovine serum albumin were conjugated with m-[125I]IPM (yield: 40 and 80%, respectively).  In addition, m-[125I]IPM was conjugated to rabbit IgG subunits (HL) in 70% yield.  The in vitro stability of the radiolabeled proteins in serum showed less than 1% deiodination over 24 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmd7360MZz1xOk4JA3soTqfW6udTcc2eageiJpMnwWlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zjt1answ%253D%253D&md5=20828860ce798c22f74866ba325adde3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2F0883-2897%2892%2990113-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2897%252892%252990113-D%26sid%3Dliteratum%253Aachs%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3Dvan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DKassis%26aufirst%3DA.%2BI.%26atitle%3DN-%2528m-%255B125I%255DIodophenyl%2529maleimide%253A%2520an%2520agent%2520for%2520high%2520yield%2520radiolabeling%2520of%2520antibodies%26jtitle%3DInt.%2520J.%2520Radiat.%2520Appl.%2520Instrum.%2520B%26date%3D1992%26volume%3D19%26spage%3D289%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Shen, B. Q.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Conjugation site modulates the in vivo stability and therapeutic activity of antibody–drug conjugates</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1038%2Fnbt.2108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=22267010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=184-189&author=B.+Q.+Shen&title=Conjugation+site+modulates+the+in+vivo+stability+and+therapeutic+activity+of+antibody%E2%80%93drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span></div><div class="casAuthors">Shen, Ben-Quan; Xu, Keyang; Liu, Luna; Raab, Helga; Bhakta, Sunil; Kenrick, Margaret; Parsons-Reponte, Kathryn L.; Tien, Janet; Yu, Shang-Fan; Mai, Elaine; Li, Dongwei; Tibbitts, Jay; Baudys, Jakub; Saad, Ola M.; Scales, Suzie J.; McDonald, Paul J.; Hass, Philip E.; Eigenbrot, Charles; Nguyen, Trung; Solis, Willy A.; Fuji, Reina N.; Flagella, Kelly M.; Patel, Darshana; Spencer, Susan D.; Khawli, Leslie A.; Ebens, Allen; Wong, Wai Lee; Vandlen, Richard; Kaur, Surinder; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates.  To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge.  The highly solvent-accessible site rapidly lost conjugated thiol-reactive linkers in plasma owing to maleimide exchange with reactive thiols in albumin, free cysteine or glutathione.  In contrast, a partially accessible site with a pos. charged environment promoted hydrolysis of the succinimide ring in the linker, thereby preventing this exchange reaction.  The site with partial solvent-accessibility and neutral charge displayed both properties.  In a mouse mammary tumor model, the stability and therapeutic activity of the antibody conjugate were affected pos. by succinimide ring hydrolysis and neg. by maleimide exchange with thiol-reactive constituents in plasma.  Thus, the chem. and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkINkMwQTMFrVg90H21EOLACvtfcHk0lh_3UqWmJR78g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D&md5=c647fc5bdfe93dfdabb15ca40934837f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2108%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.%2BQ.%26atitle%3DConjugation%2520site%2520modulates%2520the%2520in%2520vivo%2520stability%2520and%2520therapeutic%2520activity%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DNature%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D184%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Kurebayashi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otsuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochizuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonoo, H.</span><span> </span><span class="NLM_article-title">Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">717</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1038%2Fsj.bjc.6690114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=10070858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK1MXhslCns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1999&pages=707-717&author=J.+Kurebayashiauthor=T.+Otsukiauthor=C.+K.+Tangauthor=M.+Kurosumiauthor=S.+Yamamotoauthor=K.+Tanakaauthor=M.+Mochizukiauthor=H.+Nakamuraauthor=H.+Sonoo&title=Isolation+and+characterization+of+a+new+human+breast+cancer+cell+line%2C+KPL-4%2C+expressing+the+Erb+B+family+receptors+and+interleukin-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6</span></div><div class="casAuthors">Kurebayashi, J.; Otsuki, T.; Tang, C. K.; Kurosumi, M.; Yamamoto, S.; Tanaka, K.; Mochizuki, M.; Nakamura, H.; Sonoo, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">707-717</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">A new human breast cancer cell line, KPL-4, was recently isolated from the malignant pleural effusion of a breast cancer patient with an inflammatory skin metastasis.  This cell line can be cultured under serum-free conditions and is tumorigenic in female athymic nude mice.  Flow cytometric anal. revealed the expression of Erb B-1, -2 and -3.  Dot blot hybridization showed a 15-fold amplification of the erb B-2.  Reverse transcription-polymerase chain reaction anal. showed a detectable level of mRNA expression of all the Erb B family receptors.  In addn., all the receptors were autophosphorylated under a serum-supplemented condition.  Unexpectedly, transplanted KPL-4 tumors induced cachexia of recipient mice.  A high concn. of interleukin-6 (IL-6) was detected in both the culture medium and the serum of mice.  The wt. of tumors significantly correlated with the serum IL-6 level.  The antiproliferative effect of a humanized anti-Erb B-2 monoclonal antibody, rhuMAbHER2, was investigated.  This antibody significantly inhibited the growth of KPL-4 cells in vitro but modestly in vivo.  Loss of mouse body wt. was partly reversed by rhuMAbHER2.  These findings suggest that KPL-4 cells may be useful in the development of new strategies against breast cancer overexpressing the Erb B family receptors and against IL-6-induced cachexia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnsnxu39EMvbVg90H21EOLACvtfcHk0ljP0ZmB7zo8gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslCns7k%253D&md5=37483c121356ef173a09e2ae3a3759f6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6690114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6690114%26sid%3Dliteratum%253Aachs%26aulast%3DKurebayashi%26aufirst%3DJ.%26aulast%3DOtsuki%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DC.%2BK.%26aulast%3DKurosumi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DMochizuki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DSonoo%26aufirst%3DH.%26atitle%3DIsolation%2520and%2520characterization%2520of%2520a%2520new%2520human%2520breast%2520cancer%2520cell%2520line%252C%2520KPL-4%252C%2520expressing%2520the%2520Erb%2520B%2520family%2520receptors%2520and%2520interleukin-6%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1999%26volume%3D79%26spage%3D707%26epage%3D717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Pastuskovas, C. V.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">752</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1158%2F1535-7163.MCT-11-0742-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=22222630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=752-762&author=C.+V.+Pastuskovas&title=Effects+of+anti-VEGF+on+pharmacokinetics%2C+biodistribution%2C+and+tumor+penetration+of+trastuzumab+in+a+preclinical+breast+cancer+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model</span></div><div class="casAuthors">Pastuskovas, Cinthia V.; Mundo, Eduardo E.; Williams, Simon P.; Nayak, Tapan K.; Ho, Jason; Ulufatu, Sheila; Clark, Suzanna; Ross, Sarajane; Cheng, Eric; Parsons-Reponte, Kathryn; Cain, Gary; Van Hoy, Marjie; Majidy, Nicholas; Bheddah, Sheila; dela Cruz Chuh, Josefa; Kozak, Katherine R.; Lewin-Koh, Nicholas; Nauka, Peter; Bumbaca, Daniela; Sliwkowski, Mark; Tibbitts, Jay; Theil, Frank-Peter; Fielder, Paul J.; Khawli, Leslie A.; Boswell, C. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">752-762</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Both human epidermal growth factor receptor 2 (HER-2/neu) and VEGF overexpression correlate with aggressive phenotypes and decreased survival among breast cancer patients.  Concordantly, the combination of trastuzumab (anti-HER2) with bevacizumab (anti-VEGF) has shown promising results in preclin. xenograft studies and in clin. trials.  However, despite the known antiangiogenic mechanism of anti-VEGF antibodies, relatively little is known about their effects on the pharmacokinetics and tissue distribution of other antibodies.  This study aimed to measure the disposition properties, with a particular emphasis on tumor uptake, of trastuzumab in the presence or absence of anti-VEGF.  Radiolabeled trastuzumab was administered alone or in combination with an anti-VEGF antibody to mice bearing HER2-expressing KPL-4 breast cancer xenografts.  Biodistribution, autoradiog., and single-photon emission computed tomog.-X-ray computed tomog. imaging all showed that anti-VEGF administration reduced accumulation of trastuzumab in tumors despite comparable blood exposures and similar distributions in most other tissues.  A similar trend was also obsd. for an isotype-matched IgG with no affinity for HER2, showing reduced vascular permeability to macromols.  Reduced tumor blood flow (P < 0.05) was obsd. following anti-VEGF treatment, with no significant differences in the other physiol. parameters measured despite immunohistochem. evidence of reduced vascular d.  In conclusion, anti-VEGF preadministration decreased tumor uptake of trastuzumab, and this phenomenon was mechanistically attributed to reduced vascular permeability and blood perfusion.  These findings may ultimately help inform dosing strategies to achieve improved clin. outcomes.  Mol Cancer Ther; 11(3); 752-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZzCP7G3uB07Vg90H21EOLACvtfcHk0ljP0ZmB7zo8gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisb8%253D&md5=9dceb9fe2573007c6aed664f6c4d8aa1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0742-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0742-T%26sid%3Dliteratum%253Aachs%26aulast%3DPastuskovas%26aufirst%3DC.%2BV.%26atitle%3DEffects%2520of%2520anti-VEGF%2520on%2520pharmacokinetics%252C%2520biodistribution%252C%2520and%2520tumor%2520penetration%2520of%2520trastuzumab%2520in%2520a%2520preclinical%2520breast%2520cancer%2520model%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D752%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Viola-Villegas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, R. P.</span><span> </span><span class="NLM_article-title">The coordination chemistry of 1,4,7,10-tetraazacyclododecane-<i>N,N</i>′<i>,N</i>″<i>,N</i>″-tetraacetic acid (H<sub>4</sub>DOTA): structural overview and analyses on structure–stability relationships</span> <span class="citation_source-journal">Coord. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">253</span><span class="NLM_x">, </span> <span class="NLM_fpage">1906</span><span class="NLM_x">–</span> <span class="NLM_lpage">1925</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=2009&pages=1906-1925&author=N.+Viola-Villegasauthor=R.+P.+Doyle&title=The+coordination+chemistry+of+1%2C4%2C7%2C10-tetraazacyclododecane-N%2CN%E2%80%B2%2CN%E2%80%B3%2CN%E2%80%B3-tetraacetic+acid+%28H4DOTA%29%3A+structural+overview+and+analyses+on+structure%E2%80%93stability+relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DViola-Villegas%26aufirst%3DN.%26aulast%3DDoyle%26aufirst%3DR.%2BP.%26atitle%3DThe%2520coordination%2520chemistry%2520of%25201%252C4%252C7%252C10-tetraazacyclododecane-N%252CN%25E2%2580%25B2%252CN%25E2%2580%25B3%252CN%25E2%2580%25B3-tetraacetic%2520acid%2520%2528H4DOTA%2529%253A%2520structural%2520overview%2520and%2520analyses%2520on%2520structure%25E2%2580%2593stability%2520relationships%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2009%26volume%3D253%26spage%3D1906%26epage%3D1925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Gnidehou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caillou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohayon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaniewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noel-Hudson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agnangji, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sezan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virion, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuy, C.</span><span> </span><span class="NLM_article-title">Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the recycling of iodide close to the thyroglobulin iodination site</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1574</span><span class="NLM_x">–</span> <span class="NLM_lpage">1576</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=1574-1576&author=S.+Gnidehouauthor=B.+Caillouauthor=M.+Talbotauthor=R.+Ohayonauthor=J.+Kaniewskiauthor=M.+S.+Noel-Hudsonauthor=S.+Morandauthor=D.+Agnangjiauthor=A.+Sezanauthor=F.+Courtinauthor=A.+Virionauthor=C.+Dupuy&title=Iodotyrosine+dehalogenase+1+%28DEHAL1%29+is+a+transmembrane+protein+involved+in+the+recycling+of+iodide+close+to+the+thyroglobulin+iodination+site"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGnidehou%26aufirst%3DS.%26aulast%3DCaillou%26aufirst%3DB.%26aulast%3DTalbot%26aufirst%3DM.%26aulast%3DOhayon%26aufirst%3DR.%26aulast%3DKaniewski%26aufirst%3DJ.%26aulast%3DNoel-Hudson%26aufirst%3DM.%2BS.%26aulast%3DMorand%26aufirst%3DS.%26aulast%3DAgnangji%26aufirst%3DD.%26aulast%3DSezan%26aufirst%3DA.%26aulast%3DCourtin%26aufirst%3DF.%26aulast%3DVirion%26aufirst%3DA.%26aulast%3DDupuy%26aufirst%3DC.%26atitle%3DIodotyrosine%2520dehalogenase%25201%2520%2528DEHAL1%2529%2520is%2520a%2520transmembrane%2520protein%2520involved%2520in%2520the%2520recycling%2520of%2520iodide%2520close%2520to%2520the%2520thyroglobulin%2520iodination%2520site%26jtitle%3DFASEB%2520J.%26date%3D2004%26volume%3D18%26spage%3D1574%26epage%3D1576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Auf Dem Brinke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesch, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohrle, J.</span><span> </span><span class="NLM_article-title">Re-examination of the subcellular localization of thyroxine 5′-deiodination in rat liver</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=1979&pages=273-279&author=D.+Auf+Dem+Brinkeauthor=R.+D.+Heschauthor=J.+Kohrle&title=Re-examination+of+the+subcellular+localization+of+thyroxine+5%E2%80%B2-deiodination+in+rat+liver"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAuf%2BDem%2BBrinke%26aufirst%3DD.%26aulast%3DHesch%26aufirst%3DR.%2BD.%26aulast%3DKohrle%26aufirst%3DJ.%26atitle%3DRe-examination%2520of%2520the%2520subcellular%2520localization%2520of%2520thyroxine%25205%25E2%2580%25B2-deiodination%2520in%2520rat%2520liver%26jtitle%3DBiochem.%2520J.%26date%3D1979%26volume%3D180%26spage%3D273%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Khawli, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, A. I.</span><span> </span><span class="NLM_article-title">Synthesis of <sup>125</sup>I labeled <i>N</i>-succinimidyl <i>p</i>-iodobenzoate for use in radiolabeling antibodies</span> <span class="citation_source-journal">Int. J. Radiat. Appl. Instrum. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1016%2F0883-2897%2889%2990146-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=2613529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK3cXktVKjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1989&pages=727-733&author=L.+A.+Khawliauthor=A.+I.+Kassis&title=Synthesis+of+125I+labeled+N-succinimidyl+p-iodobenzoate+for+use+in+radiolabeling+antibodies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of iodine-125-labeled N-succinimidyl p-iodobenzoate for use in radiolabeling antibodies</span></div><div class="casAuthors">Khawli, Leslie A.; Kassis, Amin I.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">727-33</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    </div><div class="casAbstract">A new method is reported for the synthesis of N-succinimidyl p-[125/127I]iodobenzoate (NS-p-IB) from N-succinimidyl p-(tributylstannyl)benzoate via an iodination-destannylation reaction.  The tin precursor was obtained in 70% overall yield from 4-BrC6H4COCl after a four-step synthesis.  The radiochem. yield of NS-p-[125I]IB was 75%.  Conjugation of NS-p-[125I]IB to rabbit IgG or bovine serum albumin gave yields of 52 and 60% resp.  In vitro the radiolabeled proteins in serum at 37° showed <1% deiodination by 24 h.  In vivo the stability of mouse IgG (MIgG) labeled with NS-p-[125I]IB was superior to MIgG radioiodinated in the presence of chloramine-T.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc3gxB4iZBArVg90H21EOLACvtfcHk0lhCMtK13SvQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktVKjtbg%253D&md5=c9756394cdbe4e8096f7a2de877431b2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2F0883-2897%2889%2990146-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2897%252889%252990146-3%26sid%3Dliteratum%253Aachs%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DKassis%26aufirst%3DA.%2BI.%26atitle%3DSynthesis%2520of%2520125I%2520labeled%2520N-succinimidyl%2520p-iodobenzoate%2520for%2520use%2520in%2520radiolabeling%2520antibodies%26jtitle%3DInt.%2520J.%2520Radiat.%2520Appl.%2520Instrum.%2520B%26date%3D1989%26volume%3D16%26spage%3D727%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Zalutsky, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, A. S.</span><span> </span><span class="NLM_article-title">Radiohalogenation of a monoclonal antibody using an <i>N</i>-succinimidyl 3-(tri-<i>n</i>-butylstannyl)benzoate intermediate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1446</span><span class="NLM_x">–</span> <span class="NLM_lpage">1450</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1988&pages=1446-1450&author=M.+R.+Zalutskyauthor=A.+S.+Narula&title=Radiohalogenation+of+a+monoclonal+antibody+using+an+N-succinimidyl+3-%28tri-n-butylstannyl%29benzoate+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26aulast%3DNarula%26aufirst%3DA.%2BS.%26atitle%3DRadiohalogenation%2520of%2520a%2520monoclonal%2520antibody%2520using%2520an%2520N-succinimidyl%25203-%2528tri-n-butylstannyl%2529benzoate%2520intermediate%26jtitle%3DCancer%2520Res.%26date%3D1988%26volume%3D48%26spage%3D1446%26epage%3D1450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2727</span><span class="NLM_x">–</span> <span class="NLM_lpage">2734</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1158%2F1078-0432.CCR-04-2100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=15814655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFKisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=2727-2734&author=R.+Steinauthor=S.+V.+Govindanauthor=M.+Hayesauthor=G.+L.+Griffithsauthor=H.+J.+Hansenauthor=I.+D.+Horakauthor=D.+M.+Goldenberg&title=Advantage+of+a+residualizing+iodine+radiolabel+in+the+therapy+of+a+colon+cancer+xenograft+targeted+with+an+anticarcinoembryonic+antigen+monoclonal+antibody"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody</span></div><div class="casAuthors">Stein, Rhona; Govindan, Serengulam V.; Hayes, Marianne; Griffiths, Gary L.; Hansen, Hans J.; Horak, Ivan D.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2727-2734</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A disadvantage of conventionally radioiodinated monoclonal antibodies (mAb) for cancer therapy is the short retention time of the radionuclide within target cells.  To address this issue, we recently developed a method in which radioiodine is introduced onto antibodies using an adduct consisting of a nonmetabolizable peptide attached to the aminopolycarboxylate diethylenetriaminepentaacetic acid, designated IMP-R4.  This adduct causes the radioiodine to become trapped in lysosomes following antibody catabolism.  Clin.-scale prodn. of 131I-IMP-R4-labeled antibodies is possible using a recently developed facile method.  The properties of 131I-IMP-R4-labeled anticarcinoembryonic antigen (CEA) humanized mAb hMN-14 were compared with the directly radioiodinated hMN-14 (131I-hMN-14) in CEA-expressing human colon cancer cell lines, LoVo and LS174T, and in nude mice bearing established LoVo tumor xenografts.  125I-IMP-R4-hMN-14 retention in the cell lines was significantly increased (61.5% after 3 days) compared with 125I-hMN-14.  In vivo, a significant improvement in tumor accretion of radiolabel was obtained using 131I-IMP-R4-hMN-14, which led to a marked improvement in therapeutic efficacy.  Eight weeks post-treatment, mean tumor vols. were 0.16±0.19 and 1.99±1.35 cm3 in mice treated with 131I-IMP-R4-hMN-14 and 131I-hMN-14, resp., with complete remissions obsd. in 27% of mice treated with 131I-IMP-R4-hMN-14 and none using 131I-hMN-14.  131I-IMP-R4-hMN-14 provides a significant therapeutic advantage in comparison to the conventionally 131I-labeled antibody.  The ability of this labeling method to lend itself to clin.-scale labeling, the broad applicability of a humanized anti-CEA mAb for CEA-expressing cancers, and the clin. benefits of radioimmunotherapy with anti-CEA mAb shown recently for small-vol. and minimal residual disease combine to make 131I-IMP-R4-hMN-14 a promising new agent for radioimmunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuHNIfXNJGybVg90H21EOLACvtfcHk0lhCMtK13SvQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFKisLg%253D&md5=3133b13294a6cfb96f3e1af623e5fd8a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2100%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DR.%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DHayes%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DHorak%26aufirst%3DI.%2BD.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DAdvantage%2520of%2520a%2520residualizing%2520iodine%2520radiolabel%2520in%2520the%2520therapy%2520of%2520a%2520colon%2520cancer%2520xenograft%2520targeted%2520with%2520an%2520anticarcinoembryonic%2520antigen%2520monoclonal%2520antibody%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D2727%26epage%3D2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Behr, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharkey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juweid, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3825</span><span class="NLM_x">–</span> <span class="NLM_lpage">3834</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=3825-3834&author=T.+M.+Behrauthor=R.+M.+Sharkeyauthor=M.+E.+Juweidauthor=R.+D.+Blumenthalauthor=R.+M.+Dunnauthor=G.+L.+Griffithsauthor=H.-J.+Bairauthor=F.+G.+Wolfauthor=W.+S.+Beckerauthor=D.+M.+Goldenberg&title=Reduction+of+the+renal+uptake+of+radiolabeled+monoclonal+antibody+fragments+by+cationic+amino+acids+and+their+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBehr%26aufirst%3DT.%2BM.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DJuweid%26aufirst%3DM.%2BE.%26aulast%3DBlumenthal%26aufirst%3DR.%2BD.%26aulast%3DDunn%26aufirst%3DR.%2BM.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DBair%26aufirst%3DH.-J.%26aulast%3DWolf%26aufirst%3DF.%2BG.%26aulast%3DBecker%26aufirst%3DW.%2BS.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DReduction%2520of%2520the%2520renal%2520uptake%2520of%2520radiolabeled%2520monoclonal%2520antibody%2520fragments%2520by%2520cationic%2520amino%2520acids%2520and%2520their%2520derivatives%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D3825%26epage%3D3834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferl, G. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mundo, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweiger, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theil, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielder, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawli, L. A.</span><span> </span><span class="NLM_article-title">Development and evaluation of a novel method for preclinical measurement of tissue vascular volume</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1848</span><span class="NLM_x">–</span> <span class="NLM_lpage">1857</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp100183k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVSmsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=1848-1857&author=C.+A.+Boswellauthor=G.+Z.+Ferlauthor=E.+E.+Mundoauthor=M.+G.+Schweigerauthor=J.+Marikauthor=M.+P.+Reichauthor=F.+P.+Theilauthor=P.+J.+Fielderauthor=L.+A.+Khawli&title=Development+and+evaluation+of+a+novel+method+for+preclinical+measurement+of+tissue+vascular+volume"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Evaluation of a Novel Method for Preclinical Measurement of Tissue Vascular Volume</span></div><div class="casAuthors">Boswell, C. Andrew; Ferl, Gregory Z.; Mundo, Eduardo E.; Schweiger, Michelle G.; Marik, Jan; Reich, Michael P.; Theil, Frank-Peter; Fielder, Paul J.; Khawli, Leslie A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1848-1857</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of clin. predictive models of disposition kinetics for antibody therapeutics is an ongoing pursuit in drug development.  To encourage translation of drug candidates from early research to clin. trials, clin. diagnostic agents may be used to characterize antibody disposition in physiol. relevant preclin. models.  TechneScan PYP was employed to measure tissue vascular vols. (Vv) in healthy mice.  Two methods of red blood cell (RBC) labeling were compared: a direct in vivo method that is analogous to a clin. blood pool imaging protocol, and an indirect method in which radiolabeled blood was transfused from donor mice into recipient mice.  The indirect method gave higher precision in RBC labeling yields, lower Vv values in most tissues, and lower 99mTc uptake in kidneys and bladder by single photon emission computed tomog. (SPECT) imaging relative to the direct method.  Furthermore, the relative influence of each method on the calcd. area under the first 7 days of the concn.-time curve (AUC0-7) of an IgG in nude mice was assessed using a physiol. based pharmacokinetic model.  The model was sensitive to the source of Vv values, whether obtained from the literature or measured by either method, when used to predict exptl. AUC0-7 values for radiolabeled trastuzumab in healthy murine tissues.  In summary, a novel indirect method for preclin. detn. of Vv offered higher precision in RBC labeling efficiency and lower renal uptake of 99mTc than the direct method.  In addn., these observations emphasize the importance of obtaining accurate physiol. parameter values for modeling antibody uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrngP-XJuxqWLVg90H21EOLACvtfcHk0liLcLdV0PvoqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVSmsL3L&md5=6fdc1d64b618a981fa9551e769eb9816</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fmp100183k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp100183k%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26aulast%3DFerl%26aufirst%3DG.%2BZ.%26aulast%3DMundo%26aufirst%3DE.%2BE.%26aulast%3DSchweiger%26aufirst%3DM.%2BG.%26aulast%3DMarik%26aufirst%3DJ.%26aulast%3DReich%26aufirst%3DM.%2BP.%26aulast%3DTheil%26aufirst%3DF.%2BP.%26aulast%3DFielder%26aufirst%3DP.%2BJ.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26atitle%3DDevelopment%2520and%2520evaluation%2520of%2520a%2520novel%2520method%2520for%2520preclinical%2520measurement%2520of%2520tissue%2520vascular%2520volume%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2010%26volume%3D7%26spage%3D1848%26epage%3D1857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody–drug conjugates in rats</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1994</span><span class="NLM_x">–</span> <span class="NLM_lpage">2004</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc200212a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GgtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=1994-2004&author=C.+A.+Boswell&title=Impact+of+drug+conjugation+on+pharmacokinetics+and+tissue+distribution+of+anti-STEAP1+antibody%E2%80%93drug+conjugates+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody-Drug Conjugates in Rats</span></div><div class="casAuthors">Boswell, C. Andrew; Mundo, Eduardo E.; Zhang, Crystal; Bumbaca, Daniela; Valle, Nicole R.; Kozak, Katherine R.; Fourie, Aimee; Chuh, Josefa; Koppada, Neelima; Saad, Ola; Gill, Herman; Shen, Ben-Quan; Rubinfeld, Bonnee; Tibbitts, Jay; Kaur, Surinder; Theil, Frank-Peter; Fielder, Paul J.; Khawli, Leslie A.; Lin, Kedan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1994-2004</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are designed to combine the exquisite specificity of antibodies to target tumor antigens with the cytotoxic potency of chemotherapeutic drugs.  In addn. to the general chem. stability of the linker, a thorough understanding of the relationship between ADC compn. and biol. disposition is necessary to ensure that the therapeutic window is not compromised by altered pharmacokinetics (PK), tissue distribution, and/or potential organ toxicity.  The six-transmembrane epithelial antigen of prostate 1 (STEAP1) is being pursued as a tumor antigen target.  To assess the role of ADC compn. in PK, we evaluated plasma and tissue PK profiles in rats, following a single dose, of a humanized anti-STEAP1 IgG1 antibody, a thio-anti-STEAP1 (ThioMab) variant, and two corresponding thioether-linked monomethylauristatin E (MMAE) drug conjugates modified through interchain disulfide cysteine residues (ADC) and engineered cysteines (TDC), resp.  Plasma PK of total antibody measured by ELISA revealed ∼45% faster clearance for the ADC relative to the parent antibody, but no apparent difference in clearance between the TDC and unconjugated parent ThioMab.  Total antibody clearances of the two unconjugated antibodies were similar, suggesting minimal effects on PK from cysteine mutation.  An ELISA specific for MMAE-conjugated antibody indicated that the ADC cleared more rapidly than the TDC, but total antibody ELISA showed comparable clearance for the two drug conjugates.  Furthermore, consistent with relative drug load, the ADC had a greater magnitude of drug deconjugation than the TDC in terms of free plasma MMAE levels.  Antibody conjugation had a noticeable, albeit minor, impact on tissue distribution with a general trend toward increased hepatic uptake and reduced levels in other highly vascularized organs.  Liver uptakes of ADC and TDC at 5 days postinjection were 2-fold and 1.3-fold higher, resp., relative to the unmodified antibodies.  Taken together, these results indicate that the degree of overall structural modification in anti-STEAP1-MMAE conjugates has a corresponding level of impact on both PK and tissue distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplvgyLOeqItbVg90H21EOLACvtfcHk0liLcLdV0PvoqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GgtbzJ&md5=1b084b2365da4d16525ec1f98454dcd1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbc200212a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc200212a%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26atitle%3DImpact%2520of%2520drug%2520conjugation%2520on%2520pharmacokinetics%2520and%2520tissue%2520distribution%2520of%2520anti-STEAP1%2520antibody%25E2%2580%2593drug%2520conjugates%2520in%2520rats%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D1994%26epage%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">An integrated approach to identify normal tissue expression of targets for antibody–drug conjugates: case study of TENB2</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">168</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1111%2Fj.1476-5381.2012.02138.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFOmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2013&pages=445-457&author=C.+A.+Boswell&title=An+integrated+approach+to+identify+normal+tissue+expression+of+targets+for+antibody%E2%80%93drug+conjugates%3A+case+study+of+TENB2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2</span></div><div class="casAuthors">Boswell, C. Andrew; Mundo, Eduardo E.; Firestein, Ron; Zhang, Crystal; Mao, Weiguang; Gill, Herman; Young, Cynthia; Ljumanovic, Nina; Stainton, Shannon; Ulufatu, Sheila; Fourie, Aimee; Kozak, Katherine R.; Fuji, Reina; Polakis, Paul; Khawli, Leslie A.; Lin, Kedan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">445-457</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose The success of antibody-drug conjugates (ADCs) depends on the therapeutic window rendered by the differential expression between normal and pathol. tissues.  The ability to identify and visualize target expression in normal tissues could reveal causes for target-mediated clearance obsd. in pharmacokinetic characterization.  TENB2 is a prostate cancer target assocd. with the progression of poorly differentiated and androgen-independent tumor types, and ADCs specific for TENB2 are candidate therapeutics.  The objective of this study was to locate antigen expression of TENB2 in normal tissues, thereby elucidating the underlying causes of target-mediated clearance.  Exptl. Approach A series of pharmacokinetics, tissue distribution and mass balance studies were conducted in mice using a radiolabeled anti-TENB2 ADC.  These data were complemented by non-invasive single photon emission computed tomog. - X-ray computed tomog. imaging and immunohistochem.  Key Results The intestines were identified as a saturable and specific antigen sink that contributes, at least in part, to the rapid target-mediated clearance of the anti-TENB2 antibody and its drug conjugate in rodents.  As a proof of concept, we also demonstrated the selective disposition of the ADC in a tumoral environment in vivo using the LuCaP 77 transplant mouse model.  High tumor uptake was obsd. despite the presence of the antigen sink, and antigen specificity was confirmed by antigen blockade.  Conclusions and Implications Our findings provide the anatomical location and biol. interpretation of target-mediated clearance of anti-TENB2 antibodies and corresponding drug conjugates.  Further investigations may be beneficial in addressing the relative contributions to ADC disposition from antigen expression in both normal and pathol. tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYaAS89AVP4bVg90H21EOLACvtfcHk0liV0GcWp0aFDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFOmsA%253D%253D&md5=9f430a3c4f18a7987f9398fd40c79ee5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02138.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02138.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26atitle%3DAn%2520integrated%2520approach%2520to%2520identify%2520normal%2520tissue%2520expression%2520of%2520targets%2520for%2520antibody%25E2%2580%2593drug%2520conjugates%253A%2520case%2520study%2520of%2520TENB2%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D168%26spage%3D445%26epage%3D457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 28 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Weijun Wei, Zachary T. Rosenkrans, Jianjun Liu, Gang Huang, Quan-Yong Luo, <span class="NLM_string-name hlFld-ContribAuthor">Weibo Cai</span>. </span><span class="cited-content_cbyCitation_article-title">ImmunoPET: Concept, Design, and Applications. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2020,</strong> <em>120 </em>
                                    (8)
                                     , 3787-3851. <a href="https://doi.org/10.1021/acs.chemrev.9b00738" title="DOI URL">https://doi.org/10.1021/acs.chemrev.9b00738</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.9b00738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.9b00738%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DImmunoPET%25253A%252BConcept%25252C%252BDesign%25252C%252Band%252BApplications%26aulast%3DWei%26aufirst%3DWeijun%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D13112019%26date%3D23032020%26volume%3D120%26issue%3D8%26spage%3D3787%26epage%3D3851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brendon E.  Cook</span>, <span class="hlFld-ContribAuthor ">Pierre  Adumeau</span>, <span class="hlFld-ContribAuthor ">Rosemery  Membreno</span>, <span class="hlFld-ContribAuthor ">Kathryn E.  Carnazza</span>, <span class="hlFld-ContribAuthor ">Christian  Brand</span>, <span class="hlFld-ContribAuthor ">Thomas  Reiner</span>, <span class="hlFld-ContribAuthor ">Brian J.  Agnew</span>, <span class="hlFld-ContribAuthor ">Jason S.  Lewis</span>, and <span class="hlFld-ContribAuthor ">Brian M.  Zeglis</span>  . </span><span class="cited-content_cbyCitation_article-title">Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2016,</strong> <em>27 </em>
                                    (8)
                                     , 1789-1795. <a href="https://doi.org/10.1021/acs.bioconjchem.6b00235" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.6b00235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.6b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.6b00235%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DPretargeted%252BPET%252BImaging%252BUsing%252Ba%252BSite-Specifically%252BLabeled%252BImmunoconjugate%26aulast%3DCook%26aufirst%3DBrendon%2BE.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D10052016%26date%3D24062016%26date%3D14072016%26date%3D17082016%26date%3D29062016%26volume%3D27%26issue%3D8%26spage%3D1789%26epage%3D1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian M.  Zeglis</span>, <span class="hlFld-ContribAuthor ">Charles B.  Davis</span>, <span class="hlFld-ContribAuthor ">Dalya  Abdel-Atti</span>, <span class="hlFld-ContribAuthor ">Sean D.  Carlin</span>, <span class="hlFld-ContribAuthor ">Aimei  Chen</span>, <span class="hlFld-ContribAuthor ">Robert  Aggeler</span>, <span class="hlFld-ContribAuthor ">Brian J.  Agnew</span>, and <span class="hlFld-ContribAuthor ">Jason S.  Lewis</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemoenzymatic Strategy for the Synthesis of Site-Specifically Labeled Immunoconjugates for Multimodal PET and Optical Imaging. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2014,</strong> <em>25 </em>
                                    (12)
                                     , 2123-2128. <a href="https://doi.org/10.1021/bc500499h" title="DOI URL">https://doi.org/10.1021/bc500499h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bc500499h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbc500499h%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DChemoenzymatic%252BStrategy%252Bfor%252Bthe%252BSynthesis%252Bof%252BSite-Specifically%252BLabeled%252BImmunoconjugates%252Bfor%252BMultimodal%252BPET%252Band%252BOptical%252BImaging%26aulast%3DZeglis%26aufirst%3DBrian%2BM.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D31102014%26date%3D21112014%26date%3D26112014%26date%3D17122014%26date%3D24112014%26volume%3D25%26issue%3D12%26spage%3D2123%26epage%3D2128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen J.  Archibald</span>  . </span><span class="cited-content_cbyCitation_article-title">Antibody Radiolabeling Techniques To Optimize Cellular Retention. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (23)
                                     , 9415-9417. <a href="https://doi.org/10.1021/jm401794v" title="DOI URL">https://doi.org/10.1021/jm401794v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401794v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401794v%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAntibody%252BRadiolabeling%252BTechniques%252BTo%252BOptimize%252BCellular%252BRetention%26aulast%3DArchibald%26aufirst%3DStephen%2BJ.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D19112013%26date%3D27112013%26date%3D12122013%26volume%3D56%26issue%3D23%26spage%3D9415%26epage%3D9417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hideto  Miyabe</span>. </span><span class="cited-content_cbyCitation_article-title">Aryne-Mediated Synthesis of Oxygen Heterocycles and Application to Cysteine-Selective Trapping. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2021,</strong> <em>102 </em>
                                    (1)
                                     , 3. <a href="https://doi.org/10.3987/REV-20-934" title="DOI URL">https://doi.org/10.3987/REV-20-934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/REV-20-934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FREV-20-934%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DAryne-Mediated%252BSynthesis%252Bof%252BOxygen%252BHeterocycles%252Band%252BApplication%252Bto%252BCysteine-Selective%252BTrapping%26aulast%3DMiyabe%26aufirst%3DHideto%26date%3D2021%26volume%3D102%26issue%3D1%26spage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Cai</span>, <span class="hlFld-ContribAuthor ">Victor  Yip</span>, <span class="hlFld-ContribAuthor ">M. Violet  Lee</span>, <span class="hlFld-ContribAuthor ">Sylvia  Wong</span>, <span class="hlFld-ContribAuthor ">Ola  Saad</span>, <span class="hlFld-ContribAuthor ">Shuguang  Ma</span>, <span class="hlFld-ContribAuthor ">Nina  Ljumanovic</span>, <span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Amrita V.  Kamath</span>, <span class="hlFld-ContribAuthor ">Ben-Quan  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of Tissue Distribution, Catabolism, and Elimination of an Anti–
              Staphylococcus aureus
              THIOMAB Antibody-Antibiotic Conjugate in Rats. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2020,</strong> <em>48 </em>
                                    (11)
                                     , 1161-1168. <a href="https://doi.org/10.1124/dmd.120.000092" title="DOI URL">https://doi.org/10.1124/dmd.120.000092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.120.000092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.120.000092%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DCharacterization%252Bof%252BTissue%252BDistribution%25252C%252BCatabolism%25252C%252Band%252BElimination%252Bof%252Ban%252BAnti%2525E2%252580%252593%252BStaphylococcus%252Baureus%252BTHIOMAB%252BAntibody-Antibiotic%252BConjugate%252Bin%252BRats%26aulast%3DCai%26aufirst%3DHao%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D11%26spage%3D1161%26epage%3D1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Yu</span>, <span class="hlFld-ContribAuthor ">Lixin  Wang</span>, <span class="hlFld-ContribAuthor ">Jin  Ding</span>, <span class="hlFld-ContribAuthor ">Zhi  Yang</span>, <span class="hlFld-ContribAuthor ">Chengchao  Shou</span>, <span class="hlFld-ContribAuthor ">Chuanke  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of 111In-DOTA-F56 peptide targeting VEGFR1 for potential non-invasive gastric cancer xenografted tumor mice Micro-SPECT imaging. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (14)
                                     , 127248. <a href="https://doi.org/10.1016/j.bmcl.2020.127248" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127248%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEvaluation%252Bof%252B111In-DOTA-F56%252Bpeptide%252Btargeting%252BVEGFR1%252Bfor%252Bpotential%252Bnon-invasive%252Bgastric%252Bcancer%252Bxenografted%252Btumor%252Bmice%252BMicro-SPECT%252Bimaging%26aulast%3DYu%26aufirst%3DQian%26date%3D2020%26volume%3D30%26issue%3D14%26spage%3D127248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lidia  Nazarova</span>, <span class="hlFld-ContribAuthor ">Hanine  Rafidi</span>, <span class="hlFld-ContribAuthor ">Danielle  Mandikian</span>, <span class="hlFld-ContribAuthor ">Gregory Z.  Ferl</span>, <span class="hlFld-ContribAuthor ">James T.  Koerber</span>, <span class="hlFld-ContribAuthor ">Christopher W.  Davies</span>, <span class="hlFld-ContribAuthor ">Sheila  Ulufatu</span>, <span class="hlFld-ContribAuthor ">Jason  Ho</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Lau</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">James  Ernst</span>, <span class="hlFld-ContribAuthor ">Jack D.  Sadowsky</span>, <span class="hlFld-ContribAuthor ">C. Andrew  Boswell</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (4)
                                     , 1052-1058. <a href="https://doi.org/10.1158/1535-7163.MCT-19-1015" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-1015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-1015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-1015%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DEffect%252Bof%252BModulating%252BFcRn%252BBinding%252Bon%252BDirect%252Band%252BPretargeted%252BTumor%252BUptake%252Bof%252BFull-length%252BAntibodies%26aulast%3DNazarova%26aufirst%3DLidia%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D4%26spage%3D1052%26epage%3D1058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C. Andrew  Boswell</span>, <span class="hlFld-ContribAuthor ">Daniela Bumbaca  Yadav</span>, <span class="hlFld-ContribAuthor ">Eduardo E.  Mundo</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">Jennifer Arca  Lacap</span>, <span class="hlFld-ContribAuthor ">Aimee  Fourie-O’Donohue</span>, <span class="hlFld-ContribAuthor ">Katherine R.  Kozak</span>, <span class="hlFld-ContribAuthor ">Gregory Z.  Ferl</span>, <span class="hlFld-ContribAuthor ">Crystal  Zhang</span>, <span class="hlFld-ContribAuthor ">Jason  Ho</span>, <span class="hlFld-ContribAuthor ">Sheila  Ulufatu</span>, <span class="hlFld-ContribAuthor ">Leslie A.  Khawli</span>, <span class="hlFld-ContribAuthor ">Kedan  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2019,</strong> <em>10 </em>
                                    (58)
                                     , 6234-6244. <a href="https://doi.org/10.18632/oncotarget.27263" title="DOI URL">https://doi.org/10.18632/oncotarget.27263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.27263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.27263%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DBiodistribution%252Band%252Befficacy%252Bof%252Ban%252Banti-TENB2%252Bantibody-drug%252Bconjugate%252Bin%252Ba%252Bpatient-derived%252Bmodel%252Bof%252Bprostate%252Bcancer%26aulast%3DBoswell%26aufirst%3DC.%2BAndrew%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D58%26spage%3D6234%26epage%3D6244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ganesan  Vaidyanathan</span>, <span class="hlFld-ContribAuthor ">Michael R.  Zalutsky</span>. </span><span class="cited-content_cbyCitation_article-title">The Radiopharmaceutical Chemistry of the Radioisotopes of Iodine. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 391-408. <a href="https://doi.org/10.1007/978-3-319-98947-1_22" title="DOI URL">https://doi.org/10.1007/978-3-319-98947-1_22</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-98947-1_22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-98947-1_22%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRadiopharmaceutical%252BChemistry%252Bof%252Bthe%252BRadioisotopes%252Bof%252BIodine%26aulast%3DVaidyanathan%26aufirst%3DGanesan%26date%3D2019%26date%3D2019%26spage%3D391%26epage%3D408%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DRadiopharmaceutical%252BChemistry%26aulast%3DLewis%26aufirst%3DJason%2BS.%26date%3D2019%26volume%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Myriam  Laprise-Pelletier</span>, <span class="hlFld-ContribAuthor ">Teresa  Simão</span>, <span class="hlFld-ContribAuthor ">Marc-André  Fortin</span>. </span><span class="cited-content_cbyCitation_article-title">Gold Nanoparticles in Radiotherapy and Recent Progress in Nanobrachytherapy. </span><span class="cited-content_cbyCitation_journal-name">Advanced Healthcare Materials</span><span> <strong>2018,</strong> <em>7 </em>
                                    (16)
                                     , 1701460. <a href="https://doi.org/10.1002/adhm.201701460" title="DOI URL">https://doi.org/10.1002/adhm.201701460</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adhm.201701460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadhm.201701460%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Healthcare%2520Materials%26atitle%3DGold%252BNanoparticles%252Bin%252BRadiotherapy%252Band%252BRecent%252BProgress%252Bin%252BNanobrachytherapy%26aulast%3DLaprise-Pelletier%26aufirst%3DMyriam%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D16%26spage%3D1701460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhengyuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Satish K  Chitneni</span>, <span class="hlFld-ContribAuthor ">Nick  Devoogdt</span>, <span class="hlFld-ContribAuthor ">Michael R.  Zalutsky</span>, <span class="hlFld-ContribAuthor ">Ganesan  Vaidyanathan</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (8)
                                     , 1939-1949. <a href="https://doi.org/10.1016/j.bmc.2018.02.040" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.02.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.02.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.02.040%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DFluorine-18%252Blabeling%252Bof%252Ban%252Banti-HER2%252BVHH%252Busing%252Ba%252Bresidualizing%252Bprosthetic%252Bgroup%252Bvia%252Ba%252Bstrain-promoted%252Bclick%252Breaction%25253A%252BChemistry%252Band%252Bpreliminary%252Bevaluation%26aulast%3DZhou%26aufirst%3DZhengyuan%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1939%26epage%3D1949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marek  Pruszynski</span>, <span class="hlFld-ContribAuthor ">Choong  Kang</span>, <span class="hlFld-ContribAuthor ">Eftychia  Koumarianou</span>, <span class="hlFld-ContribAuthor ">Ganesan  Vaidyanathan</span>, <span class="hlFld-ContribAuthor ">Michael  Zalutsky</span>. </span><span class="cited-content_cbyCitation_article-title">d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (5)
                                     , 1223. <a href="https://doi.org/10.3390/molecules23051223" title="DOI URL">https://doi.org/10.3390/molecules23051223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23051223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23051223%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3Dd-Amino%252BAcid%252BPeptide%252BResidualizing%252BAgents%252Bfor%252BProtein%252BRadioiodination%25253A%252BEffect%252Bof%252BAspartate%252Bfor%252BGlutamate%252BSubstitution%26aulast%3DPruszynski%26aufirst%3DMarek%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D5%26spage%3D1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William C.  Eckelman</span>, <span class="hlFld-ContribAuthor ">Marie  Boyd</span>, <span class="hlFld-ContribAuthor ">Robert J.  Mairs</span>. </span><span class="cited-content_cbyCitation_article-title">Principles of Molecular Targeting for Radionuclide Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 35-65. <a href="https://doi.org/10.1007/978-3-319-26236-9_32" title="DOI URL">https://doi.org/10.1007/978-3-319-26236-9_32</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-26236-9_32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-26236-9_32%26sid%3Dliteratum%253Aachs%26atitle%3DPrinciples%252Bof%252BMolecular%252BTargeting%252Bfor%252BRadionuclide%252BTherapy%26aulast%3DEckelman%26aufirst%3DWilliam%2BC.%26date%3D2017%26date%3D2017%26spage%3D35%26epage%3D65%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNuclear%252BOncology%26aulast%3DStrauss%26aufirst%3DH.%2BWilliam%26date%3D2017%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eun Jung  Kim</span>, <span class="hlFld-ContribAuthor ">Byoung Soo  Kim</span>, <span class="hlFld-ContribAuthor ">Dan Bee  Choi</span>, <span class="hlFld-ContribAuthor ">Sung-Gil  Chi</span>, <span class="hlFld-ContribAuthor ">Tae Hyun  Choi</span>. </span><span class="cited-content_cbyCitation_article-title">Improved
              In Vivo
              Stability of Radioiodinated Rituximab Using an Iodination Linker for Radioimmunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Cancer Biotherapy and Radiopharmaceuticals</span><span> <strong>2016,</strong> <em>31 </em>
                                    (8)
                                     , 287-294. <a href="https://doi.org/10.1089/cbr.2016.2047" title="DOI URL">https://doi.org/10.1089/cbr.2016.2047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/cbr.2016.2047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fcbr.2016.2047%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Biotherapy%2520and%2520Radiopharmaceuticals%26atitle%3DImproved%252BIn%252BVivo%252BStability%252Bof%252BRadioiodinated%252BRituximab%252BUsing%252Ban%252BIodination%252BLinker%252Bfor%252BRadioimmunotherapy%26aulast%3DKim%26aufirst%3DEun%2BJung%26date%3D2016%26volume%3D31%26issue%3D8%26spage%3D287%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sam  Massa</span>, <span class="hlFld-ContribAuthor ">Catarina  Xavier</span>, <span class="hlFld-ContribAuthor ">Serge  Muyldermans</span>, <span class="hlFld-ContribAuthor ">Nick  Devoogdt</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging site-specific bioconjugation strategies for radioimmunotracer development. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Delivery</span><span> <strong>2016,</strong> <em>13 </em>
                                    (8)
                                     , 1149-1163. <a href="https://doi.org/10.1080/17425247.2016.1178235" title="DOI URL">https://doi.org/10.1080/17425247.2016.1178235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425247.2016.1178235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425247.2016.1178235%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Delivery%26atitle%3DEmerging%252Bsite-specific%252Bbioconjugation%252Bstrategies%252Bfor%252Bradioimmunotracer%252Bdevelopment%26aulast%3DMassa%26aufirst%3DSam%26date%3D2016%26date%3D2016%26volume%3D13%26issue%3D8%26spage%3D1149%26epage%3D1163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">EUN JUNG  KIM</span>, <span class="hlFld-ContribAuthor ">BYOUNG SOO  KIM</span>, <span class="hlFld-ContribAuthor ">DAN BEE  CHOI</span>, <span class="hlFld-ContribAuthor ">SUNG-GIL  CHI</span>, <span class="hlFld-ContribAuthor ">TAE HYUN  CHOI</span>. </span><span class="cited-content_cbyCitation_article-title">Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Oncology Reports</span><span> <strong>2016,</strong> <em>35 </em>
                                    (6)
                                     , 3159-3168. <a href="https://doi.org/10.3892/or.2016.4706" title="DOI URL">https://doi.org/10.3892/or.2016.4706</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/or.2016.4706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2For.2016.4706%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Reports%26atitle%3DEnhanced%252Btumor%252Bretention%252Bof%252Bradioiodinated%252Banti-epidermal%252Bgrowth%252Bfactor%252Breceptor%252Bantibody%252Busing%252Bnovel%252Bbifunctional%252Biodination%252Blinker%252Bfor%252Bradioimmunotherapy%26aulast%3DKIM%26aufirst%3DEUN%2BJUNG%26date%3D2016%26date%3D2016%26volume%3D35%26issue%3D6%26spage%3D3159%26epage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Adumeau</span>, <span class="hlFld-ContribAuthor ">Sai Kiran  Sharma</span>, <span class="hlFld-ContribAuthor ">Colleen  Brent</span>, <span class="hlFld-ContribAuthor ">Brian M.  Zeglis</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 1: Cysteine Residues and Glycans. </span><span class="cited-content_cbyCitation_journal-name">Molecular Imaging and Biology</span><span> <strong>2016,</strong> <em>18 </em>
                                    (1)
                                     , 1-17. <a href="https://doi.org/10.1007/s11307-015-0919-4" title="DOI URL">https://doi.org/10.1007/s11307-015-0919-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11307-015-0919-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11307-015-0919-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Imaging%2520and%2520Biology%26atitle%3DSite-Specifically%252BLabeled%252BImmunoconjugates%252Bfor%252BMolecular%252BImaging%2525E2%252580%252594Part%252B1%25253A%252BCysteine%252BResidues%252Band%252BGlycans%26aulast%3DAdumeau%26aufirst%3DPierre%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D1%26spage%3D1%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William C.  Eckelman</span>, <span class="hlFld-ContribAuthor ">Marie  Boyd</span>, <span class="hlFld-ContribAuthor ">Robert J.  Mairs</span>. </span><span class="cited-content_cbyCitation_article-title">Principles of Molecular Targeting for Radionuclide Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 1-31. <a href="https://doi.org/10.1007/978-3-319-26067-9_32-1" title="DOI URL">https://doi.org/10.1007/978-3-319-26067-9_32-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-26067-9_32-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-26067-9_32-1%26sid%3Dliteratum%253Aachs%26atitle%3DPrinciples%252Bof%252BMolecular%252BTargeting%252Bfor%252BRadionuclide%252BTherapy%26aulast%3DEckelman%26aufirst%3DWilliam%2BC.%26date%3D2016%26date%3D2016%26spage%3D1%26epage%3D31%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNuclear%252BOncology%26aulast%3DStrauss%26aufirst%3DH.%2BWilliam%26date%3D2016%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ganesan  Vaidyanathan</span>, <span class="hlFld-ContribAuthor ">Darryl  McDougald</span>, <span class="hlFld-ContribAuthor ">Jaeyeon  Choi</span>, <span class="hlFld-ContribAuthor ">Marek  Pruszynski</span>, <span class="hlFld-ContribAuthor ">Eftychia  Koumarianou</span>, <span class="hlFld-ContribAuthor ">Zhengyuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael R.  Zalutsky</span>. </span><span class="cited-content_cbyCitation_article-title">N-Succinimidyl 3-((4-(4-[
              18
              F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([
              18
              F]SFBTMGMB): a residualizing label for
              18
              F-labeling of internalizing biomolecules. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2016,</strong> <em>14 </em>
                                    (4)
                                     , 1261-1271. <a href="https://doi.org/10.1039/C5OB02258D" title="DOI URL">https://doi.org/10.1039/C5OB02258D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5OB02258D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5OB02258D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DN-Succinimidyl%252B3-%252528%2525284-%2525284-%25255B%252B18%252BF%25255Dfluorobutyl%252529-1H-1%25252C2%25252C3-triazol-1-yl%252529methyl%252529-5-%252528guanidinomethyl%252529benzoate%252B%252528%25255B%252B18%252BF%25255DSFBTMGMB%252529%25253A%252Ba%252Bresidualizing%252Blabel%252Bfor%252B18%252BF-labeling%252Bof%252Binternalizing%252Bbiomolecules%26aulast%3DVaidyanathan%26aufirst%3DGanesan%26date%3D2016%26date%3D2016%26volume%3D14%26issue%3D4%26spage%3D1261%26epage%3D1271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Padma  Akkapeddi</span>, <span class="hlFld-ContribAuthor ">Saara-Anne  Azizi</span>, <span class="hlFld-ContribAuthor ">Allyson M.  Freedy</span>, <span class="hlFld-ContribAuthor ">Pedro M. S. D.  Cal</span>, <span class="hlFld-ContribAuthor ">Pedro M. P.  Gois</span>, <span class="hlFld-ContribAuthor ">Gonçalo J. L.  Bernardes</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2016,</strong> <em>7 </em>
                                    (5)
                                     , 2954-2963. <a href="https://doi.org/10.1039/C6SC00170J" title="DOI URL">https://doi.org/10.1039/C6SC00170J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6SC00170J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6SC00170J%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DConstruction%252Bof%252Bhomogeneous%252Bantibody%2525E2%252580%252593drug%252Bconjugates%252Busing%252Bsite-selective%252Bprotein%252Bchemistry%26aulast%3DAkkapeddi%26aufirst%3DPadma%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D5%26spage%3D2954%26epage%3D2963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julie K.  Jang</span>, <span class="hlFld-ContribAuthor ">David  Canter</span>, <span class="hlFld-ContribAuthor ">Peisheng  Hu</span>, <span class="hlFld-ContribAuthor ">Alan L.  Epstein</span>, <span class="hlFld-ContribAuthor ">Leslie A.  Khawli</span>. </span><span class="cited-content_cbyCitation_article-title">Labeling and Imaging Techniques for Quantification of Therapeutic Biologics. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 1-24. <a href="https://doi.org/10.1002/9780470571224.pse554" title="DOI URL">https://doi.org/10.1002/9780470571224.pse554</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9780470571224.pse554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9780470571224.pse554%26sid%3Dliteratum%253Aachs%26atitle%3DLabeling%252Band%252BImaging%252BTechniques%252Bfor%252BQuantification%252Bof%252BTherapeutic%252BBiologics%26aulast%3DJang%26aufirst%3DJulie%2BK.%26date%3D2015%26date%3D2015%26spage%3D1%26epage%3D24%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPharmaceutical%252BSciences%252BEncyclopedia%26aulast%3DGad%26aufirst%3DShayne%2BCox%26date%3D2010%26date%3D2010%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jongho  Jeon</span>, <span class="hlFld-ContribAuthor ">Jung Ae  Kang</span>, <span class="hlFld-ContribAuthor ">Ha Eun  Shim</span>, <span class="hlFld-ContribAuthor ">You Ree  Nam</span>, <span class="hlFld-ContribAuthor ">Seonhye  Yoon</span>, <span class="hlFld-ContribAuthor ">Hye Rim  Kim</span>, <span class="hlFld-ContribAuthor ">Dong Eun  Lee</span>, <span class="hlFld-ContribAuthor ">Sang Hyun  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient method for iodine radioisotope labeling of cyclooctyne-containing molecules using strain-promoted copper-free click reaction. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (13)
                                     , 3303-3308. <a href="https://doi.org/10.1016/j.bmc.2015.04.045" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.04.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.04.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.04.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DEfficient%252Bmethod%252Bfor%252Biodine%252Bradioisotope%252Blabeling%252Bof%252Bcyclooctyne-containing%252Bmolecules%252Busing%252Bstrain-promoted%252Bcopper-free%252Bclick%252Breaction%26aulast%3DJeon%26aufirst%3DJongho%26date%3D2015%26volume%3D23%26issue%3D13%26spage%3D3303%26epage%3D3308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia T.  Mendler</span>, <span class="hlFld-ContribAuthor ">Torben  Gehring</span>, <span class="hlFld-ContribAuthor ">Hans-Jürgen  Wester</span>, <span class="hlFld-ContribAuthor ">Markus  Schwaiger</span>, <span class="hlFld-ContribAuthor ">Arne  Skerra</span>. </span><span class="cited-content_cbyCitation_article-title">89
              Zr-Labeled Versus
              124
              I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Nuclear Medicine</span><span> <strong>2015,</strong> <em>56 </em>
                                    (7)
                                     , 1112-1118. <a href="https://doi.org/10.2967/jnumed.114.149690" title="DOI URL">https://doi.org/10.2967/jnumed.114.149690</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2967/jnumed.114.149690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2967%2Fjnumed.114.149690%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Nuclear%2520Medicine%26atitle%3D89%252BZr-Labeled%252BVersus%252B124%252BI-Labeled%252B%2525CE%2525B1HER2%252BFab%252Bwith%252BOptimized%252BPlasma%252BHalf-Life%252Bfor%252BHigh-Contrast%252BTumor%252BImaging%252BIn%252BVivo%26aulast%3DMendler%26aufirst%3DClaudia%2BT.%26date%3D2015%26date%3D2015%26volume%3D56%26issue%3D7%26spage%3D1112%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna  Strand</span>, <span class="hlFld-ContribAuthor ">Patrik  Nordeman</span>, <span class="hlFld-ContribAuthor ">Hadis  Honarvar</span>, <span class="hlFld-ContribAuthor ">Mohamed  Altai</span>, <span class="hlFld-ContribAuthor ">Anna  Orlova</span>, <span class="hlFld-ContribAuthor ">Mats  Larhed</span>, <span class="hlFld-ContribAuthor ">Vladimir  Tolmachev</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity. </span><span class="cited-content_cbyCitation_journal-name">ChemistryOpen</span><span> <strong>2015,</strong> <em>4 </em>
                                    (2)
                                     , 174-182. <a href="https://doi.org/10.1002/open.201402097" title="DOI URL">https://doi.org/10.1002/open.201402097</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/open.201402097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fopen.201402097%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistryOpen%26atitle%3DSite-Specific%252BRadioiodination%252Bof%252BHER2-Targeting%252BAffibody%252BMolecules%252Busing%252B4-Iodophenethylmaleimide%252BDecreases%252BRenal%252BUptake%252Bof%252BRadioactivity%26aulast%3DStrand%26aufirst%3DJoanna%26date%3D2015%26date%3D2015%26volume%3D4%26issue%3D2%26spage%3D174%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia T  Mendler</span>, <span class="hlFld-ContribAuthor ">Lars  Friedrich</span>, <span class="hlFld-ContribAuthor ">Iina  Laitinen</span>, <span class="hlFld-ContribAuthor ">Martin  Schlapschy</span>, <span class="hlFld-ContribAuthor ">Markus  Schwaiger</span>, <span class="hlFld-ContribAuthor ">Hans-Jürgen  Wester</span>, <span class="hlFld-ContribAuthor ">Arne  Skerra</span>. </span><span class="cited-content_cbyCitation_article-title">High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. </span><span class="cited-content_cbyCitation_journal-name">mAbs</span><span> <strong>2015,</strong> <em>7 </em>
                                    (1)
                                     , 96-109. <a href="https://doi.org/10.4161/19420862.2014.985522" title="DOI URL">https://doi.org/10.4161/19420862.2014.985522</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4161/19420862.2014.985522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4161%2F19420862.2014.985522%26sid%3Dliteratum%253Aachs%26jtitle%3DmAbs%26atitle%3DHigh%252Bcontrast%252Btumor%252Bimaging%252Bwith%252Bradio-labeled%252Bantibody%252BFab%252Bfragments%252Btailored%252Bfor%252Boptimized%252Bpharmacokinetics%252Bvia%252BPASylation%26aulast%3DMendler%26aufirst%3DClaudia%2BT%26date%3D2015%26date%3D2015%26volume%3D7%26issue%3D1%26spage%3D96%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oleksandr  Koniev</span>, <span class="hlFld-ContribAuthor ">Alain  Wagner</span>. </span><span class="cited-content_cbyCitation_article-title">Developments and recent advancements in the field of endogenous amino acid selective bond forming reactions for bioconjugation. </span><span class="cited-content_cbyCitation_journal-name">Chem. Soc. Rev.</span><span> <strong>2015,</strong> <em>44 </em>
                                    (15)
                                     , 5495-5551. <a href="https://doi.org/10.1039/C5CS00048C" title="DOI URL">https://doi.org/10.1039/C5CS00048C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5CS00048C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5CS00048C%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Soc.%2520Rev.%26atitle%3DDevelopments%252Band%252Brecent%252Badvancements%252Bin%252Bthe%252Bfield%252Bof%252Bendogenous%252Bamino%252Bacid%252Bselective%252Bbond%252Bforming%252Breactions%252Bfor%252Bbioconjugation%26aulast%3DKoniev%26aufirst%3DOleksandr%26date%3D2015%26date%3D2015%26volume%3D44%26issue%3D15%26spage%3D5495%26epage%3D5551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Baumann</span>, <span class="hlFld-ContribAuthor ">Kelly  Flagella</span>, <span class="hlFld-ContribAuthor ">Roy  Forster</span>, <span class="hlFld-ContribAuthor ">Lolke  de Haan</span>, <span class="hlFld-ContribAuthor ">Sven  Kronenberg</span>, <span class="hlFld-ContribAuthor ">Mathias  Locher</span>, <span class="hlFld-ContribAuthor ">Wolfgang F.  Richter</span>, <span class="hlFld-ContribAuthor ">Frank-Peter  Theil</span>, <span class="hlFld-ContribAuthor ">Marque  Todd</span>. </span><span class="cited-content_cbyCitation_article-title">New challenges and opportunities in nonclinical safety testing of biologics. </span><span class="cited-content_cbyCitation_journal-name">Regulatory Toxicology and Pharmacology</span><span> <strong>2014,</strong> <em>69 </em>
                                    (2)
                                     , 226-233. <a href="https://doi.org/10.1016/j.yrtph.2014.04.005" title="DOI URL">https://doi.org/10.1016/j.yrtph.2014.04.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.yrtph.2014.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.yrtph.2014.04.005%26sid%3Dliteratum%253Aachs%26jtitle%3DRegulatory%2520Toxicology%2520and%2520Pharmacology%26atitle%3DNew%252Bchallenges%252Band%252Bopportunities%252Bin%252Bnonclinical%252Bsafety%252Btesting%252Bof%252Bbiologics%26aulast%3DBaumann%26aufirst%3DAndreas%26date%3D2014%26volume%3D69%26issue%3D2%26spage%3D226%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected nonresidualizing (A) and residualizing (B–D) methods of radiolabeling antibodies including (A) oxidative tyrosine radioiodination, (B) lysine modification with radiometal chelate, (C) lysine modification with charged iodinated groups,<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> and (D) thiol modification with the novel compound <b>6</b>, designated [<sup>125</sup>I]HIP-DOTA, that can be attached to either the Fc region or the heavy (HC) or light (LC) chains of an antibody containing engineered cysteine residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic depicting the cellular fates of nonresidualizing and residualizing labels following antibody binding to an internalizing cell-surface antigen. Antibodies labeled by both methods undergo receptor-mediated endocytosis and lysosomal degradation. Diffusion of radioactivity out of the lysosome and/or cell occurs readily for iodotyrosine but is resisted for radiometal–chelate complexes and other residualizing labels.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Synthetic route to the shelf compound, maleimide <b>4</b>, and its radiolabeling and antibody conjugation to LC-V205C thio-trastuzumab.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SDS-PAGE analysis by protein staining (top) and phosphorimaging (bottom) of trastuzumab labeled site specifically with [<sup>125</sup>I]<b>6</b> through its heavy chain (HC-A114C), light chain (LC-V205C), and Fc (Fc-S396C) region. Digestion of antibodies with the endoprotease, Lys-C, results in cleavage between the Fab and Fc regions. In contrast, dithiothreitol (DTT) reduction separates the heavy (still attached to Fc) and light chains. Differential exposure of radioactivity in selected bands is evident despite equal loading of proteins, demonstrating the site-specificity of labeling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma pharmacokinetics (A) and biodistribution at 3 days (B) of trastuzumab radiolabeled by various methods in KPL-4 xenograft-bearing mice. Trastuzumab was labeled with <sup>125</sup>I by traditional tyrosine modification (black), by site-specific (HC-A114C/LC-V205C/Fc-S396C) modification with [<sup>125</sup>I]<b>6</b> (blue, green, and red, respectively), or by lysine modification with <sup>111</sup>In-DOTA (gray). Uptake is expressed as percentage of injected dose per g of tissue (%ID/g).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/medium/jm-2013-01365h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. SPECT-CT imaging (upper) at 24 and 72 h and whole-body autoradiographic imaging (lower) at 72 h indicate relative degrees of tracer residualization in KPL-4 xenograft-bearing mice following intravenous administration of trastuzumab radiolabeled by five different methods. In the three-dimensional volume renderings from a coronal perspective (upper), the skeletal images are derived from the X-ray (anatomical) CT data while the relative levels of radioactivity from the SPECT data are indicated in a false-color scale. Tumor-to-blood (T:B) ratios of radioactive uptake are shown. Post-mortem cryosection images from a sagittal perspective (lower) were acquired from the same mice as in the upper panel. False-colored phosphorimages (left) and digital photographs (right) are shown for each mouse in the tumoral plane. Tissues are labeled as tumor (T), liver (L), and kidney (K).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm401365h/production/images/large/jm-2013-01365h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401365h&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23650" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23650" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Wu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0li2Hbqz86vsUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNature%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1137%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Davies, A. J.</span><span> </span><span class="NLM_article-title">Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3614</span><span class="NLM_x">–</span> <span class="NLM_lpage">3628</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3614-3628&author=A.+J.+Davies&title=Radioimmunotherapy+for+B-cell+lymphoma%3A+Y-90+ibritumomab+tiuxetan+and+I-131+tositumomab"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DA.%2BJ.%26atitle%3DRadioimmunotherapy%2520for%2520B-cell%2520lymphoma%253A%2520Y-90%2520ibritumomab%2520tiuxetan%2520and%2520I-131%2520tositumomab%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3614%26epage%3D3628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brechbiel, M. W.</span><span> </span><span class="NLM_article-title">Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view</span> <span class="citation_source-journal">Nucl. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">757</span><span class="NLM_x">–</span> <span class="NLM_lpage">778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1016%2Fj.nucmedbio.2007.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=17921028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFeiu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2007&pages=757-778&author=C.+A.+Boswellauthor=M.+W.+Brechbiel&title=Development+of+radioimmunotherapeutic+and+diagnostic+antibodies%3A+an+inside-out+view"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view</span></div><div class="casAuthors">Boswell, C. Andrew; Brechbiel, Martin W.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">757-778</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Only a handful of radiolabeled antibodies (Abs) have gained US Food and Drug Administration (FDA) approval for use in clin. oncol., including four immunodiagnostic agents and two targeted radioimmunotherapeutic agents.  Despite the advent of nonimmunogenic Abs and the availability of a diverse library of radionuclides, progress beyond early Phase II radioimmunotherapy (RIT) studies in solid tumors has been marginal.  Furthermore, [18F]fluorodeoxyglucose continues to dominate the mol. imaging domain, underscored by a decade-long absence of any newly approved Ab-based imaging agent (none since 1996).  Why has the development of clin. successful Abs for RIT been limited to lymphoma What obstacles must be overcome to allow the FDA approval of immuno-positron emission tomog. (immuno-PET) imaging agents How can we address the unique challenges that have thus far prevented the introduction of Ab-based imaging agents and therapeutics for solid tumors Many poor decisions have been made regarding radiolabeled Abs, but useful insight can be gained from these mistakes.  The following review addresses the phys., chem., biol., clin., regulatory and financial limitations that impede the progress of this increasingly important class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWac-JAg4C47Vg90H21EOLACvtfcHk0li2Hbqz86vsUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFeiu77K&md5=8351453e5e8524c7146da9cc71641c71</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2007.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2007.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26aulast%3DBrechbiel%26aufirst%3DM.%2BW.%26atitle%3DDevelopment%2520of%2520radioimmunotherapeutic%2520and%2520diagnostic%2520antibodies%253A%2520an%2520inside-out%2520view%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2007%26volume%3D34%26spage%3D757%26epage%3D778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Vaidyanathan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalutsky, M. R.</span><span> </span><span class="NLM_article-title">A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: <i>N</i>-succinimidyl 4-guanidinomethyl-3-[<sup>131</sup>I]iodobenzoate ([<sup>131</sup>I]SGMIB)</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">438</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc0001490" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD3MXislKiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=428-438&author=G.+Vaidyanathanauthor=D.+J.+Affleckauthor=J.+Liauthor=P.+Welshauthor=M.+R.+Zalutsky&title=A+polar+substituent-containing+acylation+agent+for+the+radioiodination+of+internalizing+monoclonal+antibodies%3A+N-succinimidyl+4-guanidinomethyl-3-%5B131I%5Diodobenzoate+%28%5B131I%5DSGMIB%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Polar Substituent-Containing Acylation Agent for the Radioiodination of Internalizing Monoclonal Antibodies: N-Succinimidyl 4-Guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB)</span></div><div class="casAuthors">Vaidyanathan, Ganesan; Affleck, Donna J.; Li, Jean; Welsh, Phil; Zalutsky, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">428-438</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The objective of this study was to develop an acylation agent for the radioiodination of monoclonal antibodies that would maximize retention of the label in tumor cells following receptor- or antigen-mediated internalization.  The strategy taken was to add a polar substituent to the labeled arom. ring to impede transport of labeled catabolites across lysosomal and cell membranes after antibody degrdn.  Prepn. of unlabeled N-succinimidyl 4-guanidinomethyl-3-iodobenzoate (SGMIB) was achieved in six steps from 3-iodo-4-methylbenzoic acid.  Prepn. of 4-guanidinomethyl-3-[131I]iodobenzoic acid from the silicon precursor, 4-(N1,N2-bis-tert-butyloxycarbonyl)guanidinomethyl-3-trimethylsilylbenzoic acid proceeded in less than 5% radiochem. yield.  A more successful approach was to prep. [131I]SGMIB directly from the tin precursor, N-succinimidyl 4-(N1,N2-bis-tert-butyloxycarbonyl)guanidinomethyl-3-trimethylstannylbenzoate, which was achieved in 60-65% radiochem. yield.  A rapidly internalizing anti-epidermal growth factor receptor variant III antibody L8A4 was labeled using [131I]SGMIB in 65% conjugation efficiency and with preservation of immunoreactivity. Paired-label in vitro internalization assays demonstrated that the amt. of radioactivity retained in cells after internalization for L8A4 labeled with [131I]SGMIB was 3-4-fold higher than that for L8A4 labeled with 125I using either Iodogen or [125I]SIPC.  Catabolite assays documented that the increased retention of radioiodine in tumor cells for antibody labeled using [131I]SGMIB was due to pos. charged, low mol. wt. species.  These results suggest that [131I]SGMIB warrants further evaluation as a reagent for labeling internalizing antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTgKj6Gpbii7Vg90H21EOLACvtfcHk0ljgujrkQ1AXQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXislKiu7g%253D&md5=65bb874502a26b04b761bbeca56416e3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fbc0001490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0001490%26sid%3Dliteratum%253Aachs%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DAffleck%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWelsh%26aufirst%3DP.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26atitle%3DA%2520polar%2520substituent-containing%2520acylation%2520agent%2520for%2520the%2520radioiodination%2520of%2520internalizing%2520monoclonal%2520antibodies%253A%2520N-succinimidyl%25204-guanidinomethyl-3-%255B131I%255Diodobenzoate%2520%2528%255B131I%255DSGMIB%2529%26jtitle%3DBioconjugate%2520Chem.%26date%3D2001%26volume%3D12%26spage%3D428%26epage%3D438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Shankar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidyanathan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalutsky, M. R.</span><span> </span><span class="NLM_article-title"><i>N</i>-Succinimidyl 3-[<sup>131</sup>I]iodo-4-phosphonomethylbenzoate ([<sup>131</sup>I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc025636p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlequw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=331-341&author=S.+Shankarauthor=G.+Vaidyanathanauthor=D.+Affleckauthor=P.+C.+Welshauthor=M.+R.+Zalutsky&title=N-Succinimidyl+3-%5B131I%5Diodo-4-phosphonomethylbenzoate+%28%5B131I%5DSIPMB%29%2C+a+negatively+charged+substituent-bearing+acylation+agent+for+the+radioiodination+of+peptides+and+mAbs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">N-Succinimidyl 3-[131I]Iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a Negatively Charged Substituent-Bearing Acylation Agent for the Radioiodination of Peptides and mAbs</span></div><div class="casAuthors">Shankar, Sriram; Vaidyanathan, Ganesan; Affleck, Donna; Welsh, Phillip C.; Zalutsky, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-341</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An important criterion in design of acylation agents for the radioiodination of internalizing monoclonal antibodies (mAbs) is to maximize the retention of radioiodine in the tumor following mAb intracellular processing.  We have previously shown that labeling methods that generate pos. charged catabolites have enhanced tumor retention.  Herein we have extended this strategy to investigate the potential utility of labeling internalizing mAbs with an acylation agent that yielded labeled catabolites that would be neg. charged at lysosomal pH.  The neg. charged acylation agent, N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), was prepd. from its tin precursor, N-succinimidyl 4-di-tert-butylphosphonomethyl-3-trimethylstannylbenzoate (tBu-SPMTB), in 40% radiochem. yield.  The free acid, 3-[131I]iodo-4-phosphonomethylbenzoic acid ([131I]IPMBA), was also prepd. from the corresponding precursor, 4-di-tert-butylphosphonomethyl-3-trimethylstannylbenzoic acid (tBu-PMTBA), in 80% radiochem. yield.  The rapidly internalizing mAb L8A4 was conjugated to [131I]SIPMB in 25-40% yield with preservation of its immunoreactivity.  Internalization and processing in the U87ΔEGFR glioma cell line was studied in a paired label format with L8A4 labeled with 125I using the Iodogen method.  Retention of initially bound radioactivity in these cells at 24 h from [131I]SIPMB-labeled mAb was approx. 6-fold higher than that for directly labeled mAb.  Catabolite anal. demonstrated that this difference reflected an order of magnitude higher retention of low mol. wt. species in these cells.  The [131I]SIPMB-L8A4 conjugate was intact over the first 2 h; thereafter, lysine-[131I]SIPMB was the predominant catabolite.  In contrast, L8A4 labeled using Iodogen rapidly gave rise to mono-[125I]iodotyrosine within 2 h, which then cleared rapidly from the cells.  These results suggest that SIPMB could be a potent candidate for labeling internalizing mAbs and warrant further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRVCKOZlLgRLVg90H21EOLACvtfcHk0ljgujrkQ1AXQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlequw%253D%253D&md5=0b1303531683396585a47d8a5f969089</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fbc025636p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc025636p%26sid%3Dliteratum%253Aachs%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DAffleck%26aufirst%3DD.%26aulast%3DWelsh%26aufirst%3DP.%2BC.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26atitle%3DN-Succinimidyl%25203-%255B131I%255Diodo-4-phosphonomethylbenzoate%2520%2528%255B131I%255DSIPMB%2529%252C%2520a%2520negatively%2520charged%2520substituent-bearing%2520acylation%2520agent%2520for%2520the%2520radioiodination%2520of%2520peptides%2520and%2520mAbs%26jtitle%3DBioconjugate%2520Chem.%26date%3D2003%26volume%3D14%26spage%3D331%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Vaidyanathan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalutsky, M. R.</span><span> </span><span class="NLM_article-title">SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6929</span><span class="NLM_x">–</span> <span class="NLM_lpage">6939</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=6929-6939&author=G.+Vaidyanathanauthor=B.+J.+Whiteauthor=D.+J.+Affleckauthor=X.+G.+Zhaoauthor=P.+C.+Welshauthor=D.+McDougaldauthor=J.+Choiauthor=M.+R.+Zalutsky&title=SIB-DOTA%3A+a+trifunctional+prosthetic+group+potentially+amenable+for+multi-modal+labeling+that+enhances+tumor+uptake+of+internalizing+monoclonal+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DWhite%26aufirst%3DB.%2BJ.%26aulast%3DAffleck%26aufirst%3DD.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%2BG.%26aulast%3DWelsh%26aufirst%3DP.%2BC.%26aulast%3DMcDougald%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26atitle%3DSIB-DOTA%253A%2520a%2520trifunctional%2520prosthetic%2520group%2520potentially%2520amenable%2520for%2520multi-modal%2520labeling%2520that%2520enhances%2520tumor%2520uptake%2520of%2520internalizing%2520monoclonal%2520antibodies%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D6929%26epage%3D6939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumbaca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielder, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawli, L. A.</span><span> </span><span class="NLM_article-title">Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations</span> <span class="citation_source-journal">AAAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1208%2Fs12248-012-9374-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=22648903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFWit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=612-618&author=C.+A.+Boswellauthor=D.+Bumbacaauthor=P.+J.+Fielderauthor=L.+A.+Khawli&title=Compartmental+tissue+distribution+of+antibody+therapeutics%3A+experimental+approaches+and+interpretations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations</span></div><div class="casAuthors">Boswell, C. Andrew; Bumbaca, Daniela; Fielder, Paul J.; Khawli, Leslie A.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">612-618</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Monoclonal antibodies have provided many validated and potential new therapeutic candidates for various diseases encompassing the realms of neurol., ophthalmol., immunol., and esp. oncol.  The mechanism of action for these biol. mols. typically involves specific binding to a sol. ligand or cell surface protein in order to block or alter a mol. pathway, induce a desired cellular response, or deplete a target cell.  Many antigens reside within the interstitial space, the fluid-filled compartment that lies between the outer endothelial vessel wall and the plasma membranes of cells.  This mini-review examines the concepts relevant to the kinetics and behavior of antibodies within the interstitium with a special emphasis on radiometric measurement of quant. pharmacol.  Mol. probes are discussed to outline chem. techniques, selection criteria, data interpretation, and relevance to the study of antibody pharmacokinetics.  The importance of studying the tissue uptake of antibodies at a compartmental level is highlighted, including a brief overview of receptor occupancy and its interpretation in radiotracer studies.  Exptl. methods for measuring the spatial compn. of tissues are examd. in terms of relative vascular, interstitial, and cellular vols. using solid tumors as a representative example.  Exptl. methods and physiol. based pharmacokinetic modeling are introduced as distinct approaches to distinguish between free and bound fractions of interstitial antibody.  Overall, the review outlines the available methods for pharmacokinetic measurements of antibodies and physiol. measurements of the compartments that they occupy, while emphasizing that such approaches may not fully capture the complexities of dynamic, heterogeneous tumors and other tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8CMde9lWmd7Vg90H21EOLACvtfcHk0ljgujrkQ1AXQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFWit7c%253D&md5=aba3c854ae7af154dff08f3c0365671c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1208%2Fs12248-012-9374-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-012-9374-1%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26aulast%3DBumbaca%26aufirst%3DD.%26aulast%3DFielder%26aufirst%3DP.%2BJ.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26atitle%3DCompartmental%2520tissue%2520distribution%2520of%2520antibody%2520therapeutics%253A%2520experimental%2520approaches%2520and%2520interpretations%26jtitle%3DAAAPS%2520J.%26date%3D2012%26volume%3D14%26spage%3D612%26epage%3D618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wilbur, D. S.</span><span> </span><span class="NLM_article-title">Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling</span> <span class="citation_source-journal">Bioconjugate Chem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc00018a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A280%3ADyaK3s%252FpvFWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1992&pages=433-470&author=D.+S.+Wilbur&title=Radiohalogenation+of+proteins%3A+an+overview+of+radionuclides%2C+labeling+methods%2C+and+reagents+for+conjugate+labeling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling</span></div><div class="casAuthors">Wilbur D S</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">433-70</span>
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    </div><div class="casAbstract">Direct labeling of proteins with radionuclides of iodine will continue to be the method of choice to answer questions addressed in many future studies.  However, it seems likely that a increasing number of applications of radiohalogenated proteins will require, or benefit from, conjugate labeling.  While many radiohalogen conjugates have been studied, a large proportion of them have only undergone preliminary studies to date, leaving a question of their overall utility.  Phenolic conjugates give good radioiodination labeling yields, but mixtures of radiohalogenated products and problems with in vivo stability can be expected.  This fact, along with the fact that phenolic compounds do not have a general application to radiohalogens, makes them less attractive than other alternatives.  Radiohalogen labeling through the use of organometallic intermediates has proven to be facile, resulting in high yields of high specific activity labeled small-molecule conjugates.  Although the choice of which organometallic intermediate to use may depend somewhat on the radionuclide employed, arylstannanes appear to have the most general applicability.  Fluorine-18 labeling of small-molecule conjugates has been best accomplished by ipso aromatic nucleophilic substitution (exchange) reactions.  Radiohalogenated small molecules have been prepared which can be conjugated with specific functional groups (e.g. amines, sulfhydryl groups, and carbohydrates) or conjugated nonspecifically with groups in the proximity of the conjugate when it is photolyzed.  On the basis of previous studies, good conjugation yields (i.e. 60-90%) can be expected for reactions with specific groups, whereas low yields (i.e. 1-5%) can be expected for conjugations with reactive nitrenes and carbenes.  However, recent developments in the chemistry of conjugates that produce nitrenes and carbenes will likely improve the radiolabeling yields.  There have been too few comparative studies to readily assess which is the best approach to take when beginning a study involving radiohalogenation of a protein or peptide.  However, it is clear that radiohalogenated conjugates of proteins can offer an advantage over direct labeling in that conjugates may be designed which provide some control over in vivo stability and secondary distribution of metabolites.  Conjugates can be prepared which are designed to utilize in vivo biochemical processes to release a radiohalogenated small molecule from a tissue (i.e. kidney or liver) or retain the radioactivity at the target tissue (e.g. tumor).  Aside from the designing of conjugates with linking molecules for desired biological effects, the ultimate future goal for the radiolabeling chemical should be to prepare protein conjugates which can be radiohalogenated in a single one-step procedure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUoGk4A6rPKcAKB7Fa-xrUfW6udTcc2eYhcwL93p94NLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FpvFWktA%253D%253D&md5=a54a3d73963329ff4c62d93b41b4f032</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fbc00018a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc00018a001%26sid%3Dliteratum%253Aachs%26aulast%3DWilbur%26aufirst%3DD.%2BS.%26atitle%3DRadiohalogenation%2520of%2520proteins%253A%2520an%2520overview%2520of%2520radionuclides%252C%2520labeling%2520methods%252C%2520and%2520reagents%2520for%2520conjugate%2520labeling%26jtitle%3DBioconjugate%2520Chem%26date%3D1992%26volume%3D3%26spage%3D433%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Nayak, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brechbiel, M. W.</span><span> </span><span class="NLM_article-title">Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc800299f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=825-841&author=T.+K.+Nayakauthor=M.+W.+Brechbiel&title=Radioimmunoimaging+with+longer-lived+positron-emitting+radionuclides%3A+potentials+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges</span></div><div class="casAuthors">Nayak, Tapan K.; Brechbiel, Martin W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">825-841</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Radioimmunoimaging and therapy has been an area of interest for several decades.  Steady progress has been made toward clin. translation of radiolabeled monoclonal antibodies for diagnosis and treatment of diseases.  Tremendous advances have been made in imaging technologies such as positron emission tomog. (PET).  However, these advances have so far eluded routine translation into clin. radioimmunoimaging applications due to the mismatch between the short half-lives of routinely used positron-emitting radionuclides such as 18F vs. the pharmacokinetics of most intact monoclonal antibodies of interest.  The lack of suitable positron-emitting radionuclides that match the pharmacokinetics of intact antibodies has generated interest in exploring the use of longer-lived positron emitters that are more suitable for radioimmunoimaging and dosimetry applications with intact monoclonal antibodies.  In this review, we examine the opportunities and challenges of radioimmunoimaging with select longer-lived positron-emitting radionuclides such as 124I, 89Zr, and 86Y with respect to radionuclide prodn., ease of radiolabeling intact antibodies, imaging characteristics, radiation dosimetry, and clin. translation potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHIpatPkW8rLVg90H21EOLACvtfcHk0ljJUpA9dCBPTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVWktA%253D%253D&md5=643de8bbc974fd0c1de9dd7360257a09</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fbc800299f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc800299f%26sid%3Dliteratum%253Aachs%26aulast%3DNayak%26aufirst%3DT.%2BK.%26aulast%3DBrechbiel%26aufirst%3DM.%2BW.%26atitle%3DRadioimmunoimaging%2520with%2520longer-lived%2520positron-emitting%2520radionuclides%253A%2520potentials%2520and%2520challenges%26jtitle%3DBioconjugate%2520Chem.%26date%3D2009%26volume%3D20%26spage%3D825%26epage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Shih, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diril, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattes, M. J.</span><span> </span><span class="NLM_article-title">The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">899</span><span class="NLM_x">–</span> <span class="NLM_lpage">908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=8176479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK2cXlt1yqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1994&pages=899-908&author=L.+B.+Shihauthor=S.+R.+Thorpeauthor=G.+L.+Griffithsauthor=H.+Dirilauthor=G.+L.+Ongauthor=H.+J.+Hansenauthor=D.+M.+Goldenbergauthor=M.+J.+Mattes&title=The+processing+and+fate+of+antibodies+and+their+radiolabels+bound+to+the+surface+of+tumor+cells+in+vitro%3A+a+comparison+of+nine+radiolabels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels</span></div><div class="casAuthors">Shih, Lisa B.; Thorpe, Suzanne R.; Griffiths, Gary L.; Diril, Habibe; Ong, Gaik Lin; Hansen, Hans J.; Goldenberg, David M.; Mattes, M. Jules</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">899-908</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    </div><div class="casAbstract">Processing radiolabeled degrdn. products is the key factor affecting retention of antibodies within the cell.  In this study, the authors have analyzed the processing of antibodies labeled in nine different ways.  Antibodies were labeled with three different radioisotopes and seven different forms of 125I.  Eight of the radiolabels (except 188Re) were conjugated to the same antibody, MA103, and tested on the renal carcinoma cell line SK-RC-18 and/or the ovarian carcinoma cell line SK-OV-6.  Rhenium conjugation utilized the antibody RS7, the target cell line ME180 and three of the other radiolabels were also tested with this antibody-target cell combination for comparison.  Iodine conjugated to antibodies by conventional methods was rapidly released from the cell after antibody catabolism.  In contrast, iodinated moieties, such as dilactitol-tyramine and inulintyramine were retained within cells four to five times longer.  The use of radiolabels that are trapped within cells after antibody catabolism can potentially increase the dose of radiation delivered to the tumor, from the same amt. of radioactivity deposited by a factor of four or five.  The prolonged retention of 111In relative to 125I is not due to deiodination of iodine conjugates, but rather to intracellular retention of catabolic products contg. 111In, perhaps within lysosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0_XPmaUYEBrVg90H21EOLACvtfcHk0lhX6JDt2DY5wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlt1yqs78%253D&md5=f401ef5ffc86967a29cb58d3a3d6c377</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DL.%2BB.%26aulast%3DThorpe%26aufirst%3DS.%2BR.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DDiril%26aufirst%3DH.%26aulast%3DOng%26aufirst%3DG.%2BL.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DMattes%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520processing%2520and%2520fate%2520of%2520antibodies%2520and%2520their%2520radiolabels%2520bound%2520to%2520the%2520surface%2520of%2520tumor%2520cells%2520in%2520vitro%253A%2520a%2520comparison%2520of%2520nine%2520radiolabels%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1994%26volume%3D35%26spage%3D899%26epage%3D908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Perera, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoncu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johns, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pypaert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Old, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toomre, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A. M.</span><span> </span><span class="NLM_article-title">Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1099</span><span class="NLM_x">–</span> <span class="NLM_lpage">1110</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=1099-1110&author=R.+M.+Pereraauthor=R.+Zoncuauthor=T.+G.+Johnsauthor=M.+Pypaertauthor=F.+T.+Leeauthor=I.+Mellmanauthor=L.+J.+Oldauthor=D.+K.+Toomreauthor=A.+M.+Scott&title=Internalization%2C+intracellular+trafficking%2C+and+biodistribution+of+monoclonal+antibody+806%3A+a+novel+anti-epidermal+growth+factor+receptor+antibody"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DR.%2BM.%26aulast%3DZoncu%26aufirst%3DR.%26aulast%3DJohns%26aufirst%3DT.%2BG.%26aulast%3DPypaert%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%2BT.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26aulast%3DToomre%26aufirst%3DD.%2BK.%26aulast%3DScott%26aufirst%3DA.%2BM.%26atitle%3DInternalization%252C%2520intracellular%2520trafficking%252C%2520and%2520biodistribution%2520of%2520monoclonal%2520antibody%2520806%253A%2520a%2520novel%2520anti-epidermal%2520growth%2520factor%2520receptor%2520antibody%26jtitle%3DNeoplasia%26date%3D2007%26volume%3D9%26spage%3D1099%26epage%3D1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Rogers, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franano, F. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connett, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M. J.</span><span> </span><span class="NLM_article-title">Identification of metabolites of <sup>111</sup>In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5714s</span><span class="NLM_x">–</span> <span class="NLM_lpage">5720s</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=5714s-5720s&author=B.+E.+Rogersauthor=F.+N.+Frananoauthor=J.+R.+Duncanauthor=W.+B.+Edwardsauthor=C.+J.+Andersonauthor=J.+M.+Connettauthor=M.+J.+Welch&title=Identification+of+metabolites+of+111In-diethylenetriaminepentaacetic+acid-monoclonal+antibodies+and+antibody+fragments+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DB.%2BE.%26aulast%3DFranano%26aufirst%3DF.%2BN.%26aulast%3DDuncan%26aufirst%3DJ.%2BR.%26aulast%3DEdwards%26aufirst%3DW.%2BB.%26aulast%3DAnderson%26aufirst%3DC.%2BJ.%26aulast%3DConnett%26aufirst%3DJ.%2BM.%26aulast%3DWelch%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520metabolites%2520of%2520111In-diethylenetriaminepentaacetic%2520acid-monoclonal%2520antibodies%2520and%2520antibody%2520fragments%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D5714s%26epage%3D5720s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Milenic, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brechbiel, M. W.</span><span> </span><span class="NLM_article-title">Antibody-targeted radiation cancer therapy</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=488-499&author=D.+E.+Milenicauthor=E.+D.+Bradyauthor=M.+W.+Brechbiel&title=Antibody-targeted+radiation+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilenic%26aufirst%3DD.%2BE.%26aulast%3DBrady%26aufirst%3DE.%2BD.%26aulast%3DBrechbiel%26aufirst%3DM.%2BW.%26atitle%3DAntibody-targeted%2520radiation%2520cancer%2520therapy%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D488%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Thorpe, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baynes, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chroneos, Z. C.</span><span> </span><span class="NLM_article-title">The design and application of residualizing labels for studies of protein catabolism</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1993&pages=399-405&author=S.+R.+Thorpeauthor=J.+W.+Baynesauthor=Z.+C.+Chroneos&title=The+design+and+application+of+residualizing+labels+for+studies+of+protein+catabolism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DS.%2BR.%26aulast%3DBaynes%26aufirst%3DJ.%2BW.%26aulast%3DChroneos%26aufirst%3DZ.%2BC.%26atitle%3DThe%2520design%2520and%2520application%2520of%2520residualizing%2520labels%2520for%2520studies%2520of%2520protein%2520catabolism%26jtitle%3DFASEB%2520J.%26date%3D1993%26volume%3D7%26spage%3D399%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Jefferis, R.</span><span> </span><span class="NLM_article-title">Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=356-362&author=R.+Jefferis&title=Recombinant+antibody+therapeutics%3A+the+impact+of+glycosylation+on+mechanisms+of+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJefferis%26aufirst%3DR.%26atitle%3DRecombinant%2520antibody%2520therapeutics%253A%2520the%2520impact%2520of%2520glycosylation%2520on%2520mechanisms%2520of%2520action%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D356%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattes, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newsome, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Improved iodine radiolabels for monoclonal antibody therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=12517786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvFKhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=111-118&author=R.+Steinauthor=S.+V.+Govindanauthor=M.+J.+Mattesauthor=S.+Chenauthor=L.+Reedauthor=G.+Newsomeauthor=B.+J.+McBrideauthor=G.+L.+Griffithsauthor=H.+J.+Hansenauthor=D.+M.+Goldenberg&title=Improved+iodine+radiolabels+for+monoclonal+antibody+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Improved Iodine Radiolabels for Monoclonal Antibody Therapy</span></div><div class="casAuthors">Stein, Rhona; Govindan, Serengulam V.; Mattes, M. Jules; Chen, Susan; Reed, Linda; Newsome, Guy; McBride, Bill J.; Griffiths, Gary L.; Hansen, Hans J.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A major disadvantage of 131iodine (I)-labeled monoclonal antibodies (MAbs) for radioimmunotherapy has been the rapid diffusion of iodotyrosine from target cells after internalization and catabolism of the radioiodinated MAbs.  We recently reported that a radioiodinated, diethylenetriaminepentaacetic acid-appended peptide, designated immunomedics' residualizing peptide 1 (IMP-R1), was a residualizing iodine label that overcame many of the limitations that had impeded the development of residualizing iodine for clin. use.  To det. the factors governing the therapeutic index of the labeled MAb, as well as the factors required for prodn. of radioiodinated MAb in high yield and with high specific activity, variations in the peptide structure of IMP-R1 were evaluated.  A series of radioiodinated, diethylenetriaminepentaacetic acid-appended peptide moieties (IMP-R1 through IMP-R8) that differed in overall hydrophilicity and charge were compared.  Radioiodinations of the peptides followed by conjugations to disulfide-reduced RS7 (an anti-epithelial glycoprotein-1 MAb) furnished radioimmunoconjugates in good overall incorporations, with immunoreactivities comparable to that of directly radioiodinated RS7.  Specific activities of up to 8 mCi/mg and yields > 80% have been achieved.  In vitro processing expts. showed marked increases in radioiodine retention with all of the adducts; radioiodine retention at 45 h was up to 86% greater in cells than with directly iodinated RS7.  Each of the 125I-peptide-RS7 conjugates was compared with 131I-RS7 (labeled by the chloramine-T method) in paired-label biodistribution studies in nude mice bearing human lung tumor xenografts.  All of the residualizing substrates exhibited significantly enhanced retention in tumor in comparison to directly radioiodinated RS7, but the nontarget uptakes differed significantly among the residualizing labels.  The best labels were IMP-R4 and IMP-R8, showing superior tumor-to-non-tumor ratios by virtue of high tumor uptake and retention and low normal organ uptake, as well as superior radiochem. properties.  The therapeutic efficacy of 131I-IMP-R4-RS7 was compared with that of conventionally 131I-labeled RS7 and 90yttrium-RS7 in the nude mice lung cancer model.  The therapeutic efficacy of 131I-IMP-R4-RS7 and 90yttrium-RS7 were equiv., and both agents yielded significantly improved control of tumor growth compared with conventional 131I-labeled RS7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0ALo7p9Ech7Vg90H21EOLACvtfcHk0lgpsysOYiIz3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvFKhtg%253D%253D&md5=45c0808b7d874b461ad5c20c828aec18</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DR.%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DMattes%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DReed%26aufirst%3DL.%26aulast%3DNewsome%26aufirst%3DG.%26aulast%3DMcBride%26aufirst%3DB.%2BJ.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DImproved%2520iodine%2520radiolabels%2520for%2520monoclonal%2520antibody%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D111%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Govindan, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattes, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karacay, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span> </span><span class="NLM_article-title">Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing <span class="smallcaps smallerCapital">d</span>-amino acids</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc980075g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK1MXptVSisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=231-240&author=S.+V.+Govindanauthor=M.+J.+Mattesauthor=R.+Steinauthor=B.+J.+McBrideauthor=H.+Karacayauthor=D.+M.+Goldenbergauthor=H.+J.+Hansenauthor=G.+L.+Griffiths&title=Labeling+of+monoclonal+antibodies+with+diethylenetriaminepentaacetic+acid-appended+radioiodinated+peptides+containing+d-amino+acids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid-Appended Radioiodinated Peptides Containing D-Amino Acids</span></div><div class="casAuthors">Govindan, Serengulam V.; Mattes, M. Jules; Stein, Rhona; McBride, Bill J.; Karacay, Habibe; Goldenberg, David M.; Hansen, Hans J.; Griffiths, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-240</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimal use of radioiodinated internalizing monoclonal antibodies (mAbs) for radio-immunotherapy necessitates the development of practical methods for increasing the level of retention of 131I in the tumor.  Lysosomally trapped ("residualizing") iodine radiolabels that have been previously designed are based mostly on carbohydrate-tyramine adducts, but these methods have drawbacks of low overall yields and/or high levels of mAb aggregation.  We have developed a method using thiol-reactive diethylenetriaminepentaacetic acid (DTPA)-peptide adducts wherein the peptides are assembled with one or more D-amino acids, including D-tyrosine.  Two such substrates, R-Gly-D-Tyr-D-Lys[1-(p-thiocarbonylaminobenzyl)DTPA], referred to as IMP-R1, and [R-D-Ala-D-Tyr-D-Tyr-D-Lys]2(CA-DTPA), referred to as IMP-R2, wherein R is 4-(N-maleimidomethyl)cyclohexane-1-carbonyl, were synthesized by prepg. functional group-protected peptides on a solid phase, selectively derivatizing the lysine side chain with 1-(p-isothiocyanatobenzyl)DTPA or DTPA dianhydride (CA-DTPA), deprotecting other functional groups, and finally derivatizing the peptide's N-terminus so it contained a maleimide group.  Radioiodinations of the peptides followed by conjugations to disulfide-reduced mAbs, carried out as a one-vial procedure, resulted in 32-89% overall yields, at specific activities of 1.8-11.1 mCi/mg, with less than 2% aggregation.  Two internalizing mAbs, LL2 (anti-CD 22 B-cell lymphoma mAb) and RS7 (an anti-adenocarcinoma mAb which targets EGP-1 antigen), labeled with this procedure exhibited a 2-3-fold better cellular retention in Ramos and Calu-3 tumor cell lines, in vitro, resp., compared to the same mAbs radioiodinated with the chloramine-T method.  The rationale for the new approach, syntheses, radiochem. and in vitro data are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7tvCUmZNebVg90H21EOLACvtfcHk0lgditpCDvIjEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXptVSisg%253D%253D&md5=c4e4e629db5533b344268542e0c0ccd4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbc980075g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc980075g%26sid%3Dliteratum%253Aachs%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DMattes%26aufirst%3DM.%2BJ.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DMcBride%26aufirst%3DB.%2BJ.%26aulast%3DKaracay%26aufirst%3DH.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26atitle%3DLabeling%2520of%2520monoclonal%2520antibodies%2520with%2520diethylenetriaminepentaacetic%2520acid-appended%2520radioiodinated%2520peptides%2520containing%2520d-amino%2520acids%26jtitle%3DBioconjugate%2520Chem.%26date%3D1999%26volume%3D10%26spage%3D231%26epage%3D240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ugi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fetzer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbruckner, C.</span><span> </span><span class="NLM_article-title">Versuche mit Isonitrilen</span> <span class="citation_source-journal">Angew. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1959</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1959&pages=386&author=I.+Ugiauthor=R.+Meyrauthor=U.+Fetzerauthor=C.+Steinbruckner&title=Versuche+mit+Isonitrilen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUgi%26aufirst%3DI.%26aulast%3DMeyr%26aufirst%3DR.%26aulast%3DFetzer%26aufirst%3DU.%26aulast%3DSteinbruckner%26aufirst%3DC.%26atitle%3DVersuche%2520mit%2520Isonitrilen%26jtitle%3DAngew.%2520Chem.%26date%3D1959%26volume%3D71%26spage%3D386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Domling, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugi, I. I.</span><span> </span><span class="NLM_article-title">Multicomponent Reactions with Isocyanides</span> <span class="citation_source-journal">Angew. Chem., Int. Ed. Engl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3168</span><span class="NLM_x">–</span> <span class="NLM_lpage">3210</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=3168-3210&author=A.+Domlingauthor=I.+I.+Ugi&title=Multicomponent+Reactions+with+Isocyanides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DUgi%26aufirst%3DI.%2BI.%26atitle%3DMulticomponent%2520Reactions%2520with%2520Isocyanides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D2000%26volume%3D39%26spage%3D3168%26epage%3D3210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1038%2Fnbt.1480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=18641636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=925-932&author=J.+R.+Junutula&title=Site-specific+conjugation+of+a+cytotoxic+drug+to+an+antibody+improves+the+therapeutic+index"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span></div><div class="casAuthors">Junutula, Jagath R.; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D.; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S.; Lu, Yanmei; Meng, Y. Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C.; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin; Flagella, Kelly; Venook, Rayna; Ross, Sarajane; Spencer, Susan D.; Wong, Wai Lee; Lowman, Henry B.; Vandlen, Richard; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Mallet, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">925-932</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs.  However, conventional drug conjugation strategies yield heterogeneous conjugates with relatively narrow therapeutic index (max. tolerated dose/curative dose).  Using leads from the authors' previously described phage display-based method to predict suitable conjugation sites, the authors engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb Ig folding and assembly, or alter antigen binding.  When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models.  Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepd. by conventional approaches.  The favorable in vivo properties of the near-homogeneous compn. of this conjugate suggest that this strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4HIiPBABzRLVg90H21EOLACvtfcHk0lj9Vz2APVTlNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D&md5=d55f59594fb6349d0337dfed2783e83c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1480%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DSite-specific%2520conjugation%2520of%2520a%2520cytotoxic%2520drug%2520to%2520an%2520antibody%2520improves%2520the%2520therapeutic%2520index%26jtitle%3DNature%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D925%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">DeNardo, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeNardo, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroger, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukis, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meares, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, S.</span><span> </span><span class="NLM_article-title">Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Clin. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.3816%2FCLM.2000.n.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A280%3ADC%252BD3MnlsVCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=118-126&author=G.+L.+DeNardoauthor=S.+J.+DeNardoauthor=R.+T.+O%E2%80%99Donnellauthor=L.+A.+Krogerauthor=D.+L.+Kukisauthor=C.+F.+Mearesauthor=D.+S.+Goldsteinauthor=S.+Shen&title=Are+radiometal-labeled+antibodies+better+than+iodine-131-labeled+antibodies%3A+comparative+pharmacokinetics+and+dosimetry+of+copper-67-%2C+iodine-131-%2C+and+yttrium-90-labeled+Lym-1+antibody+in+patients+with+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma</span></div><div class="casAuthors">DeNardo G L; DeNardo S J; O'Donnell R T; Kroger L A; Kukis D L; Meares C F; Goldstein D S; Shen S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-26</span>
        ISSN:<span class="NLM_cas:issn">1526-9655</span>.
    </div><div class="casAbstract">Radioimmunotherapy using radiolabeled monoclonal antibodies against tumor-associated antigens has been efficacious, particularly in the treatment of radiosensitive malignancies such as lymphoma.  Antilymphoma monoclonal antibody Lym-1, labeled with copper-67 ((67)Cu), iodine-131 ((131)I), or yttrium-90 ((90)Y), has been effective salvage therapy for patients with non-Hodgkin's lymphoma.  Although (131)I has had the dominant role in radioimmunotherapy thus far, several properties of radiometals are preferable.  A total of 70 patients with B-lymphocytic non-Hodgkin's lymphoma were studied using (67)Cu-2IT-BAT-Lym-1, (131)I-Lym-1, or (111)In-2IT-BAD-Lym-1.  Because (90)Y does not have good emissions for imaging, indium-111 ((111)In), its analogue, was used as a surrogate to estimate (90)Y-2IT-BAD-Lym-1 pharmacokinetics and radiation dosimetry.  Subsets of four patients in each group received (67)Cu- and (131)I-labeled Lym-1 or (111)In- and (131)I-labeled Lym-1, allowing direct comparisons of the radioimmunoconjugates.  Sequential blood samples and planar images were used to quantitate radioimmunoconjugate in tissues in order to determine pharmacokinetics and radiation dosimetry. (67)Cu-2IT-BAT-Lym-1 and (90)Y-2IT-BAD-Lym-1 exhibited higher cumulated activity concentrations and radiation absorbed doses per unit of administered radioactivity for tumors than did (131)I-Lym-1.  The mean tumor cumulated activity (area under the time-activity curve) concentrations per unit of administered radioactivity for (67)Cu-2IT-BAT-Lym-1, (131)I-Lym-1, and (90)Y-2IT-BAD-Lym-1 were 96.89, 33.96, and 43.42 GBq-s/GBq/g, respectively.  The mean tumor radiation doses from (67)Cu-2IT-BAT-Lym-1, (131)I-Lym-1, and (90)Y-2IT-BAD-Lym-1 were 2.5, 1.0, and 6.6 Gy/GBq, respectively, because (90)Y deposits more radiation per unit of administered radioactivity.  Per unit of administered radioactivity, radiation doses from (67)Cu-2IT-BAT-Lym-1 and (131)I-Lym-1 to normal tissues were similar except that the liver received a higher dose from (67)Cu-2IT-BAT-Lym-1 than from (131)I-Lym-1; radiation doses to normal tissues from (90)Y-2IT-BAD-Lym-1 were generally higher.  Consequently, the therapeutic indices (ratio of radiation doses to tumor and normal tissues) for (67)Cu-2IT-BAT-Lym-1, and less generally for (90)Y-2IT-BAD-Lym-1, were more favorable when compared to those for (131)I-Lym-1.  Data from the matched subsets of patients showed similar therapeutic indices to those for the groups of patients. (67)Cu-2IT-BAT-Lym-1 showed more potential than (131)I-Lym-1 or (90)Y-2IT-BAD-Lym-1 for non-Hodgkin's lymphoma radioimmunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQUuAA5tMMxoOWhZTslLrfffW6udTcc2eYq9LKOj-Md27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnlsVCrug%253D%253D&md5=3ef62c67ce058435c12d377c68ae0b97</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3816%2FCLM.2000.n.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLM.2000.n.010%26sid%3Dliteratum%253Aachs%26aulast%3DDeNardo%26aufirst%3DG.%2BL.%26aulast%3DDeNardo%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DR.%2BT.%26aulast%3DKroger%26aufirst%3DL.%2BA.%26aulast%3DKukis%26aufirst%3DD.%2BL.%26aulast%3DMeares%26aufirst%3DC.%2BF.%26aulast%3DGoldstein%26aufirst%3DD.%2BS.%26aulast%3DShen%26aufirst%3DS.%26atitle%3DAre%2520radiometal-labeled%2520antibodies%2520better%2520than%2520iodine-131-labeled%2520antibodies%253A%2520comparative%2520pharmacokinetics%2520and%2520dosimetry%2520of%2520copper-67-%252C%2520iodine-131-%252C%2520and%2520yttrium-90-labeled%2520Lym-1%2520antibody%2520in%2520patients%2520with%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DClin.%2520Lymphoma%26date%3D2000%26volume%3D1%26spage%3D118%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Sharkey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattes, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juweid, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22</span> <span class="citation_source-journal">Cancer Immunol. Immunother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1007%2Fs002620050371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=9191878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK2sXktl2iurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1997&pages=179-188&author=R.+M.+Sharkeyauthor=T.+M.+Behrauthor=M.+J.+Mattesauthor=R.+Steinauthor=G.+L.+Griffithsauthor=L.+B.+Shihauthor=H.+J.+Hansenauthor=R.+D.+Blumenthalauthor=R.+M.+Dunnauthor=M.+E.+Juweidauthor=D.+M.+Goldenberg&title=Advantage+of+residualizing+radiolabels+for+an+internalizing+antibody+against+the+B-cell+lymphoma+antigen%2C+CD22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22</span></div><div class="casAuthors">Sharkey, Robert M.; Behr, Thomas M.; Mattes, M. Jules; Stein, Rhona; Griffiths, Gary L.; Shih, Lisa B.; Hansen, Hans J.; Blumenthal, Rosalyn D.; Dunn, Robert M.; Juweid, Malik E.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">LL2 is an anti-CD22 pan-B-cell monoclonal antibody which, when radiolabeled, has a high sensitivity for detecting B-cell, non-Hodgkin's lymphoma (NHL), as well as an antitumor efficacy in therapeutic applications.  The aim of this study was to det. whether intracellularly retained radiolabels have an advantage in the diagnosis and therapy of lymphoma with LL2.  In vitro studies showed that iodinated LL2 is intracellularly catabolized, with a rapid release of the radioiodine from the cell.  In contrast, residualizing radiolabels, such as radioactive metals, are retained intracellularly for substantially longer.  In vivo studies were performed using LL2-labeled with radioiodine by a non-residualizing (chloramine-T) or a residualizing method (dilactitol-tyramine, DLT), or with a radioactive metal (111In).  The biodistribution of a mixt. of 125I (non-residualizing chloramine-T compared to residualizing DLT), 111In-labeled LL2 murine IgG2a or its fragments [F(ab')2, Fab'], as well as its humanized, CDR-grafted form, was studied in nude mice bearing the RL human B-cell NHL cell line.  Radiation doses were calcd. from the biodistribution data according to the Medical International Radiation Dose scheme to assess the potential advantage for therapeutic applications.  At all assay times, tumor uptake was higher with the residualizing labels (i.e., 111In and DLT-125I) than with the non-residualizing iodine label.  For example, tumor/blood ratios of 111In-labeled IgG were 3.2-, 3.5- and 2.8-fold higher than for non-residualizing iodinated IgG on days 3, 7 and 14, resp.  Similar results were obtained for DLT-labeled IgG and fragments with residualized radiolabels.  Tumor/organ ratios also were higher with residualizing labels.  No significant differences in tumor, blood and organ uptake were obsd. between murine and humanized LL2.  The conventionally iodinated anti-CD20 antibody, 1F5, had tumor uptake values comparable to those of iodinated LL2, the uptake of both antibodies being strongly dependent on tumor size.  These data suggest that, with internalizing antibodies such as LL2, labeling with intracellularly retained isotopes has an advantage over released ones, which justifies further clin. trials with residualizing 111In-labeled LL2 for diagnosis, and residualizing 131I and 90Y labels for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUZUEOenuqNbVg90H21EOLACvtfcHk0lhKwH9p5AOXmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktl2iurY%253D&md5=72bc030830e660c544512669540ed4ad</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs002620050371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002620050371%26sid%3Dliteratum%253Aachs%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DBehr%26aufirst%3DT.%2BM.%26aulast%3DMattes%26aufirst%3DM.%2BJ.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DShih%26aufirst%3DL.%2BB.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DBlumenthal%26aufirst%3DR.%2BD.%26aulast%3DDunn%26aufirst%3DR.%2BM.%26aulast%3DJuweid%26aufirst%3DM.%2BE.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DAdvantage%2520of%2520residualizing%2520radiolabels%2520for%2520an%2520internalizing%2520antibody%2520against%2520the%2520B-cell%2520lymphoma%2520antigen%252C%2520CD22%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D1997%26volume%3D44%26spage%3D179%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Li, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bugaj, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erion, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. J.</span><span> </span><span class="NLM_article-title">DOTA-<span class="smallcaps smallerCapital">d</span>-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">728</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc015590k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFahurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=721-728&author=W.+P.+Liauthor=J.+S.+Lewisauthor=J.+Kimauthor=J.+E.+Bugajauthor=M.+A.+Johnsonauthor=J.+L.+Erionauthor=C.+J.+Anderson&title=DOTA-d-Tyr%281%29-octreotate%3A+a+somatostatin+analogue+for+labeling+with+metal+and+halogen+radionuclides+for+cancer+imaging+and+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">DOTA-D-Tyr1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy</span></div><div class="casAuthors">Li, Wen Ping; Lewis, Jason S.; Kim, Joonyoung; Bugaj, Joseph E.; Johnson, Michael A.; Erion, Jack L.; Anderson, Carolyn J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">721-728</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The goal of this study was to evaluate a somatostatin receptor ligand, DOTA-D-Tyr1-octreotate (DOTA-DY1-TATE), that has the chelator 1,4,7,10-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (DOTA) attached to the D-Tyr1 residue, allowing radiolabeling with both radiohalogens and radiometals.  A potential advantage of having a chelator attached to the Tyr1 residue is that halogen radiolabels may residualize or remain trapped in tumor cells rather than clear from the tumor.  DOTA-DY1-TATE was synthesized by solid-phase methods and radiolabeled with 61Cu, 64Cu, and 125I in high radiochem. purity and specific activity.  A competitive binding assay demonstrated that natCu-DOTA-DY1-TATE and DOTA-natI-DY1-TATE had comparable affinity to natIn-DTPA-OC in AR42J rat pancreatic tumor cells membranes.  61Cu-DOTA-DY1-TATE had a dissocn. const. (Kd) of 176.4 pM and a receptor concn. (Bmax) of 244.4 fmol/mg.  A tumor uptake of 1.515 %ID/g was detd. for 64Cu-DOTA-DY1-TATE and 0.814 %ID/g for DOTA-125I-DY1-TATE in AR42J tumor bearing Lewis rats at 1 h postinjection.  DOTA-125I-DY1-TATE remained in the tumor at a higher concn. out to 4 h postinjection, suggesting that the iodine may have residualized in the tumor cells.  MicroPET imaging of 64Cu-DOTA-DY1-TATE in AR42J tumor bearing rats and SCID mice at 2 h postinjection showed significant uptake and good contrast in the thigh tumors in the rat model and in the neck and thigh tumors of the mouse.  This study demonstrates that DOTA-DY1-TATE is a somatostatin analog that can be labeled with both metal and halogen radionuclides, and its 64Cu- and 125I-radiolabeled compds. showed somatostatin receptor-mediated uptake in normal and tumor tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonwvS8jTPGF7Vg90H21EOLACvtfcHk0lhKwH9p5AOXmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFahurk%253D&md5=30881b1597e077c40cfa8fb00ae78d38</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbc015590k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc015590k%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%2BP.%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DBugaj%26aufirst%3DJ.%2BE.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DErion%26aufirst%3DJ.%2BL.%26aulast%3DAnderson%26aufirst%3DC.%2BJ.%26atitle%3DDOTA-d-Tyr%25281%2529-octreotate%253A%2520a%2520somatostatin%2520analogue%2520for%2520labeling%2520with%2520metal%2520and%2520halogen%2520radionuclides%2520for%2520cancer%2520imaging%2520and%2520therapy%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26spage%3D721%26epage%3D728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Tei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gugliotta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avedano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovenzana, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Application of the Ugi four-component reaction to the synthesis of ditopic bifunctional chelating agents</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1039%2Fb907932g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=19830289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=4406-4414&author=L.+Teiauthor=G.+Gugliottaauthor=S.+Avedanoauthor=G.+B.+Giovenzanaauthor=M.+Botta&title=Application+of+the+Ugi+four-component+reaction+to+the+synthesis+of+ditopic+bifunctional+chelating+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Application of the Ugi four-component reaction to the synthesis of ditopic bifunctional chelating agents</span></div><div class="casAuthors">Tei, Lorenzo; Gugliotta, Giuseppe; Avedano, Stefano; Giovenzana, Giovanni B.; Botta, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4406-4414</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The Ugi four-component reaction (Ugi 4CR) of an amine, tri-tert-Bu 10-[H2N(CH2)nNHCOCH2]-1,4,7,10-tetraazadodecane-1,4,7-tricarboxylate [DOTAMA(OtBu)3CnNH2, 1, n = 2; 2, n = 6] with a carboxylic acid 10-[HO2C(CH2)5NHCOCH2]-1,4,7,10-tetraazadodecane-1,4,7-tricarboxylate [3, DOTAMA(OtBu)3C5CO2H], an aldehyde R1CHO and an isocyanide R2NC was exploited for the first time for prepn. of bifunctional ditopic chelators I [4-8, X = CO2tBu; M1, M2 = electron pair; R1 = H, C9H19, CbzNH(CH2)5; R2 = cyclohexyl, C18H37, CH2CO2Me; L1, L2, X = CO2H, R1 = H; R2 = cyclohexyl, C18H37, M = electron pair] and their gadolinium-yttrium complex [11, X = CO2-, M1 = Y, M2 = Gd; R1 = H, R2 = cyclohexyl] in a single synthetic step.  Variation of the components allows the insertion of another functional group into the α-acylaminoamide skeleton for further conjugation to biomols.  The optimal reaction conditions were found by using methanol as solvent and ultrasound irradn. at a power of 60 W (20 kHz) for 3 h.  The Gd(III) complexes of the dimeric ligands L1 and L2 were fully characterized in aq. media by relaxometric techniques with varying temp. and magnetic field strength.  The relaxivity of Gd2L1 and Gd2L2 (in the aggregated form), at 20 MHz and 310 K, are 5.6 and 20.0 mM-1 s-1, resp.  The enhanced value found for Gd2L2 indicates that this lipophilic complex forms micelles at concns. <0.1 mM.  Finally, the binding of Gd2L2 to human serum albumin (HSA) was investigated by proton relaxometry, and the affinity const. of the complex and the relaxivity of the macromol. adduct (rb1p = 38.1 mM-1 s-1; 20 MHz and 310 K) derived.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3QERuF4U7U7Vg90H21EOLACvtfcHk0lhKwH9p5AOXmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb7K&md5=09d6d929962527143300c0381d83d7f1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2Fb907932g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb907932g%26sid%3Dliteratum%253Aachs%26aulast%3DTei%26aufirst%3DL.%26aulast%3DGugliotta%26aufirst%3DG.%26aulast%3DAvedano%26aufirst%3DS.%26aulast%3DGiovenzana%26aufirst%3DG.%2BB.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DApplication%2520of%2520the%2520Ugi%2520four-component%2520reaction%2520to%2520the%2520synthesis%2520of%2520ditopic%2520bifunctional%2520chelating%2520agents%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26spage%3D4406%26epage%3D4414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Khawli, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, A. I.</span><span> </span><span class="NLM_article-title"><i>N</i>-(<i>m</i>-[<sup>125</sup>I]Iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies</span> <span class="citation_source-journal">Int. J. Radiat. Appl. Instrum. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1016%2F0883-2897%2892%2990113-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A280%3ADyaK38zjt1answ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1992&pages=289-295&author=L.+A.+Khawliauthor=A.+D.+van+den+Abbeeleauthor=A.+I.+Kassis&title=N-%28m-%5B125I%5DIodophenyl%29maleimide%3A+an+agent+for+high+yield+radiolabeling+of+antibodies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies</span></div><div class="casAuthors">Khawli L A; van den Abbeele A D; Kassis A I</div><div class="citationInfo"><span class="NLM_cas:title">International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-95</span>
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    </div><div class="casAbstract">In an effort to radiolabel antibodies, N-(m-[125I]iodophenyl)maleimide (m-[125I]IPM) was prepared by the demetallation of an N-[m-tri-(n-butyl)stannylphenyl]maleimide intermediate.  The unlabeled intermediate was synthesized in greater than or equal to 75% yield using a palladium catalyzed reaction of hexabutylditin with m-bromoaniline, followed by reaction with maleic anhydride and ring annulation.  All products were confirmed by NMR and elemental analysis.  Labeling with 125I was carried out in a biphasic mixture containing chloramine-T (radiochemical yield greater than or equal to 70%).  Rabbit IgG modified with the heterobifunctional crosslinking agent N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) and bovine serum albumin were conjugated with m-[125I]IPM (yield: 40 and 80%, respectively).  In addition, m-[125I]IPM was conjugated to rabbit IgG subunits (HL) in 70% yield.  The in vitro stability of the radiolabeled proteins in serum showed less than 1% deiodination over 24 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmd7360MZz1xOk4JA3soTqfW6udTcc2ebpK5OqsFViHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zjt1answ%253D%253D&md5=20828860ce798c22f74866ba325adde3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2F0883-2897%2892%2990113-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2897%252892%252990113-D%26sid%3Dliteratum%253Aachs%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3Dvan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DKassis%26aufirst%3DA.%2BI.%26atitle%3DN-%2528m-%255B125I%255DIodophenyl%2529maleimide%253A%2520an%2520agent%2520for%2520high%2520yield%2520radiolabeling%2520of%2520antibodies%26jtitle%3DInt.%2520J.%2520Radiat.%2520Appl.%2520Instrum.%2520B%26date%3D1992%26volume%3D19%26spage%3D289%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Shen, B. Q.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Conjugation site modulates the in vivo stability and therapeutic activity of antibody–drug conjugates</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1038%2Fnbt.2108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=22267010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=184-189&author=B.+Q.+Shen&title=Conjugation+site+modulates+the+in+vivo+stability+and+therapeutic+activity+of+antibody%E2%80%93drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span></div><div class="casAuthors">Shen, Ben-Quan; Xu, Keyang; Liu, Luna; Raab, Helga; Bhakta, Sunil; Kenrick, Margaret; Parsons-Reponte, Kathryn L.; Tien, Janet; Yu, Shang-Fan; Mai, Elaine; Li, Dongwei; Tibbitts, Jay; Baudys, Jakub; Saad, Ola M.; Scales, Suzie J.; McDonald, Paul J.; Hass, Philip E.; Eigenbrot, Charles; Nguyen, Trung; Solis, Willy A.; Fuji, Reina N.; Flagella, Kelly M.; Patel, Darshana; Spencer, Susan D.; Khawli, Leslie A.; Ebens, Allen; Wong, Wai Lee; Vandlen, Richard; Kaur, Surinder; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates.  To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge.  The highly solvent-accessible site rapidly lost conjugated thiol-reactive linkers in plasma owing to maleimide exchange with reactive thiols in albumin, free cysteine or glutathione.  In contrast, a partially accessible site with a pos. charged environment promoted hydrolysis of the succinimide ring in the linker, thereby preventing this exchange reaction.  The site with partial solvent-accessibility and neutral charge displayed both properties.  In a mouse mammary tumor model, the stability and therapeutic activity of the antibody conjugate were affected pos. by succinimide ring hydrolysis and neg. by maleimide exchange with thiol-reactive constituents in plasma.  Thus, the chem. and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkINkMwQTMFrVg90H21EOLACvtfcHk0ljR5kXcQTjbkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D&md5=c647fc5bdfe93dfdabb15ca40934837f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2108%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.%2BQ.%26atitle%3DConjugation%2520site%2520modulates%2520the%2520in%2520vivo%2520stability%2520and%2520therapeutic%2520activity%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DNature%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D184%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Kurebayashi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otsuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochizuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonoo, H.</span><span> </span><span class="NLM_article-title">Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">717</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1038%2Fsj.bjc.6690114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=10070858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK1MXhslCns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1999&pages=707-717&author=J.+Kurebayashiauthor=T.+Otsukiauthor=C.+K.+Tangauthor=M.+Kurosumiauthor=S.+Yamamotoauthor=K.+Tanakaauthor=M.+Mochizukiauthor=H.+Nakamuraauthor=H.+Sonoo&title=Isolation+and+characterization+of+a+new+human+breast+cancer+cell+line%2C+KPL-4%2C+expressing+the+Erb+B+family+receptors+and+interleukin-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6</span></div><div class="casAuthors">Kurebayashi, J.; Otsuki, T.; Tang, C. K.; Kurosumi, M.; Yamamoto, S.; Tanaka, K.; Mochizuki, M.; Nakamura, H.; Sonoo, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">707-717</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">A new human breast cancer cell line, KPL-4, was recently isolated from the malignant pleural effusion of a breast cancer patient with an inflammatory skin metastasis.  This cell line can be cultured under serum-free conditions and is tumorigenic in female athymic nude mice.  Flow cytometric anal. revealed the expression of Erb B-1, -2 and -3.  Dot blot hybridization showed a 15-fold amplification of the erb B-2.  Reverse transcription-polymerase chain reaction anal. showed a detectable level of mRNA expression of all the Erb B family receptors.  In addn., all the receptors were autophosphorylated under a serum-supplemented condition.  Unexpectedly, transplanted KPL-4 tumors induced cachexia of recipient mice.  A high concn. of interleukin-6 (IL-6) was detected in both the culture medium and the serum of mice.  The wt. of tumors significantly correlated with the serum IL-6 level.  The antiproliferative effect of a humanized anti-Erb B-2 monoclonal antibody, rhuMAbHER2, was investigated.  This antibody significantly inhibited the growth of KPL-4 cells in vitro but modestly in vivo.  Loss of mouse body wt. was partly reversed by rhuMAbHER2.  These findings suggest that KPL-4 cells may be useful in the development of new strategies against breast cancer overexpressing the Erb B family receptors and against IL-6-induced cachexia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnsnxu39EMvbVg90H21EOLACvtfcHk0lg_g-z6saWVxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslCns7k%253D&md5=37483c121356ef173a09e2ae3a3759f6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6690114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6690114%26sid%3Dliteratum%253Aachs%26aulast%3DKurebayashi%26aufirst%3DJ.%26aulast%3DOtsuki%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DC.%2BK.%26aulast%3DKurosumi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DMochizuki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DSonoo%26aufirst%3DH.%26atitle%3DIsolation%2520and%2520characterization%2520of%2520a%2520new%2520human%2520breast%2520cancer%2520cell%2520line%252C%2520KPL-4%252C%2520expressing%2520the%2520Erb%2520B%2520family%2520receptors%2520and%2520interleukin-6%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1999%26volume%3D79%26spage%3D707%26epage%3D717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Pastuskovas, C. V.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">752</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1158%2F1535-7163.MCT-11-0742-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=22222630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=752-762&author=C.+V.+Pastuskovas&title=Effects+of+anti-VEGF+on+pharmacokinetics%2C+biodistribution%2C+and+tumor+penetration+of+trastuzumab+in+a+preclinical+breast+cancer+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model</span></div><div class="casAuthors">Pastuskovas, Cinthia V.; Mundo, Eduardo E.; Williams, Simon P.; Nayak, Tapan K.; Ho, Jason; Ulufatu, Sheila; Clark, Suzanna; Ross, Sarajane; Cheng, Eric; Parsons-Reponte, Kathryn; Cain, Gary; Van Hoy, Marjie; Majidy, Nicholas; Bheddah, Sheila; dela Cruz Chuh, Josefa; Kozak, Katherine R.; Lewin-Koh, Nicholas; Nauka, Peter; Bumbaca, Daniela; Sliwkowski, Mark; Tibbitts, Jay; Theil, Frank-Peter; Fielder, Paul J.; Khawli, Leslie A.; Boswell, C. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">752-762</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Both human epidermal growth factor receptor 2 (HER-2/neu) and VEGF overexpression correlate with aggressive phenotypes and decreased survival among breast cancer patients.  Concordantly, the combination of trastuzumab (anti-HER2) with bevacizumab (anti-VEGF) has shown promising results in preclin. xenograft studies and in clin. trials.  However, despite the known antiangiogenic mechanism of anti-VEGF antibodies, relatively little is known about their effects on the pharmacokinetics and tissue distribution of other antibodies.  This study aimed to measure the disposition properties, with a particular emphasis on tumor uptake, of trastuzumab in the presence or absence of anti-VEGF.  Radiolabeled trastuzumab was administered alone or in combination with an anti-VEGF antibody to mice bearing HER2-expressing KPL-4 breast cancer xenografts.  Biodistribution, autoradiog., and single-photon emission computed tomog.-X-ray computed tomog. imaging all showed that anti-VEGF administration reduced accumulation of trastuzumab in tumors despite comparable blood exposures and similar distributions in most other tissues.  A similar trend was also obsd. for an isotype-matched IgG with no affinity for HER2, showing reduced vascular permeability to macromols.  Reduced tumor blood flow (P < 0.05) was obsd. following anti-VEGF treatment, with no significant differences in the other physiol. parameters measured despite immunohistochem. evidence of reduced vascular d.  In conclusion, anti-VEGF preadministration decreased tumor uptake of trastuzumab, and this phenomenon was mechanistically attributed to reduced vascular permeability and blood perfusion.  These findings may ultimately help inform dosing strategies to achieve improved clin. outcomes.  Mol Cancer Ther; 11(3); 752-62.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZzCP7G3uB07Vg90H21EOLACvtfcHk0lg_g-z6saWVxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisb8%253D&md5=9dceb9fe2573007c6aed664f6c4d8aa1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0742-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0742-T%26sid%3Dliteratum%253Aachs%26aulast%3DPastuskovas%26aufirst%3DC.%2BV.%26atitle%3DEffects%2520of%2520anti-VEGF%2520on%2520pharmacokinetics%252C%2520biodistribution%252C%2520and%2520tumor%2520penetration%2520of%2520trastuzumab%2520in%2520a%2520preclinical%2520breast%2520cancer%2520model%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D752%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Viola-Villegas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, R. P.</span><span> </span><span class="NLM_article-title">The coordination chemistry of 1,4,7,10-tetraazacyclododecane-<i>N,N</i>′<i>,N</i>″<i>,N</i>″-tetraacetic acid (H<sub>4</sub>DOTA): structural overview and analyses on structure–stability relationships</span> <span class="citation_source-journal">Coord. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">253</span><span class="NLM_x">, </span> <span class="NLM_fpage">1906</span><span class="NLM_x">–</span> <span class="NLM_lpage">1925</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=2009&pages=1906-1925&author=N.+Viola-Villegasauthor=R.+P.+Doyle&title=The+coordination+chemistry+of+1%2C4%2C7%2C10-tetraazacyclododecane-N%2CN%E2%80%B2%2CN%E2%80%B3%2CN%E2%80%B3-tetraacetic+acid+%28H4DOTA%29%3A+structural+overview+and+analyses+on+structure%E2%80%93stability+relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DViola-Villegas%26aufirst%3DN.%26aulast%3DDoyle%26aufirst%3DR.%2BP.%26atitle%3DThe%2520coordination%2520chemistry%2520of%25201%252C4%252C7%252C10-tetraazacyclododecane-N%252CN%25E2%2580%25B2%252CN%25E2%2580%25B3%252CN%25E2%2580%25B3-tetraacetic%2520acid%2520%2528H4DOTA%2529%253A%2520structural%2520overview%2520and%2520analyses%2520on%2520structure%25E2%2580%2593stability%2520relationships%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2009%26volume%3D253%26spage%3D1906%26epage%3D1925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Gnidehou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caillou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohayon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaniewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noel-Hudson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agnangji, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sezan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virion, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuy, C.</span><span> </span><span class="NLM_article-title">Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the recycling of iodide close to the thyroglobulin iodination site</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1574</span><span class="NLM_x">–</span> <span class="NLM_lpage">1576</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=1574-1576&author=S.+Gnidehouauthor=B.+Caillouauthor=M.+Talbotauthor=R.+Ohayonauthor=J.+Kaniewskiauthor=M.+S.+Noel-Hudsonauthor=S.+Morandauthor=D.+Agnangjiauthor=A.+Sezanauthor=F.+Courtinauthor=A.+Virionauthor=C.+Dupuy&title=Iodotyrosine+dehalogenase+1+%28DEHAL1%29+is+a+transmembrane+protein+involved+in+the+recycling+of+iodide+close+to+the+thyroglobulin+iodination+site"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGnidehou%26aufirst%3DS.%26aulast%3DCaillou%26aufirst%3DB.%26aulast%3DTalbot%26aufirst%3DM.%26aulast%3DOhayon%26aufirst%3DR.%26aulast%3DKaniewski%26aufirst%3DJ.%26aulast%3DNoel-Hudson%26aufirst%3DM.%2BS.%26aulast%3DMorand%26aufirst%3DS.%26aulast%3DAgnangji%26aufirst%3DD.%26aulast%3DSezan%26aufirst%3DA.%26aulast%3DCourtin%26aufirst%3DF.%26aulast%3DVirion%26aufirst%3DA.%26aulast%3DDupuy%26aufirst%3DC.%26atitle%3DIodotyrosine%2520dehalogenase%25201%2520%2528DEHAL1%2529%2520is%2520a%2520transmembrane%2520protein%2520involved%2520in%2520the%2520recycling%2520of%2520iodide%2520close%2520to%2520the%2520thyroglobulin%2520iodination%2520site%26jtitle%3DFASEB%2520J.%26date%3D2004%26volume%3D18%26spage%3D1574%26epage%3D1576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Auf Dem Brinke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesch, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohrle, J.</span><span> </span><span class="NLM_article-title">Re-examination of the subcellular localization of thyroxine 5′-deiodination in rat liver</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=1979&pages=273-279&author=D.+Auf+Dem+Brinkeauthor=R.+D.+Heschauthor=J.+Kohrle&title=Re-examination+of+the+subcellular+localization+of+thyroxine+5%E2%80%B2-deiodination+in+rat+liver"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAuf%2BDem%2BBrinke%26aufirst%3DD.%26aulast%3DHesch%26aufirst%3DR.%2BD.%26aulast%3DKohrle%26aufirst%3DJ.%26atitle%3DRe-examination%2520of%2520the%2520subcellular%2520localization%2520of%2520thyroxine%25205%25E2%2580%25B2-deiodination%2520in%2520rat%2520liver%26jtitle%3DBiochem.%2520J.%26date%3D1979%26volume%3D180%26spage%3D273%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Khawli, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, A. I.</span><span> </span><span class="NLM_article-title">Synthesis of <sup>125</sup>I labeled <i>N</i>-succinimidyl <i>p</i>-iodobenzoate for use in radiolabeling antibodies</span> <span class="citation_source-journal">Int. J. Radiat. Appl. Instrum. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1016%2F0883-2897%2889%2990146-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=2613529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADyaK3cXktVKjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1989&pages=727-733&author=L.+A.+Khawliauthor=A.+I.+Kassis&title=Synthesis+of+125I+labeled+N-succinimidyl+p-iodobenzoate+for+use+in+radiolabeling+antibodies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of iodine-125-labeled N-succinimidyl p-iodobenzoate for use in radiolabeling antibodies</span></div><div class="casAuthors">Khawli, Leslie A.; Kassis, Amin I.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">727-33</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0883-2897</span>.
    </div><div class="casAbstract">A new method is reported for the synthesis of N-succinimidyl p-[125/127I]iodobenzoate (NS-p-IB) from N-succinimidyl p-(tributylstannyl)benzoate via an iodination-destannylation reaction.  The tin precursor was obtained in 70% overall yield from 4-BrC6H4COCl after a four-step synthesis.  The radiochem. yield of NS-p-[125I]IB was 75%.  Conjugation of NS-p-[125I]IB to rabbit IgG or bovine serum albumin gave yields of 52 and 60% resp.  In vitro the radiolabeled proteins in serum at 37° showed <1% deiodination by 24 h.  In vivo the stability of mouse IgG (MIgG) labeled with NS-p-[125I]IB was superior to MIgG radioiodinated in the presence of chloramine-T.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc3gxB4iZBArVg90H21EOLACvtfcHk0liMY8TWW_lWHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktVKjtbg%253D&md5=c9756394cdbe4e8096f7a2de877431b2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2F0883-2897%2889%2990146-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2897%252889%252990146-3%26sid%3Dliteratum%253Aachs%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DKassis%26aufirst%3DA.%2BI.%26atitle%3DSynthesis%2520of%2520125I%2520labeled%2520N-succinimidyl%2520p-iodobenzoate%2520for%2520use%2520in%2520radiolabeling%2520antibodies%26jtitle%3DInt.%2520J.%2520Radiat.%2520Appl.%2520Instrum.%2520B%26date%3D1989%26volume%3D16%26spage%3D727%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Zalutsky, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, A. S.</span><span> </span><span class="NLM_article-title">Radiohalogenation of a monoclonal antibody using an <i>N</i>-succinimidyl 3-(tri-<i>n</i>-butylstannyl)benzoate intermediate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1446</span><span class="NLM_x">–</span> <span class="NLM_lpage">1450</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1988&pages=1446-1450&author=M.+R.+Zalutskyauthor=A.+S.+Narula&title=Radiohalogenation+of+a+monoclonal+antibody+using+an+N-succinimidyl+3-%28tri-n-butylstannyl%29benzoate+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26aulast%3DNarula%26aufirst%3DA.%2BS.%26atitle%3DRadiohalogenation%2520of%2520a%2520monoclonal%2520antibody%2520using%2520an%2520N-succinimidyl%25203-%2528tri-n-butylstannyl%2529benzoate%2520intermediate%26jtitle%3DCancer%2520Res.%26date%3D1988%26volume%3D48%26spage%3D1446%26epage%3D1450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2727</span><span class="NLM_x">–</span> <span class="NLM_lpage">2734</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1158%2F1078-0432.CCR-04-2100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm401365h&amp;key=15814655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFKisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=2727-2734&author=R.+Steinauthor=S.+V.+Govindanauthor=M.+Hayesauthor=G.+L.+Griffithsauthor=H.+J.+Hansenauthor=I.+D.+Horakauthor=D.+M.+Goldenberg&title=Advantage+of+a+residualizing+iodine+radiolabel+in+the+therapy+of+a+colon+cancer+xenograft+targeted+with+an+anticarcinoembryonic+antigen+monoclonal+antibody"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody</span></div><div class="casAuthors">Stein, Rhona; Govindan, Serengulam V.; Hayes, Marianne; Griffiths, Gary L.; Hansen, Hans J.; Horak, Ivan D.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2727-2734</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A disadvantage of conventionally radioiodinated monoclonal antibodies (mAb) for cancer therapy is the short retention time of the radionuclide within target cells.  To address this issue, we recently developed a method in which radioiodine is introduced onto antibodies using an adduct consisting of a nonmetabolizable peptide attached to the aminopolycarboxylate diethylenetriaminepentaacetic acid, designated IMP-R4.  This adduct causes the radioiodine to become trapped in lysosomes following antibody catabolism.  Clin.-scale prodn. of 131I-IMP-R4-labeled antibodies is possible using a recently developed facile method.  The properties of 131I-IMP-R4-labeled anticarcinoembryonic antigen (CEA) humanized mAb hMN-14 were compared with the directly radioiodinated hMN-14 (131I-hMN-14) in CEA-expressing human colon cancer cell lines, LoVo and LS174T, and in nude mice bearing established LoVo tumor xenografts.  125I-IMP-R4-hMN-14 retention in the cell lines was significantly increased (61.5% after 3 days) compared with 125I-hMN-14.  In vivo, a significant improvement in tumor accretion of radiolabel was obtained using 131I-IMP-R4-hMN-14, which led to a marked improvement in therapeutic efficacy.  Eight weeks post-treatment, mean tumor vols. were 0.16±0.19 and 1.99±1.35 cm3 in mice treated with 131I-IMP-R4-hMN-14 and 131I-hMN-14, resp., with complete remissions obsd. in 27% of mice treated with 131I-IMP-R4-hMN-14 and none using 131I-hMN-14.  131I-IMP-R4-hMN-14 provides a significant therapeutic advantage in comparison to the conventionally 131I-labeled antibody.  The ability of this labeling method to lend itself to clin.-scale labeling, the broad applicability of a humanized anti-CEA mAb for CEA-expressing cancers, and the clin. benefits of radioimmunotherapy with anti-CEA mAb shown recently for small-vol. and minimal residual disease combine to make 131I-IMP-R4-hMN-14 a promising new agent for radioimmunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuHNIfXNJGybVg90H21EOLACvtfcHk0liMY8TWW_lWHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFKisLg%253D&md5=3133b13294a6cfb96f3e1af623e5fd8a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2100%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DR.%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DHayes%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DHansen%26aufirst%3DH.%2BJ.%26aulast%3DHorak%26aufirst%3DI.%2BD.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DAdvantage%2520of%2520a%2520residualizing%2520iodine%2520radiolabel%2520in%2520the%2520therapy%2520of%2520a%2520colon%2520cancer%2520xenograft%2520targeted%2520with%2520an%2520anticarcinoembryonic%2520antigen%2520monoclonal%2520antibody%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D2727%26epage%3D2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Behr, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharkey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juweid, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3825</span><span class="NLM_x">–</span> <span class="NLM_lpage">3834</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=3825-3834&author=T.+M.+Behrauthor=R.+M.+Sharkeyauthor=M.+E.+Juweidauthor=R.+D.+Blumenthalauthor=R.+M.+Dunnauthor=G.+L.+Griffithsauthor=H.-J.+Bairauthor=F.+G.+Wolfauthor=W.+S.+Beckerauthor=D.+M.+Goldenberg&title=Reduction+of+the+renal+uptake+of+radiolabeled+monoclonal+antibody+fragments+by+cationic+amino+acids+and+their+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBehr%26aufirst%3DT.%2BM.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DJuweid%26aufirst%3DM.%2BE.%26aulast%3DBlumenthal%26aufirst%3DR.%2BD.%26aulast%3DDunn%26aufirst%3DR.%2BM.%26aulast%3DGriffiths%26aufirst%3DG.%2BL.%26aulast%3DBair%26aufirst%3DH.-J.%26aulast%3DWolf%26aufirst%3DF.%2BG.%26aulast%3DBecker%26aufirst%3DW.%2BS.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DReduction%2520of%2520the%2520renal%2520uptake%2520of%2520radiolabeled%2520monoclonal%2520antibody%2520fragments%2520by%2520cationic%2520amino%2520acids%2520and%2520their%2520derivatives%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D3825%26epage%3D3834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferl, G. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mundo, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweiger, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theil, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielder, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawli, L. A.</span><span> </span><span class="NLM_article-title">Development and evaluation of a novel method for preclinical measurement of tissue vascular volume</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1848</span><span class="NLM_x">–</span> <span class="NLM_lpage">1857</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp100183k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVSmsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=1848-1857&author=C.+A.+Boswellauthor=G.+Z.+Ferlauthor=E.+E.+Mundoauthor=M.+G.+Schweigerauthor=J.+Marikauthor=M.+P.+Reichauthor=F.+P.+Theilauthor=P.+J.+Fielderauthor=L.+A.+Khawli&title=Development+and+evaluation+of+a+novel+method+for+preclinical+measurement+of+tissue+vascular+volume"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Evaluation of a Novel Method for Preclinical Measurement of Tissue Vascular Volume</span></div><div class="casAuthors">Boswell, C. Andrew; Ferl, Gregory Z.; Mundo, Eduardo E.; Schweiger, Michelle G.; Marik, Jan; Reich, Michael P.; Theil, Frank-Peter; Fielder, Paul J.; Khawli, Leslie A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1848-1857</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of clin. predictive models of disposition kinetics for antibody therapeutics is an ongoing pursuit in drug development.  To encourage translation of drug candidates from early research to clin. trials, clin. diagnostic agents may be used to characterize antibody disposition in physiol. relevant preclin. models.  TechneScan PYP was employed to measure tissue vascular vols. (Vv) in healthy mice.  Two methods of red blood cell (RBC) labeling were compared: a direct in vivo method that is analogous to a clin. blood pool imaging protocol, and an indirect method in which radiolabeled blood was transfused from donor mice into recipient mice.  The indirect method gave higher precision in RBC labeling yields, lower Vv values in most tissues, and lower 99mTc uptake in kidneys and bladder by single photon emission computed tomog. (SPECT) imaging relative to the direct method.  Furthermore, the relative influence of each method on the calcd. area under the first 7 days of the concn.-time curve (AUC0-7) of an IgG in nude mice was assessed using a physiol. based pharmacokinetic model.  The model was sensitive to the source of Vv values, whether obtained from the literature or measured by either method, when used to predict exptl. AUC0-7 values for radiolabeled trastuzumab in healthy murine tissues.  In summary, a novel indirect method for preclin. detn. of Vv offered higher precision in RBC labeling efficiency and lower renal uptake of 99mTc than the direct method.  In addn., these observations emphasize the importance of obtaining accurate physiol. parameter values for modeling antibody uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrngP-XJuxqWLVg90H21EOLACvtfcHk0ljZGNPrHbKQ5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVSmsL3L&md5=6fdc1d64b618a981fa9551e769eb9816</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fmp100183k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp100183k%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26aulast%3DFerl%26aufirst%3DG.%2BZ.%26aulast%3DMundo%26aufirst%3DE.%2BE.%26aulast%3DSchweiger%26aufirst%3DM.%2BG.%26aulast%3DMarik%26aufirst%3DJ.%26aulast%3DReich%26aufirst%3DM.%2BP.%26aulast%3DTheil%26aufirst%3DF.%2BP.%26aulast%3DFielder%26aufirst%3DP.%2BJ.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26atitle%3DDevelopment%2520and%2520evaluation%2520of%2520a%2520novel%2520method%2520for%2520preclinical%2520measurement%2520of%2520tissue%2520vascular%2520volume%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2010%26volume%3D7%26spage%3D1848%26epage%3D1857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody–drug conjugates in rats</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1994</span><span class="NLM_x">–</span> <span class="NLM_lpage">2004</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc200212a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GgtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=1994-2004&author=C.+A.+Boswell&title=Impact+of+drug+conjugation+on+pharmacokinetics+and+tissue+distribution+of+anti-STEAP1+antibody%E2%80%93drug+conjugates+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody-Drug Conjugates in Rats</span></div><div class="casAuthors">Boswell, C. Andrew; Mundo, Eduardo E.; Zhang, Crystal; Bumbaca, Daniela; Valle, Nicole R.; Kozak, Katherine R.; Fourie, Aimee; Chuh, Josefa; Koppada, Neelima; Saad, Ola; Gill, Herman; Shen, Ben-Quan; Rubinfeld, Bonnee; Tibbitts, Jay; Kaur, Surinder; Theil, Frank-Peter; Fielder, Paul J.; Khawli, Leslie A.; Lin, Kedan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1994-2004</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are designed to combine the exquisite specificity of antibodies to target tumor antigens with the cytotoxic potency of chemotherapeutic drugs.  In addn. to the general chem. stability of the linker, a thorough understanding of the relationship between ADC compn. and biol. disposition is necessary to ensure that the therapeutic window is not compromised by altered pharmacokinetics (PK), tissue distribution, and/or potential organ toxicity.  The six-transmembrane epithelial antigen of prostate 1 (STEAP1) is being pursued as a tumor antigen target.  To assess the role of ADC compn. in PK, we evaluated plasma and tissue PK profiles in rats, following a single dose, of a humanized anti-STEAP1 IgG1 antibody, a thio-anti-STEAP1 (ThioMab) variant, and two corresponding thioether-linked monomethylauristatin E (MMAE) drug conjugates modified through interchain disulfide cysteine residues (ADC) and engineered cysteines (TDC), resp.  Plasma PK of total antibody measured by ELISA revealed ∼45% faster clearance for the ADC relative to the parent antibody, but no apparent difference in clearance between the TDC and unconjugated parent ThioMab.  Total antibody clearances of the two unconjugated antibodies were similar, suggesting minimal effects on PK from cysteine mutation.  An ELISA specific for MMAE-conjugated antibody indicated that the ADC cleared more rapidly than the TDC, but total antibody ELISA showed comparable clearance for the two drug conjugates.  Furthermore, consistent with relative drug load, the ADC had a greater magnitude of drug deconjugation than the TDC in terms of free plasma MMAE levels.  Antibody conjugation had a noticeable, albeit minor, impact on tissue distribution with a general trend toward increased hepatic uptake and reduced levels in other highly vascularized organs.  Liver uptakes of ADC and TDC at 5 days postinjection were 2-fold and 1.3-fold higher, resp., relative to the unmodified antibodies.  Taken together, these results indicate that the degree of overall structural modification in anti-STEAP1-MMAE conjugates has a corresponding level of impact on both PK and tissue distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplvgyLOeqItbVg90H21EOLACvtfcHk0lj6S4TSaFToGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GgtbzJ&md5=1b084b2365da4d16525ec1f98454dcd1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbc200212a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc200212a%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26atitle%3DImpact%2520of%2520drug%2520conjugation%2520on%2520pharmacokinetics%2520and%2520tissue%2520distribution%2520of%2520anti-STEAP1%2520antibody%25E2%2580%2593drug%2520conjugates%2520in%2520rats%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D1994%26epage%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Boswell, C. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">An integrated approach to identify normal tissue expression of targets for antibody–drug conjugates: case study of TENB2</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">168</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401365h&amp;key=10.1111%2Fj.1476-5381.2012.02138.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401365h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFOmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2013&pages=445-457&author=C.+A.+Boswell&title=An+integrated+approach+to+identify+normal+tissue+expression+of+targets+for+antibody%E2%80%93drug+conjugates%3A+case+study+of+TENB2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2</span></div><div class="casAuthors">Boswell, C. Andrew; Mundo, Eduardo E.; Firestein, Ron; Zhang, Crystal; Mao, Weiguang; Gill, Herman; Young, Cynthia; Ljumanovic, Nina; Stainton, Shannon; Ulufatu, Sheila; Fourie, Aimee; Kozak, Katherine R.; Fuji, Reina; Polakis, Paul; Khawli, Leslie A.; Lin, Kedan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">445-457</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose The success of antibody-drug conjugates (ADCs) depends on the therapeutic window rendered by the differential expression between normal and pathol. tissues.  The ability to identify and visualize target expression in normal tissues could reveal causes for target-mediated clearance obsd. in pharmacokinetic characterization.  TENB2 is a prostate cancer target assocd. with the progression of poorly differentiated and androgen-independent tumor types, and ADCs specific for TENB2 are candidate therapeutics.  The objective of this study was to locate antigen expression of TENB2 in normal tissues, thereby elucidating the underlying causes of target-mediated clearance.  Exptl. Approach A series of pharmacokinetics, tissue distribution and mass balance studies were conducted in mice using a radiolabeled anti-TENB2 ADC.  These data were complemented by non-invasive single photon emission computed tomog. - X-ray computed tomog. imaging and immunohistochem.  Key Results The intestines were identified as a saturable and specific antigen sink that contributes, at least in part, to the rapid target-mediated clearance of the anti-TENB2 antibody and its drug conjugate in rodents.  As a proof of concept, we also demonstrated the selective disposition of the ADC in a tumoral environment in vivo using the LuCaP 77 transplant mouse model.  High tumor uptake was obsd. despite the presence of the antigen sink, and antigen specificity was confirmed by antigen blockade.  Conclusions and Implications Our findings provide the anatomical location and biol. interpretation of target-mediated clearance of anti-TENB2 antibodies and corresponding drug conjugates.  Further investigations may be beneficial in addressing the relative contributions to ADC disposition from antigen expression in both normal and pathol. tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYaAS89AVP4bVg90H21EOLACvtfcHk0lj6S4TSaFToGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFOmsA%253D%253D&md5=9f430a3c4f18a7987f9398fd40c79ee5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02138.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02138.x%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DC.%2BA.%26atitle%3DAn%2520integrated%2520approach%2520to%2520identify%2520normal%2520tissue%2520expression%2520of%2520targets%2520for%2520antibody%25E2%2580%2593drug%2520conjugates%253A%2520case%2520study%2520of%2520TENB2%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D168%26spage%3D445%26epage%3D457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i17"><a href="/doi/suppl/10.1021/jm401365h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_01578"></div></div></div></div></div><hr /></hr><p class="last">NMR spectra, chromatographic data, mass spectra, plasma stability profiles, renal metabolite analysis, and additional biodistribution and whole-body autoradiography data. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401365h/suppl_file/jm401365h_si_001.pdf">jm401365h_si_001.pdf (1.0 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401365h&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-23%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm401365h%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401365h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799300a4cbb3db2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
